var title_f38_0_38912="Metronidazole: Patient drug information";
var content_f38_0_38912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metronidazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/48/19205?source=see_link\">",
"       Metronidazole (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/5/95?source=see_link\">",
"       Metronidazole (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10866 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38912=[""].join("\n");
var outline_f38_0_38912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/48/19205?source=related_link\">",
"      Metronidazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/5/95?source=related_link\">",
"      Metronidazole (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_0_38913="Diagnosis and treatment of intestinal ischemia IV";
var content_f38_0_38913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia IV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 663px; background-image: url(data:image/gif;base64,R0lGODlhPgKXAtUAAP///4CAgH9/fwAAAL+/vz8/P+/v79/f3y8vL8/Pz5+fn09PTx8fH19fX6+vr0BAQI+Pj29vb8DAwD+MZg8PD7/YzH+yme/18gBmM9/r5U+Vcl+ff5/Fss/i2KCgoODg4C+CWXBwcNDQ0GBgYLCwsCAgIDAwMB95TK/Pv4+8pW+ojA9vP1BQUBAQEJCQkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAA+ApcCAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIjRIBzM3Oz9DR0tPU1dbX2Nna1RLJ3t9LAQUC5OXm5+jp6uvs7e7v8PHy6wUB4Pf4QgEC+UIC9v0CHtsX8J/Ag8QI9jOIsOEvhfkYOpyoCyI+iRQz1rJ4D6PGj7A4gvMIsuQqkd9ImlxpCqU3lSxjhnKZDKbMm5xoDrnAwUKK/wxnLnTgwoFDFKFFin6xibPpJZ1CQFiokOLEmQ4quFiwEAUrgK1CwHph6rSsJKgVJuwUgmKChqEA2r5NikKDhgsAKlRQKnfoTyEcOmQwesHCBAt4OQAdDODChgkb8A6poAEyXrAZHk9tbBhx3r2KjU44nMGCiscVAAw2HNgu0ChkzcpuBPXCChUVJNe9kOHEhd29JQuZkDWFhq+3OQD3vSGFkBUZ0gLYwNXCBgATUkvX4BwFXCGCAaS4DhZEaurTq5NPLn3DhtyGM3SwWuFE7hOIx0uJPbs/IqiqGbbCdRpQZ4F9BW5lHxHZCYHBV1wBkOCBFcwHAAfXSbfCEBs22P+eBii8tpNxIKi1VQcghMXVhs9BKIR0Yon1oHTYaacWbAD5p6MjABJh3wQp6JUbkEIKV6ODLmIXpF54ZaeBjQA8iKSHN2K4QmpDgJDCBTBOdSNYUkaZZJcqIkkjlfvluOOaiUDVAZYXnFDacY3NKQRvDKZWV5IW0IknBxNYlZdaIOZ1XKGA5iWEChE6mJiJiK2AF6MSomDomCZmleSMN6KJI5ug/sePEhlocMIEIFgKgAolggAUq6iKiF2JEwwl1qqtvraCUYMC0MFoteZ16mNf0WokB8NCeiEIlXH162i2RihdBiV2IGOvR9IIBX+hdntHj1U0SIdkG/AaB7fepiv/B7hUiDvHBiCAoKkc6KprbxvsClPvvfyikW8w+/Yr8Bj/AhPwwAh7UfAvByfscBYL+9LwwxRTEXEvE1es8RMX85LxxiAr0fEuH4dschEj61LyySynnMvKLJvsMi4wxwzyzLfUbLPG4szj889ABy300OfUs/PRUCyzzdJMb/PAA01HLTU13SBtNSXMXK31R1lv7bVDXX8tdkBhj202OGWfrfZAaq7t9jBpvy23L3HPbXcudd+tNxVKT+3331E/DfjghGNT9d4UBQB14Yw37vjjkEONeEZ5q1v55Plc7q3mmKPdNr+cd+5N6KCSLjrbCZt+ejGq79j66sK87p/ssD/0//m9tNfeS+6y8a57Rbfb6/vvuAzvlPHEbxS85csnn1Dzm0PvfDDI41T99CFJH+r12LvCfUzfd3+S9qWTLz7wGvXtuOCQO3P4+Xeov/7i7bsf0jhE50+00fDj0bP+ABwa/7w3KkTorH9cwBm9zDeTAh7igAjUggLPxUBQTLANEIwgFi74hgxGgoNr8KAGqwBCDFbwEyVMgwhHOIUUhvCEnnDhGVbIwijIUIUw7MQNy0DDGnLMgYnoISOgIgACDKGIWTAiE4C4BCH6kAk7nGEOc8LEIgwAAUJQAAWqKIUBNIGLSHDiE0UGxgQQgAAJAIMSk2AABQgAAgc4wBnneIAwTv9xE1AZgAAUAIAFRIAfBihAARCQRgUgAAEFAEAgB1nICBSAARAAgAIGUIAIACACh+RjAv6YyERe8pBgBIAYx4gEmhSgAQJoACG94EkkHAABRVQAAwhADj0i8QijFNUSBvBKAqCSHwsw4gEYAIABGAAAaQwmAIYpygYokgJC8CIAIDAqBsiRAhAwohchsAAhpDEJuSQlysBYACUmgAEGcIASCeAAUTrglFkU5KgU4IAFLMAAAihAJEUphHcuoJ1DWAAfhXDMaDbxjprIIwAaYE1yFFOQBfDiAmCpTYh60aHFNCgABilICpyxlV4s5xcRKk4rmHKNDYDAO4VQgHYOgI//AgUAAY4Z00oaAAIImKk1M+oABBjgAAONZkGteNCQhDKjB+CHQ41ZhARAgAIHYOoRRyVNabaUCAQA6UYBWtSSruGkUwWANZmZUVHyI6mP5IdIs8pSbfaRq0SQphHkakej7pIIDo1AAwxwU1HylQGb3GtfMSpNqKYTAXV0gBm1qoAC8DWouCSpV1tITpS2EwINiMA+pUmOYbbToWv1pEhDukYiAPYIdI2sXZXQSkkOFAKCjCRsrzrN2LqWpf0cBwDqadNNDsGTjf2nEsI5WbBKEouKZAA6NUoOAiAXlRs1Ilujm9FUehOv9xTCPssKTsk+5ah/IK5XTYlIBOx1CJkd/wJn+aHKAixArdIVrVsN0F4gCgCR8NRod1drQO9OFgoF2ykexEuIKI6BwOL8lwKcmQcEC8LAYnDwGCFMBgkDwmVn9EJqu/rfM1D4wP6tBIZLq4UNDzfEHYYieANh4T+gpLyW3Kgjl+tcQfJRAXzsqXmPWeMC3BizEUhAeTXZAFUyeAAzvulAFbDdI6I4xWRsRIv9gJKCrpKXl4wkBY7pUIcu940A2LJZRckAxRbUANB07jGvimXNnlMIpy3ClFmowHwuII30tSkBFnBKHjugASLdwpz5gJJ8FsCjZW2uJ7tcRE9mdbqMJiigIyrTRfNjvdGdrpyfDOVSrtgJ3ERmO/8RkOMEJKCOmBVlAQ7wZkFz+oNMDDV11wtppQpAyELYc63H3MfNVloImk00PxSwgAZA1smdLgPODKmANOJ6CDedaCIJy4VB70EkoSbALIUd5gQY4L1jnuW3+UgBb4MbowuI5CRl6tNh1hHTYiWmapNNsE87gQARYECjiYAACBiArdR2NX+J4EgBBHmjWdRksaGL42UCeqAJWPiwB/rtliZS2/ZUInAHmtK60lsMOPP2bh0LVUVG9ZiN5bWJq2BtPSxspoEkcRFgHugkaBoJBljuvD8OBpz1lJG7xS9QGXDKaVO12q+GxMJmC9cjMJ0JvlWCA5q8aZ6H4cMRTvojsD7/Fq1/nOtgaHkewI50q/fc3n4Qu//Qrge1w4/sXR+4Idx+Prh3ge51sHsW8N49vQv8FX6/At+xF/i9e502bG/w4ZNdeCwMfl34C6Dk4zFAsycw8pPP/Dsqzwr5MY599QvA+yyvBc8XDvShZ8boM7d40he49ZSDvesDET6W1H72h7i9SXSP+9c7jPe9f7DsJwL84F94+GBDvvHHrnyEFH/5fXh+7KE/k+YfRPrUZ/7vrZ/9ddEv9eAPv/g/z/3uw8H040+/M1Cv/var3vypKz/8iYf9+Yuv/vYnvPzzDzv88z95/vd/vxOAAlg7BFiAq3OACCg6CriAmNOADog4EBiB/5uAfu53gfODgRpYP6sXgYqzgSAYgiI4gtAgORRIBBN4NilYQys4Ni04Qi/4NTEYQTO4NTXYPzd4NTlYd/unNjt4fz2ogkE4QiUwAEY4AC3wX0V4hElIgSNwhAPAAv/1hEcohRToAVDoAv+FhUeohRT4AVAoAv8FhkcohidoAkZYAimGhgOghicIACFghCOQYnE4AHP4hiRghB6QYnk4AHv4hsU0AB8AZUY4iID4ACbQaYgIiPoQAp0WAI7IiCJAAp02iYx4iZiYiZq4iZzYiZ74iaBYQ1A4iqRYiqZ4iqiYiqq4iqzYiq74irAYi7K4iq0wi7Z4i7ioigKRi7zYi/+++IvAGIyzWIvCWIzGaIS7uHJHg4yswIyg4Iz5AI1aI42oQI2cYI3fgI3LqIykoI2Z4I3IAI4xI46hQI6VYI7EgI4ho46dwI6R4I7AAI8VI4/fyI2YQI+9gI8Oo4+WwI+K4I+5AJACI5CSQJCGYJC1gJD2opCOwJCC4JCxAJHdIpH/aI+XQJGugJFsopGHwJF74JGqAI8d8B0j2RjfsQZYUgReQQVKwQQpyQY3kgQtyQUgSQjkWAEigpNI8JJbMJNHsJJWUJPVaJFHMAGS0hgroBZA2QVhogQxSQTaIgW34pRv0JRHMJUlRpTPSJQYcCMVgAGNUgRPuQVYWQRRSQX/QnkK8AgZXIEhasEYFYACqAEYkPEaFlAaIpIZbjEUg1EBUwGWRtEBlWEpfVkdqvEYc3GWeskrjkEclwEZ1mKYn9EYjxEZX0GXG7AYPQEkRVAYh4EXhVkEhmGZymEXnukcUQIomrKYZSItqSGYhzEFaRkI5IgB7zEd6EEZljEmdoEld3mXRNAXqrGZraEBQGEdjwEXgJKZvaIYw0mZu7lLWpmO05knVmEeagEjEyAfVsEBd1EfDkIaQyAfvkIfK6ABd4kBFUItGXAB2VEB58kVD0KeFnKW9nEBGmAUIGAU3nEavoICYFIm3BEXQ/Eg3skl9HGfckIE6GEdeRGfREAp/22BHSpwASlgHnECFOopIc5xn/npIlICFivQARYqm9XZjlwpmKUCFuGhH1+pGnLSGxoqnmxxF8FRH/eRH+RxFx2wIQcKntKBJgPqHUwwm6Wwln55GNJBJmLyJMNRoEfglpwyBFKSAofRGdoiJVKKLeDhlW+RIhwiHAHqIhsAIq/xIE6KHW/SKS/JIgCwIWf5plthAQ/iKQ0iJWnxKy9yHGMKFieAG0byBEb6B7WJHdkBFhaqASWCJCkQIT4hJkUwIfZxJlAiFk6CJbUSpFBSpiHSBIM6CkgaJ1ySncoiJuJyp0ZwGhrKpSH6HnoRHTH5IKoqJlFJI2kRlU3ZpxFiJf+pUaeYqhdsSgRhMqVFoJ5Cki3BiqfZ4ZXKEqJckahHGQWf2geFSiZaMqpIEiPyaQREwiSU2iuWeqvDAazIChgbcCVFeqLBgKSTQaqbIh5ZESdIIpaESaxRghf1IRlrSqXYUa9c+hyXsSXQUScTwCuR+aZ4kZuLsq0pEK/0EaxDUCiU8a/DgZpDYae9uijOcZSPKqIJyxVYYh5dpK6bUKhDACaPgiQo8qSQSgR9ciewOq7g+qwb0rCN8bCVciHZubDpmoxT4C5LWqoP4hjxoipWWZ7EYa8WIC/LgiookKVIqwL2yhbxYpkoQCvyASwAyhVV4RbVYSxiQrSpgi3u4iv/wDIUcYqf8XIcGBslqGK1VXsZXHsq6Ckh8TIvUDCtfGCyZYIskHEjIRovEXK0uBIr3wojpzK2YmspS5osxTIagYpaJPsLensTlasHAnkBhOsHl+sJncsSn3sHALkB+FEIoVuyk0sxp1sHq5sGrXuPqfswrysHs2sGtXuOsbuPuduPu1uRPvs1t/sGwTsGw1uQvTswxcsGyQsGy/sIzRsQz4sG0UuTx4sL04sP11sG2ZsF24sI3esN3xsG4VsF42uT1dsv5ath53uQ65uQ7buQ79uQ8fuQ8xuRx3i/+Ju/+huMxLi//huLyfi/AjzABOy//VvACEyKLDiELsjAMOjA/zIIwTQowTZIwThowTqIwTz4iBoMhBx8iT94NCGsfx/MiCNsMyfsPCncMh3cdy28MyvMJhYYguxHgu8HDDNsw9FQwzrMDWXxgT0cxM9ggg/xfUJ8xFJDxNbzwoTGxLTnxGcBxaUQw/4jxVRmxVuHxaJAxd+ixdfmxUMExigkxutCxl18fWacE2n8BlzcxGj8w2vsBm38xW98PHGML3dcxnV8E0tohE1YC32MhL0QyH8MDoR8E1RohFZYC4kchb3QyIsMDpB8E1xohF5YC5U8AJesC5m8yd/QyTdBhkZohrUgygNAyrpgyqj8DaqME2zohrfwyr8gy/1AyzdRh3d4C/+4/Au73A+9fBN9+Ie3EMy/QMz9YMw4UYi6oMyUK4jJaIg4sYi6IM2/QM39YM03AYm7oM3AwM1kE4lNYYm6IM6/QM79YM6hmM7qvM7s3M7u/M7wHM/yPM8LiMTq10L2PH4Qk8/i91X8HH6EqnkCPdDnQLK2RNAInXm9e9AJ3dD6U79JwNAOPdFBA9E0WY2yidFYYNE2uQYcPQgfzb0aLa0jHZQlfQYhTZuEetJOkNKAsNAsrb0xjQcuvdJdNNMkrZYejdN2UNOcm9E6vdE8Lb5DTQc+Ta1AbQowHdSuW9RzQLJyNAQytwUit9M3TdVnVEdQEEesK9JSENW5FgZVrQb/Pn2+ZkQAWv0EXG3UNg0bFDBQ83twRVBzTZR4+pW3XHBK93VsS9BwcvZpN+fVV0CyAvDWd90Fck0EdD1cds1d0pvXqERqUODXeAXYrSXYezsFBodc0rRnykQEQJVPA+VPaQRUtKRqdyZJdWRnp8YA0JVn81RPC1BH8pTWgprUWSBSBuBFEUdbApBUB/BOV5Vhwt1Ota1q58VOgGZEAqBvU42WmP0Em61Rnk1ioe1juZXapq1U7lVIq93dw/TagBbb9kTb42DbLW3VWqDbvM1nAPXbv13cMmVE8n3c+ZTcfyZSzX1L0Y25mk0OfORF7uZuWAVYOZcA9fRT6EQAFPBe/6GG4NH14A5gAP1mRDl1SWoVATflTEU2U1ed0+stTFCFWDH3UALgAOgEVGZ1Tj/FRx1uAH80cqrGasRkSGi9BUsNGwCOVGMlYLlm4ICV4MP0bw3+Rt0E4eUk4RSeTQBw4TFuU6n24h/+2FsgUgcw4gdQ4pR04inOR+TA4ir+4jG+UvlE48d14yXW1tsiABSeUdTkD01Wa8VGDrM0Xcz2TeV0522FTPqWSp0UX7w25bdd5ajEAEyGP7olTVfO5Ga16EqEUVtUSyr3axct1PvB5li0TaMCZlJtaXPe3B+VRaSG5wSg59R1TuQAaNQFcI1d1pDd3IdODokuBI7uD7+NTf+PPiqRLgAXdXSBbelIfemitG4YhVG5Zmn6NEf/1kr4pm+rnm/wxW5zlEahFeggjtdVnk1c1gB0xF1JhUhj9u1GF01zxNy+ftnAbtLCvke9butYhezZdEbLLtXQ/uzOvlY5dUbUDujGfu0ondfa3kzdLlfiHu73Ne7FVO6T/uuDrebSDUgIwNvIVQDfdOxCQEgC0E0mN10it1Ll1PGd1E5o9k37/msGB92CfgU1p20FlUaKXke73egwf1Expk/XRW3O1QU5vuaKFPHINPEVT+kYr/E/xfHH5PFodPQh/0wkv+rTFmMpL9NVvkYsf10vr0i9ztUxf/IbtU9phPPIheP/Du8Exc5ZoDRzFDBIo4JJgyRHnvRzq1ROcJ9GP/fzau/0y4RIQZ/eUV8FdG1Ig+RStD5kjU74r0Tx33ZI3RRwNib26f7w/mD2sIT2d/9JbT9dcx9dmV/3Qnb31X74e++p6p3bpQX4CCD4eT9IXv7bhq/3iY8Ai390G4Xdaf7TY8DwH4nb3djfXoD7/k3WTk27ZOD7eWDQwX9Xt4/umQ38TL38Sq37oMr75Tj6u/8GOdwMR+38RTDD2Z/7RDDDEmB63f/7Td38bADE1ZC7z20Fl51naLQEjvb4Q4D+0KD+rFQE7h/6cx3WDQ8EACEg8AgckUiJJIkcDKFRaZQwtV6l/4WooVEgJLAALaAaNj/NafUQvZaW3ebxkOsFY8fwOLS991uP0vr8tAjm/viiGiDIIsLQDv8GhwKtJuMKIxEBBhcbH4U09wYr3S7dMjejOhkJHLEgVTll/U7XUmlnoTxdQcVkbXPTSmHfHLruHAoWwA4UCAQAogUYBAgMBAoEDACcsxkBEhYKHIQiCsiF+g4YGgScyY69hBQKGtCivQvACRYW3gEoS7cKUIArkwjIS7as2bNp0qpdy7atm4JvQsQNPDdwXbt3CuJ1KVPvnpB8FvcJ6ffvQEB05QhCIaYGoUIhyphVhCYNojVs2rjpA5cR5kaYHd3BSyiSnj18FS+S8f8HUCDMRMLW1ER2k6HOh9R8TgyKcui4oi/VQWGXFOTSeQBIPhWqcmrLqlKCYcUy05KUbAYSUAi4wAA7AwQo/JulAAGBA+6kNSDD4BqDAwcQHDAwr5wBy7qEGEAAgYAhaQUOJGAwuDCaJwQoe76cWfQXBoVBxpTCl43fAoAFOyBsGLHiJ4wdQxYgGXbl2Zo5A5ANWvro0lqypV4tvHXa5rIxa26sGjfeKLx9QfkbmDXxxNGON348jXlsy+E3V+n8uY9o0qazU6091yZzDr/xboNHN73SG2K94Ia7rTj44JJPufoMpC266fqzDkDUBOTuAAK/u482BMtbkEE10FNRmmj/xOjHHWqu6800AAQTQrAbvYBAm4kaKYCCKgaZB0AYn1jgKO/G6PEVLw6ggLQpTmlxEgFg9GKBGSm7cZYbc8SRjCYJ8BFLbYIckroYx3wxLSXT+pJMCJ50TEo9epPJoDiuzFJGLLuc47Uxwtxxzh/RdEVIIqMwEjskAYBTl0FDKbPOKKc0b8UGTfJzS0BrZFLHIQyt1EwgFVWzyCqOfHNJOU299E4qN3WjxavU83Of0q7xklLQfvViOV4PcAABMOZZtU0s03qLRDKZZfMAARDQpMo9aY0iWi92Le0wQdsENlxhGyDWWGQZhcJRN2dxVtQYt61i2mo1pQTbrPzS9b9e/8G9sY1goSm3tGKPZVPZVtst49lK4+2GWmtrLUZbfXn91sYx/h03YHMLTrZRVh9tVuF3hfXTYXpdjLggQfKVTjABFgjtAF/JQEAIOPvRGDZuwhHAkdrWXDfaJyKIxoCFY1RGCPlaOrre8+51kVkDXo5Zupn7tTnScnLmsbTbMPK5unSHEBrSoqVD2gulAWA67aeJiJrliV2WxurCaCZAa5xj9nrnsH9uLGiQ2SXaaLUTGsNtp1NWeU03qbZb5rz35rpvMv/uOXCyK1327MNJTnxpx5qeJC/H455bPQYKQKCoajOjWYwCFEgAnQLA8LrC1h0QbRnBDw55ls20QRyACP8QaIAyzFrPDVeoD/KLddfNgR3rPNGp/fbcydzddd8XAP5jz9MiXgDjkVfeMdidz9PeUaTnvfrWr48ze9vR4b5zxngHX3x1CTc06aDjfKE7XvKWxz64oe5x1JDfAeknu/ttT2Pe6121wsc5NiHsCeZDHwLX17wFMlBPqnMQjEhIQp59RmK7kZv7TpjCFK6wJS0Uwq36QjcZMpCGnGJgn3bIQyGwMHpBLOEZWmZElU2vfTl0YRFzpcQlipBTOMxWFKVYKyYicYdAzOKmtujDHS7BhF80IwyhQEYnnpGNg1CjKdgYx8eh7nRyJGEdz4hHOzpOj8/boxL7CMU/AjKIgRz/JIMMSchDKpJPi2TkJhLpSFpEUhWUlCQkv/hGG17yh1bQZOM4WSs3SgB+obxjIU15yixacY6pXNG1BOlKUUKvkbJUmSURgUtbclGKrNTlLjf5vjUCUy+keKEYiTlJVCYTkV/0JTObOQUrQbOYtIQjNYXxy1JiU5mrPCYouVnLJw4znJKwJr7KWcllpjOXzvymH9kpznOCM55VfCc560mTdebzmr28pzqwFFCBDpSgBTXoQRGaUIUulKGwtARDIRpRiU6UogM15igqmlGNbnSi2uQTR0EaUpFiyaOIYGUTUJpSla6UpSh9gBFaGlOZzhQ9LaLpTXGKhJfmlKc3necw/3oa1JXuVKhFTWkQjZrUIxBVqUl1ZyhZ+dRFRtWIVLWjVfmpRKzWc6v+lGRXZQhWBopVqlk9JFnDidaw/tOManWcW2sFV6Sy1axerWsYPjlVumYxr1fdaxD7ekm53pVBgyVsWQ+LFcMmVpp/ZSzqFvvYHUb2sJSVbOou21bH1jOwf7QsVjrLxs/KIrR6zaxmT3vDzRqxBANw7QBaYNpBtva1sd3jaDdFW9faNrUy1C1sT4vbXIzgtQNggWz/SNzXHve2q/2icl3L3N6mELrGDa5zd+iB4roAuXvU7mu521xXfte14Z0uCck7APNKVri0+EBxRdBdO773tfEVbyrp6/9a+56XgfkdwH7Zi90dmsC1JXBkexFB4AEY2LMClqKCGcxfEkI4tQiWRQhcO4IDO9hxGB6AhhssSw+DWMIMHHGFOUxCErjWAxte5IoH0OIQuxLGMi4x6mqM4lC69gMuXiSPB2nhYg6gxzf+IZF1zMkHmOCrKVbZks/q5CBC2cgMpPJ1oRqCJh9Yy0GW8mS7XOW3hjmzpZWjCEggSTN/Ec2HXPMf2yxmx8VZznW2853xnGc975nPfT7sm+0MaAkL2s+FFuyXscxnIRua0XGVMhOaGumektKkHIa0pDEdU0r7gRgeyPSnQR3qI9jYDJcW9alRfVNSq0yuAfjRSGEN0QL/CFitro71rRE660pD4QEzwvWvgQ3rBjxgDbYO9rGRHdFhk7DVKASmAGjN4QA425XQ3vUQHoCnRhOA2Cyidp+5zWwpT5uZ1r72Jsi9S3Nz+l7ZbjQVuj2Mb/M53GMd97yrHW1ZpNuW694DMdz97iHUW97bjvdb711ufauC37L0dxwArm1GE9wMDfczxVmd8GQ+HOLSxjcnOV7sdkvc0Bjfy8fzbHJHC8Pi/V44ulEuyZCzaOQCH/jBw9ByeuM8Ys0OgwOwdAc3JIBnqJs5zff98QNAQAAKKLoaAMPAo1e85jYnA8+voPM9q3xThD45HsqlDJKP73hCd9zUS71pk+Lb/1gOsVoYbpSAV5wdu5oMuM25Ls2PA10AZlcD0aEJeDXkfaofh4Bk6AAXe9RQAMqQzFqioYCWNN4eJlFJFX5CkdJY/jQ5sQLaIYtvCtRQOt3oQm7cUgWwOKYt8mBVGWC0EthfPhzjwDfo13B3WSy96U8fggKa+AfgX5Lw58G3PRI3dgCaw++7jEDzr1D8IH98IL8nDGzUAZIFON06BtM+SPARjQsVDgAQiFkCrOIXRHN63nqTQmy2fxrtVMgxH5q/ANlxGf50CkdEB4f6hUH3NoEdniEC3g6LsCBarkABF0n6KGHeDg8KuIEkGM/xusEj4GLyLJAnyADzxKIDOS8bPP9PCPQhN4zCJJThFeoBTRygDBKi9tLBGXZC8qRhA+vA2RwwF7wu66gPTxagDHBHF5jlLTzGTcJPTEZFgBijdhJQwHbQ+KbASzAiD2JGgG6Eg8iP6UyCEY6QASLgGj6v7tROABFBAXkmGxqAG6amC2CkDiLAfCbPHoKiC9AECjKCEVYQRu7iNNIQBmMv+BAhB4lg3qqPHq5vNTjh+/yjCpLl+4RQ/OgjC88v/WCD6BgADPajJQagHBagFbhh+xTAarYPP7xgQrwvUkBCcNBGJbBuU3zOCjxh+QyG/4gwXZjlCDNGgBqhGhbw5dZuCqKECvJAeH4FCwUoWm6R/wzA/Cj/wPdMArsiLhcQI1OOJxqUhllUMRoQACQcIAEaoFwMAG2URnAgYwjYwf/I4BNrJ0FAQhy1gALQ8TSEQRB17i2G4AdDAQyOsBYfsR8LhfyW0O9uhFlSJV1MY1oKgBdHjx3KD1GsYQ6KMOiqYTnmQBD3TeOikIW+gE6kAxH3ESYiMhqaEQAgg2/KzxFGJBy4gW2mAPeyzuOsoA4NACRGUgAYwQq1Bgs5MiUTQGuCcCQhowwEBwD/IBql8RwGgCYD6gkkEkuQQWv4D0eWsiejUgg40hyzoRowpQwoYCkBwAvBkEHocd5isWyA0BajgR9xkf9yEVJ2EQfHAEvOZRbHhB3K/4FZsEQLh2VgvCQk9YZXhM4iGQ4jp8BY0GEBNKMBEIB6+tEw6ZJZIIB1FAN/gtAzCiACnsAwCyYM0Q0mp4ALqiUljCV51NAtswcLLRMzTWIxYSQylyEawgcB5k5boLHqsCIlB4BXVM8aGqM0EkAKh0Y3B9LZFNAu3WRetCA3eUU6mNEZZWEsM7KGNvJnPJIWQRItcYQbStJyTrIbngDwWDJcjkVsgAYNIoA0tAYy2OEzMuc3IRItqeYOArMVV+QVicklV4bhYs6R8HOchIAM/8ABakhAUiIcXiQ+MYJqmmZanmQoqIYbVlElEPE30/MdSkcMhoIMRocMAPEPoLMwQ/8TMUGTMY/QMUOy/CQzGigTDFIzM2HH7BCjdYwGg4CndfpQMV/zZhDPgvoSO3tSRm9O3FhuPy+pP/3zF9WtNnlN+dxAb0KTRWOzClUUdqwxNGcDdwwgSitkKrQFg0gSg95BgbJ0MWMmNl8hG+aRPneDSO1ICq9IhgSzM4dU4eRUP59NSbGNSXeu2NhUjtx0hFAnTs8t6eh0UIuyT//ISI/oP/V069QUCifuURWLMKUo6srQFw/VjARvDxRVmBjV6q6OTw1OSHNB63ZI7jahUz0VSbPo+f5AVTHrU63uQ6VgUyVwK7DAViXJUsPAVa1AUIuSUqNAAYSDMKRCDkMiCB//oysgoIaYEA25oTSATylcjytGsCUxlf2soATNAS1q8DKbAk0SIDeWDgZh4h0+QgMrTzrYsBcHFUCNiEldVVfhToloNQp8VREYwTmhIF8PKe5m8wrs8Q0kVRieUO/wwBHMLxxaIgIfpBvAQEBicfTcURooIAKeATtAZDsihF+lwQnVLlMz0hIxsSM1kRM9ERWDsfwagBSJRBsOoBFRsW2qIEJpExHsrlFV4U+nQBSWz19jEgjjgGf94F6hgAYp7/E8YvM4UATBgAZlDwXXVT1SkB4SYEqgVTo+0C0WIidk8B26ICdWzxmwwUEM4AYrpQVVwiqA1ZlQzl2WMXyEZx4U/6ALvnM16lYqSYpdsPBTaMRdVwnfhjNNDFILEJIX488yTgVN2iAkVcMpfRZWpQBew8ANz3Zrq3VsHeJ4vPUkomIlKCMDYRAPCegClaMpWlZqd9QkIkLxUncPjNYsExEVF1GAFhb9YiT/8m92448PUFYMIqJix+9hRURC3iM1wgFv5cM0LjF5abYak6ZJ2LZgb+ttR2Y0LCZeIiB1IaEfiEQ3+ZYYMbRiALeXBDcuG69jCtc4CRJ3sENgHAM0/LI3v4Azc4FysWAbA8IbIzFAlLf+3iMgTPZL7OM5gAZKLnEZ05F2u+84DjH7Zvb35CMUDwMRh5Z6BzFo+3EelHAb7/+gR2DEJvvxKkzjLbpyb/8xXvw2UH7PbsPFNCKwAdYRctnkPiw4VBnoYNcUD/QjZgZgAkMmcmIQDeoBEQsUDKLFGO+G9IjyD3T4hs53aRKAPP/nPN2PJGGEddoCbAy0ceETHjHCfv0gZ/eAKknljK1wGAfuHFRFY65yHpxELbIyLUcGH8VAH6syXOw4CC9YVHsWOznYLV2BF0uGLfNYF0pYYcC3LSulW/jFHLj3hbXAMyj5L32TTQ7vPKGgbf9NWNXlSeGCdboAIuRHNS6zDSggN8YUAaRUJcQXgjKjfNmNUKOQAoDUf16WNL80R1FUguXHi/vxRxHg9vBUVpv0EBj/GVbCZS49xmsappBJkAHuko5FpnOOcOC6h0362Ns0eB+rYCe/cyW1wA58Eo/ZJU80mQgz1CSnpmomR3q9s2ZcWQi6QDIQ1EDnwTO4mBVJlRZMVZs/D1EjRnJrLYqDKYhg1SjdQEGvhp0h5YoHcnOUeW0UhxG/BiOuGDI4ojs9I04Y8Io5sqNhF4O17kTzmXVUUzPRRRpY06OpbQBslBveYpXPj4IciDGRJ4LGwJRVc3YyFiMGYECpVJsbIGA5uePmVGCVjwGliKA98w18Fo2MKKFt0w0ME0Rs2jRp50ZweaJrNnkEh4O9FEcVwzE7SDFJ9JCzZ0TTbw1i95HigKkZ/4iI+Nnekvo+s/XfBNqOqHpJQfWtjYiS5Npx8hbe+pmW8bpOYe5O31VnU46k9/rGjtpWPDkM6NUkaCcMLoNBnBqx04BXoyAjzMCx1aCv8/SvIXtU7bpU9xpoDbH0sGD49KKz7XQNUHUKElgOZruYAQB/wS21I/Wwa9sNkHYDCYgAcoMG72LzljW5i5WJSzuvIQ5RqZUpCGAAmo4G4aEO+hBGKBAqCnQNTNuYZSmq00C067VogbvkMPgi7/oWiMQRv1F0YoQ84IFZ4A8kLnMZVze6FZtV08D+BGREvmBdOnF/F+OBSwS6w2C8e5u098iScjsMzBsLAFvPJlvk3lsNTv+0fStlKzvFduhigyocW/9bZAfvlbu3TRpASWooSYDQPTtHvHkbQLk7RWiwdkjjJzDWWhsCGtQ2HiQwG3rcdZ118VB3ELjWx73iurO7JRTEaTnwu7+1v4OUm4M7h0N2sTEBOz1cWh7mRa5wnAknrkHWs0dbxTvnRuq2jWtRd2gcZ8dQ4g68G3UnIa0BbeqhPYz3H9imEPVcCygY+wadY7tDPX6DPYr3MI43N22HcG63HBy4giG4dw0by9lblv65m/mPWaiyNjbbaZilJhlhXczcbY+Z/HQBTva8DNDmCUJ6NeDcv+9X4lpcQCvIhKNVC1Y4VL5S/6JgJE1jj8UhxiX/ZRBUmEt8fcVNIyDfJMZH+NILLstTadP/uB+jJXwyiHn0l1lGsw9N3Q0kl7VTXRfRADbsATtCkxvOejG5JptpnRbgtc1DBY5Hpk0c2WKssqj/L04SuZHP0l2wiFv2Rd91wdQHmULU8pDretozXcs33OU24YkzOEnl3K/fwBz6zmYOWCj1AzuW2Ev02fcER2linaNXA20YJ4YiB2beOU9YXQvAMzlR3qWjcL0LLcORjtw3TrptJbLjyMEB9GF+I1JYOazLoCf9YQxyOnYOoahrlZXHgV3dneqpx4O0ZXpeR6fzBN1HWaWHB61fZbDp8dWS7ezRfqCWbbX9Gej52uf9/1jigxXjEYFnCjsM6Do06MHK49rtxRKDTS3VhIqpBJ+nVq3nKjuVaJvL5X6WT3sTFIB1ij4M7v5oJd9jS9vv9ULn/aq37JOxDVVbLX7uHx/v2huq1g+YPn/0SZ/xHa7GIdzOOF+OFk2+XJ/1Hf/2FR/206BqazVgzQBVQTv4gV+KLnuTT5+Taj/KIv71T1z0G7+T6f4KDKPoxnxoZR74iZZoGWRgrcC1pR2blt/Lmj/fnl+vQT/3H3wKvnv1HCQiDCEqiGILRNBwQSIjpiEiljUn3BQIBI5CxNAoEACA4SIBMBYahmWhCTgoBAXIldEQABKLgkMpOJwVh/CYq3wTHv/vOb1uv+Pz+j09EOADBgoOEt75FRoWCCwyNjo+QkZKTlJGFvwhAhxmKgUoVoKGio5eZm4qPSTRKSwYEDAAKCAQrCnJ0r4SGDAcHCAcGCDNRYApFAAQHFMkGHDd9jolwCbTDSgALCwcSC+1HjAYLHA5JDh4g+fuAiNA0P4GJw0oHiB9M7vNxXHu8+ud9gMMiOjfPgl+DiJMqHAhwwAPHjSMKJGhBE4ECxmcqLHhw40eF1YciAmVqjkLVBVIQC3fMWQtkUD4pGgOhSnUqDGIoMvlGwVHBvCcAxTAIiVAF3wRwIBAgwUO1iBdtHSlMGExF80cCgBmBDz6BIJFVGIA2QH/LcKiTVtHQki1YC+6zcQ2bj+4dAPNfZOqjrCtBFbCaUmVgIAGf2kJVXLzWLMFNVdGaLAGKGCjZsAAALrl8BSfFJK1++vqZRJhhQ9PfoOk6J2vd18DGFF2AAvYtm/jfmM3N2+Bu3vn2UsHQtddQeEgUEz61ZQwc2ZR4alqFoHkW8scoNzyzVDWQAUsUGLggCpi4MWTJ30dGTglTrQieeW+jmvgYD3MdmF/P39TI/sDWMhvAZJUhxEIIFBGZUoUUIACg8WCQAEJzpEAAkgdQ80CCHa1lYPSEKFdNZdZBkAEEv4igIQFTHHihOkxmIQDEkY4YRnwJaFiFfTJQSA/H8wm/4KPveU1pB0D9lekkZr856OSwi0ZJR/1SSmICWSVUKVtSAbI5X5eAgdmbv9AqaWZ+fR4JiAhkDWCmnSJ+WWTRsY55pxd/lfmm1pSuecdJJDlgZ9q1RnmnT4Weluir5FZ0qBS9vloNQN8IGlYi942VllnRYkpXZqSxSmieToa1nZ7JNDhHqfeocU1gqSqB6t7RGopKibY+tahPspWVm2d7spfr2T9OuoceoKlFa2z3qGsHaw84aweC9Yh7bRp5jpHACFkG5CnsOFXln7ARhkuWeMaq1epENSiQALGzEQFGWZEoZIqmAF1wBFWYEFYPgi46t4YZcQShbMEjCGFhwIoMP8Aw2zMSxQatSADsIOKZaMKZfcqMUTEcGDbLQAikCByXcEGCGRZQpK7pMpksZxugXM04AYF5E2xgLvgYGFiA2E44J1l24QxDQULYKYYL7sk4AswSJgznrNNAwDBzw0YlsAABDT9jjDynAHH0gw0zcs3qQktzXivgmyy276hHOCVA2Qp5bdxzV33kI3SwY1PV2jBwBkUtKNETW8InZktPx0X2GVXaQEewc42RmPikGdFX0uLQICZAFx8h+8VhJeKTMhvoy5g3ACyOYCbdq8OXOuv700qXwjTwkAZRaFBo7KJAxVZatSuxIhhf9GjMR3sjEaU6EQdj5i0xTNCYugl9s7/aq2pc7/H3a8BOoCgsEsZ/vi1H1u6MdNY90Uv0W71agLEXTGUZtiJSMdKCKjUXhjEwE8onTmGd2ziv/doTgn8sxCDEEi/7FxhDQY42Om6Z8E8KKlKZKmUlDI4pA0u6UmlAwAFXtUACSHNFxO6RgIaRIZdhMgyIIpA/vJBgQlhRhY2CoYinKUABkSBgJ5DQFd0SKHp3RBgZkCQ6GBIwyugiG2KqSA/MvKRK2Ixi1qkyAXR8gBcdZEuX1QTssJ4l+1Z5BOjWCMb2+jGR5TCjN7ilhwJRUczlbGOakGjKZKmxzkIIHZ08WCUSKYlQhLIkCFsCwDy+Mew8HEgfnwkUQQZ/5fvUfJIlswkHvjGyT1ScR8BmOQjA9kfTH5SN5tMZR9slxYoOOE1gvmffSIpIFL+0ZT8QSUrealHT6KlZk+AzVAyxCzW0MWWhBhlKnUpJ1bCDZoiSV9A9HWxb3xhDvCaJLtsoZKETUEM8TKGZGxhMDNIB5wLA0bkbEIABUiRE8ocBDM/6Uz7+HIOVtwiPz3CSIDkU47A5MdSwqEAA7DDUTvRGc1sto01WI2E94hFK+QTNQgqjhpUiyjWdJHNwhCFAhGIZybmKYh6cvKehnKLJ97oUlKs0nsxleZAOdFCjPmFDmgogOAqBIu/Ve4YOVkoSsQwOctQI6jOM9wbKLDUgP+YNBAozaRKexPQTuAyQFXlB6b22c+vgjUA/wRETUsqmGP0RQnf2N0kkXASADAvqRBwDDxi1Bf78SSuQiyR4pDZj6iSNautOUws8RCBwj6LpMDZqp1YKtj+MNYiM+2EGl9q2cvGkZ6u7MfhPpdT5Cghm9rkqVEGiAwFEoB+xgHgBJF6jAGYVgAdcgoywuNXfgCWD1Pdg8MWodg5pNUOt7VDcN0SWUVNVreP5c9xp9nHbjXXEJvlx4wQoLDinrAKpCyhLYB4BGxw6AknpBAPBYBXavwwiFBMSQsb5IThyjOUFlnuiPLhgCOUIwoMAk8rrnCEVxUFCpiBwmG9AAZrvkr/AeZohRbGoQoCEIwP0WVUcr1HX/tMWLPzhW5MyyrNfeTWwoLo7cO0sA3uMnQmcwVAQRlaFOgAEAHXcEB1CtfiaxChGbNQxxAYFOE9ZHiQY/XNhRdbYTsgMrAcxggjHfnhQoTYH0U2CmGf2h0w3PWmtXWeNBaBX+vEKAyCCY8wIGQ2WAQiyJbarY/UzKgpV8nNd3DykwcR5TywOQ/OSlxR7roSaiyiOoStTJnPmlMIWS0C+JDwkc2UZ602+i1wlpKc7UDnOgfizp2E856f12cZhaezXFiEAZbhnlJLkB4EE/Wh1bML/wGi0mhJcl0mjRtZY3DIUrX1kiotQkz/Vb7P/w2EPBrUFT5jeUVOqK7CimIhHC5hRQeY0TGYPYVChxkADVBVrCPNVW8fablBg0BzYgUbXHcyuY/2U6U9DGw7C1uSb+PFINAdTUIJFqECeCfZGkcXe2tyw9lq93TfDeV439Jtf6s3uCXrWDxE1BbhqU7AiFIFJwjYDGhwwKsOwIWM4wHgdcDUow2AWC0RnJoGLynCl8nrt4n8ZA+/w8da+wpgkG3F5YBrEgAINgI4tWo/g7FgY64tdWeVWgBROj9Srq6Vsxwt65aj0UXZ8D4INrj5862MoyG4wrz2DQzlRZfBHvKrkzzpp9qmLRZsE3X+BZ4FK6dS9j33NWDBVWLQhv8BkiaA5tDB6TODOiE0bYiXD6Owf+8NMxBRdYfjGw8NYBs3qIeMCAhO0H9BoHJuqnmunf1SSG/NqRaK467oHKI/E4BI4VnRn84CC69njy4E14yhJ6E6repwwQkPCMOHmx99QShu+nJYx1/duWlZN3OUgLSgLHAKQyh1LDmvBCBeg/rz2b3oBZ7AN+y0p3d9wlwth5m3bkUlLUF/SiCE3qv9VvCNHKHvryX1rFqTX1nYAsYWsBRbJFgU4N2D+FG/gIE4lQEUKAwCCswWYFMxrAHCoJ8Q6Bf37VLy6cZjeYwSIUMSgQG18U8YoAgYKAsEoJkIQpsF3pu82QFgrNVSjZ//Xj1VX8SHeviF+7XEMgSdcPGeytVfprUcPeGf19GeOjgNQk1HZ8we0D0fHBzNGXgNwoxD1zxN7twDQhVOPZzZZFwDQ/HgKWEgVlEa2o1eC26H7mkbloFaZsQWZqgW+yjBGwYFthFFT6ngSeVJUlzWHvJhH7pUAwThSQmWTxRA/nBFmOmL8xUV8bQE5hSGU0CUTHwOt9FgankO6JDIF17gzPUaGXqf/tyQe2XX802Ie8WCd+2VeCEIwTTIQY2XgqjHSmQH4NWB/HlAWOGiRHRELvIiQ5wPkd2B8GQUabCGMEQAK6LEX8xK8UTPGngGYTSjX1UiaxTFld0hcNAaVyHe/2s8HgBko5QhQnHRxcJdIyB845Jc1Zs82rxA0GD0GM9txRvIISMqTbmVx74dkHw4R8QgAQOln+I8VS2GIYFMHXMNJAsSgjjGBb2FnkAd5Jk82gwZYs9ZF3WoyoFQCD3aAooEzYp0BkcSBQpFG1rlCBOVCHxVUhcV5H50ozYumUOm0koCQgOc3Ju0JJNxopF04zlu2ksOAk+izyfJJB/81pnc5DIN5FD2RjemHVqY2xsc3yBEJaOpzqOko5ooZfccpYZFXpQwZRmCxYIopKzQnyZypZ9cJURuo8hsJR7m5JB85SfuQQQ0CMFQ4M88gRaMAR2UWcY0oDM0CGaMpVm65f+gpKWjraVP4lNSJmZcxOWwAUIC0ps1YMM1AJAx8GXu9MKZTZTpfRZVIqWfgIpZcFJWck9bShVjjmH3QeaU0OVnAGRRHI5YWqIZQAD9gF/gqGGa9eCeDAttlGZj5gpqklVSVpYf7mFmeQtY7sGMOMHXWI9yZCY1Vo9a6Q4MlqVAVuWemMsAoMsjmWbqEKduDaRXfdUu5qKuQR5CAllxQIc1Qsc7qgbXWEf7oZlKtM9udtt2vsnLDEDMgKdw2sp4yhRWPqTMtaYeIFQVvCeJWAiGZGZIcqCOhMco6idonuWb5I1QHidyeuiHKudKQeSBfptcSor8qcnsfJJ59uJEoGf/i36EeiKXgWpJUw5cb+6J+fzg8pHomQDlJlbJj46cgLJkTAlpgIDQjrKmkgJp94RnJ9bRGDGprkxpk3LPkwZE4wEEgQLItlTpCqbSkYpoB8moiN2G8dVkJvhamRZSyXwpQPWoo8UpJ4ymqNAJc+qBAUKMXV7cnv7lA8ZCBPolUQwBXu5naL5pac5plRxmP/xmsdypiXrFEx4hTIRHOVSqFTYDFpaGZp5NZnRhUWonoiYqJTXqiJpJd35nULLntDSiJMqCu1SNJOJmtsHEJcbmlKFoqZpRnfbSoiKCfwIoqybc721OM17e10WjH02j55BgJmJoYfJqHT3qr57JhpJP/4LmwZ8dUOMNQfOFgT4+JzL6Y0rkKm/y57Sakapaq5moaLa26rZuhxE5AAg6Ab2G5I5QW06pCAda46FmKFiwKIwSrFgZnLC2q5boKLwW63Di6KV06IdKbIjWGbbGJLBmQpK2TLw+yq56C5HmBpc+yrteLBmBEcO6nGKmZld2LMa+ycKWLETe0cY27IA+rKRZisg+isauKJsGiCKRqaQOypqy7NC67JtIqbqqK5bC5dEeXs46rcwqrdIybZtF7ZBCLdQBbZj67A+KaQaqrDl2bc2y29VOLZyYrcnYqMOmK87egccxDC3ygclxY9qeLaHYbbesrc22LTDawYwQYHgsi/97cJtx5e3dLmlADGzB4uLY+oO6RazESq4W3Kzf1sHNvMEUIJhi3JdpZF7PQNgR5B7H1NYEKkYSiFNW6SzibgnaRe7kWhbFKh9GMK4fvGjBOq4qFS1o0cGNWdw2wB4uEFABAK+VdcFmpsZSLUMzlCPr6i3agWzdwimjHu7R7a50VsiYGe+fpeL1KE7n2Oa5DpXcIk71Oi+CWq6axNyp+gfNuq1O7SD2AprocK/xCg11nmtjHM6o5sYt1u7/AnAW/aLUQW/ZTi/KEmQYruOAXQOrCQ0azq9lPBBQlKsTHE42TccIrS4q6CHsevAHiwIgXlIB78n6mq/1oqMCZ9WBNMj/OCBIsz1PK0aw4jhRd5hk1QDR820IETXva1wakwIfnpGwTUYa+86uzFxK9N7GBs/f2QZxuiWxAaNvCrtv+kpxbvywkj7xHXwtninxv0VaF8OGEf9k7gpi1vJGFu/oFo/xpHGGkXWRr9ZR1Rpkb6jxD7Lxmw1Cb11nP1iLHjDxbVTrHH/xIGgpITDxHddfHtOBGD/tiHVMSzCBE+TdxfipidQlMjiMqPJvQZixbbDrkDiyF/PHVDKcHWdnlTIyClsxb8Xhz1wUOpAN02TqEjyB2WxNmjZkibpMkETq8uHf/r0KXUYMBXYI272LWnEBA0pMGqzBXYrHERSdyzpS0AiA/y7nwSHbijYD4QhH8YiVYs4kxVRszudI4uUVAGz+cR6YsJRYLBK/r/7Mcr9J5mSUgTggQ86oQdBZTS2DTfKAamXCIwAR5m3kURRA2GACV3lg856Ycjez1BADAmW0x2aIBvWcBvI4Z06t8y5bnZSQLDy3MvYWBQG8ZjxIZ/iBwdh53DnjSK6W3XcVtG2UUcSJx92ZQaF2QTapAaFWIGb8RV4qgjuhk8VZAfgJsxIQs10OwTEH5hI8WBkwoJ72NDSLV7zwiDfHMx8MRUwQheCOx/70T7nJ1hO8J/kCchGfsBLArEh/LOldxkZDp0u8YEmnBAEh60tf2efpciKP0MdInP8roBll6gyncnSonutHrZ7o6NyPvQIz0PMt2zM2cIHpQUtlZioT7iZhXwPRtWAg9q1LQnJo/YyL/ALQpSC9LuiGlGThpvUBRwnPJvD1Yi//lDUSAqSioaFoYR97lBtAcvRlaJ9zzDRslFFxsR/nfVqYWaM17qBTCU2snpzlmXQ6ozRPqDQJbeasYsW+bcdcL0JMM8sq6+5W4xazgMVxfYAHjIDeQLGUJC2xmrdieKBZM2g8TIjCWGgcniC+6rWDjmAP30UZCdNCMzeJVOK5Njd3GG+y+hH1yPV1J0NdgwHnVHgzAgZ47xt1gF5WR/Q3QxV6C8RWkUAIzA1ZFKjdzKz/WwOU2ulBR58bNY/QzSnG/BTHYCM4Mp7rBa+0goTHBIeB9JVeS9i2e163budnF9AbuKrffObqcKcpeXeCRBvlSIiAQ8zGbCgEB5V3m1bxW5vhi9dxGtMftVUBMLziSX4gjWg4DmuXmJliDY9kCDohtK32e+b3FOw3NhgqvWb4dTtbgHs43oK4+o5EiZ94lm95K33pVdFxkaKynzAdg9cSaJMqmPMDNxtuHax3e89Gik+poxey9JK5pIs4X/WGlHvjJ4NjPzz0puOBCLgAC9gpF7M6NI1yTwYC3dqBONFKesu4E1v6LuFS/lHy/rmBBIZNT0ugKliT3cXdg8Bd5+aX/6EGnpHe+vkGXyA8Ze9qOl8Ae6RPraoDsx0QTeUVlNm8A3RoIfLC40e13katHvEmAIoplsdqO8fiAeh2bu5tck/3jAJOQQ4J4BUg+ymX+hzweh00tYI2tJZ8e9+4tv4MuyDkOtbdASFOJG5WRW0SBQT4Y1GwhlIhW3GDuhJ8o/8G8Mp/xADrU7a3urH+LjdkB9dgGz6Tg+KwgmAXIUMCLG7oSbeDHzigdYVMvEDAeDgy9OBua8Wv7HwL40QWY6dSp+WxhgyWfCc/fZfjwQN0MAiDfSWIsHTRtld0b4lgW1M8hWUkN4Sga8IjNTL0ex3uG1Cj7hgcWPa1k9yLrv5Qu/85lZPAE8Am47RPdwjIuUs7sB2gqgGNcS4VWEEy9B3i0KKq+1KeseNEviO702cDlVqLVDi+tKGam/zjMroeKLLbbI+oC8IM41WrLY46f1YNZtvPG3SpABq9By9GyWZnHoNiz/wJ0ovJOdXOywfON00uG/9g3zMXeDZP7ZvpGTYSXLbOxHLzQAcats2Hz7dEziFFNsD/mcYNywLeP1V6fVfWX3vbIknqm8zqq3Drnz1A0hZm3uP33vj3C4Jf6w8QFAACAQAwABCERyMRwIgQDEkhxQiwOpnXYRFQICwIxkKisXAcjEiAmJzYKhMMYkMINh4EBfp37Mc6OGBoayBiIFD/AlBoAGhQ4Ep6iKSstLwMCLjc5Azw4qycelK7FH0ERW3STOXKjHTlfPhjpa21vbUkmLSExe38RFXUYmMjYCiwG0IoKJhCMmhAQHCgIptFFVj13ZaNFPZCUtxyMoBYoDBQZGMajtQCwwNkpBhji8crBkNIJIDDG6Tm5N4YIhCKFIDAL90SCgmseNu1rZM2ia2A0TqGANKmaAgiVOSS7VYvIyQtdQOZUiUtXZgorgTgCeZMUCJpokJ55duaalimGEpiZJ8iNEkWdOEZsogBKxA+GiD0J0KRAVOcAoCaNAIEpnAA+BtDAIERoAWoARrEQI2Ao1gPiBPQB+LNKyZByqRL/9dmLZN2KeXMG1hiS14vV+IVrNdwYiOAq7UTB+HYgiILpH1UlIBZGaRbrsQtMA1rx4DLmimLAE3a2QGhG0xJsAzBwT/RClAG4GAZoEJXIsh+u+RAVUqE6fqViJhxyr20+i6O5Hj5dE7GKSG/e5E6yObUpW/XUnHddEaVrNPE7kv5dl/dUz0H9Z39fEkuj2unj8v9cvnTw0scbzm1zIvopvRwWS8/WvYDRQIJXoGOi/4UXO68ViKsKEEKa2EwsQk3BBEXC2E6cCT8QrykQ74wbOwaFCssEML7XrRFxcA+pDHHS0ZcycGZNNQxJBZZ8TEWFwE4wCAFRJEoAq9AOdKIBP8WWGKTBJhMhUcAikTvxCApsTEvHL8kU8svgSQzzEq4pMWxQRQgIIKj/ktloDotYeBKUJysxcy80CTzsyHpGjNQHf3UEdAg1bxu0L9cDG8KZgQ4wIA9BJiCAAfseBJJBsoyZwFS9njNHSQV2AOCJAYQQAEF1Dhgoz0WgONVo9wYwgFkiotxOUUDZZSmQg2lEVGJ2EwpgAKIYLZZZ5+FNlppp6WWiAIclZELZCtxjAAKErqigQakAEqARvYwwCEuDEAA3AJSg6CRqXKrkidjpFBruH7wUMScr6gBYxBBBhwAkgU20qnXK7ZVSdlqH4Y4Yon3wHamYYlF0dhtSrRFgkz/PgY5ZJFHFvmBB0hGOeWRH7QFPiOLi6CAgjt7CIvO4rEmZ0UoYDbAcJbAR2chFNDIKzAMakJVNujUkmNcPFY5apVNlrpqlFlm72KMQdRYvYopdHo6lzfpb7jO1kHinWvsVIcfF3/O2Z6wloizDzC0cGLpi5r+GsWwt75Ca8AV7BrBvvP7m7GxL3EsDSkJEeCjNqgJAymmIjFL6C9U/SoSuAFhoygFhNBTVz9ie2OcvRUu6XAQEwdc8MHpK3wk1+eDXbDFT3JRLNPgOGCZBDRjBg7QRONCtzvmxsoyBNq64vOgkzgmGeURAEuZ2ZJimvWYbgcb/EBln5292lsWn7rc/wPbndsoWaFzcL7L/55+nAyZOH/99+e/f2ob8F6y0ie2AZLoJSUiXxO8RKz5lW99xPKA1SQ4QQlSjYIXxODIPMC+Aiqugw074JASaD8uNHB2DyRhjlCYwkqsUH0fFGC2yPY+FmbJey6kDw5rGL4dxtBQJRhAEAfQAhQhC4E0ZAWfNlQvG9pncEAUIhF76EAYplCHghmBEAfAAjIdsSI4Yw/abGHCrWVRiFyc4gmrSEKG5cgDWnQBmdooofcdwA60OlWqjBCGBSCCC7EiQBGmlLlcvQsa8RhdA9QAAVIowHjIwBIBWAWJAeiqEaNZ1o68N8cvvVGIcUzj4K4YSjJ9QP+LIigi1tpURzjMgXr4EgQCKrWPElKAMsGrFD4MJipXKmAB6SBEAzhHgQPMy3RX0BccZnYwANByXgRKoymFiEpSbm2U1QySCYJYghflrj+MkFlPjiY5MEZmWZdSHU9wVYZeNoJnRPBZ9BQ4hzowMWGh1OYAuIlNjF0zhZx8UQiCOIJuvgSgAJBPBBTJBHHczQvlXIK5+KEGvfHETmBwwwDc5jl5dkEs/OhUCTepyq0JdAAE5WegoBhEKaYUFf6kCwmCuEG/hTA+78uc2RqqqSXQUid0Y4AolKlAnlwlK4vgAxk4F1LiqK4rUsrFDdeYGJkOgKYuDZIZg4hGrE5ka0H//EBBZci4983hXdIbw2+icQ1xLEI21KgoE1SDPCxsxADOg14TPJLO2ITmRGQEHFi7GiRPBhGUg3UisR5gAhq171GI5VViB7dYyOZImkGkZmUbZc0QNNamL9PsHqVKvwB0NrQoyuc+T3uhrYmABJ4dK+9WC9jWvna1IDIpSm/but0m57MznO1oezvcW1T1qruFKWIdGx0k3iQBktsQbYk7XU4IdrjJHexy6bicfHACjHmRLnXF+xfGEhe7XTWiCJtbC10VJWaZk2SrlKBHTBZhEEAZ5FkoRamUhHe8/42Jaa8LQ6hl0MAHBhlJbXdTlejGALHKDVbypdEE3AsqanAm/6baRQBcGgAfyyJFRfwLYPG6droH5cs5/bdi/l2rIgcdYSSKopOY0SMOQOsHHcy1PABA4JyZDJCIRxqYAiPYyBRUMImVnKEFAutrKH5sSnCmm+x11w8fTUT2JJoIisLkfIdRMYvFDDEXL9nM2bFfsHhrixiH5JIJiBxWaEmcnT61c/ANKlSDPJgA6q7Ji5rqmdmY5I39+Utqrp+2CL3dlKhmWey6DS0F4JGdfkU2RVCeW0MDVy8P+U+GzhGiBe3Sa/7q0F/TbuDWy88Ro3l2oqZJkY88a1rXOmqLPgwMTQ3oFcXWfcGVbJfKB+sfhXnMx0Z2sp9VZg6SCNQ6QnSqW/8E7MKw79kvIrazR82JbDtH19emUbR/S1ZqtzDQJQF3iLrdsHQDeN3v+XaaUT1u2Z621Uwe9rlZsWszv/ul8b7EAULKCT0tR9y+jnJo750ccL+lHwryN763nSJ9r5ndmzgHljihRMYcnLWgVbhwZ7SgZUWDOemOOMMnTvHElNpL991IrOjLR/7aio9/oLkaHJmQMEAyCZsqgyVZ7m2EM7fcm/00h7xAy0N6QQEOWMAvm+DznpdqUiHGRsVf2u7/pnwTLr+EU6C+R0RcuMO0DFi+8iVLdo2BDwLoxyLPVQCBU8BgCHPHk0nqRXuL3EDgJseAMvyFj/jLmKSTuyPGpXH/bmsdFPxesteDLfFKYM8n4iTAVQBxNC8IAAKax0M8ymEZIbSjM2BKHwLxp2zWJxuAk9f2go5BAWrQc8e8QcI7BfAMc+wmfjVx/C9WbgnJWwLK+z7RcJhhd8yrzQ94Y1bO4tGuhZyNqJV490EjaGvud/9jx43E8REE+IOoCssPjwcSNMqPZnJlJxwK/te5Pt7iK+5Emh/7To+J9n6M5QsJ2D+3+wPiGB3rO728qwXxGz5hW5ClKLuGgCo8GDuE0LMpKMA4g78NgTwlq7+WOxHLMwJ0qDS18iM8mLTtAQASFEAjUIDqKT1wuD7U67UFzCHye5zhubQv+J3mkYajaEFk/xCC4OEM+Ik/TNAOhXiRVZsOe+rA8MM1E9kGURiQUjCCKWSOeXNCGtySJ6Q8lfgummhC59AOVomLsxAPkLAnBQmyMKwLgMOFjMC7SoBDmPC4NtTC84qJ+buEL5wJNnyPMTSCY2ov4EGVAtiI/DKC96KcSSohKikVTbGDP0ikzmNBZGgkZOg8PSgmZtAvXUmNSIyE0cmkRYA6UanEBlhDrQM7+qlDixs+PNxAdStCXgDEHmsEqHuwoDKGK8mTDpNACRMECuOCBEi8PRA4QsBFs2ECXwKm3PglZWwNSqGGCzuCXTpGb5gCZjKkeHHGB0vFlnPDV8PCj1tAWNTD/PDDrf+jhNZYhmzEH0SAC8/7sSKIkwKwsSAbPd+DwRkjhjb4gzLgx6RIghqrh+sLED14O0AgCtaQQd0Jx/x4rhoZRzukQXNstIHLi3R8PEA0BknhOSmIxy3jMCoDHUqgvvdDgvSzqH9UggFMCpKcHtPLAwYICNqoBpVEQIeMPQppKyKcQYosR32LRUuISIObxRaqRR8bgrZ4MHHAno6UkjhruyPQOAJ8QZ6YFwPoR6MihKzsxyF4ijkzyBLyv7JgHq9syGY7jHSDRESyxFMJpEL6xH+4IzjoyVRoxUQLSmuzBFF0ulJUA0t5F0iAMMHElFPMREpRxCbwxEN6H40UPo4iC3n/AQ5v8SsWfCtIswyC2Ksr+MFkaAcPOyuemKtpZIYI+ErNFEsDDJdlwA1+EQLR3L20/JOHxAa666VfMoYksCWqsEZXEriviIo0bLyfdMWVs0jzyEZI2EZ5KYICVIRyucVnJAYQm0aC+U1CwL6jvA62JM6VEIVB2ITw1E50VEXbrIl9/McKq5K4YgNw+pwFmcjjnLjkpASEtBvmQYdq2JkrsIKA9Ix6vMex3E4N9E7BMCsQJMqMwEjqSMdVbMCVtIa2cs8UXKj49ElaSK87FEr8AAikgM0bqwYxwkk2gMmCZM2cVJCh7Lrz3En4gUGu7Il0YoKcwlC8TD3u7CH7JEuy/7BJRaAl01lIo0jBpfhKqVxNmVRRxDnH6UpHBdzIGoHB0pzRCjUr1JzRDN0GKKUuLhVDS7CN12Se2Ig6IciMzYAD0cTSLVBNFFVSITFQ6hCEFOwUV0ERjtNSwGFREEE0L9XCLqQFUSgPKvSUlYBM+aMOOwWj36MPPizOE2pS8zTOP/UVrvvB07iEBG1Q/dBRi7AFmTPEPYq6P5gVONAV+HI7tpA6IkiAmOOcPKjLSDhV/fK5Q0oNw5wCUOUcPvKjDBQMP6VFeZtUYO0tYo1ScYzTPskTqCBGtUuSowDAOXgwSBCIIvAXImCKKcDAPGil8hTOaS1SemkmSHAAMygCc/95JbNjO5+ST3B80cHJSzwktQ7Nt2RliYjyvM6DAKJxJCT5FlK1SXYoglOwQha0g/E4gH8NwZ5BHf902J0CPSWEU51cS2ElOnJ8RXpFVrA50C6AvoHsAz3QR9xDijkYOy5QqC77o0kTgvXjh3oRo51yPl9Vy4tjxfnUy4zly41d0Y7FnoZlpynQlTnVShAdg7F7h169Ahv9o8BMyaViisA8gKKoHP3rKYkVFHet2JudVHlNKR7dmkM1wjGigMvUHkyTDWKUDWo9iB3UAqKhhCtF2LXlwefJDdMQODTFvBREgLWSSK212Xq9WKDU2aTjWSYdo+8EiVM43ONAT4yJ107/rSGwhVzJRbfEpQvxFNyaTRZjaz3WYzZ4KzpBg0XP/dxjC90apFRVANyUkLVasyDvCwAujC2v5Sc8fF3ZtTXa9bPVHQIX7SfLpYQNrUjhJbE9pQTF5QLlhYl0McrWDRTb9S0O9d2/U4k9qwTsXQlxKMrEeFLefR3j5QRjvS3yrd7uvN5TJIWbSwoIMEOsuJRMATqvGES4pJRYjQu4K8z4/TlQvELxkl4iAd/zJWC+iFSeYMbdFBiBYYLfwBLpHIJmUJdk1MXeDM5e2ofgcIRznbtr/F/qCmDRLeARDtwzXKcEQJohUBqi0biayYKHCoN3TIQqgc+e6M8QTFGJ+F5r/xJfwt1CLTRfEkZejhqIjx2AT1lHeVIbhFAIcUhZhqKbllViGPxgzo3eHj7OEA4lLVYJEsgsbBpiLkACGQXaoVqAS7oCqp2TpcgCptTgL6AGnfK/Ia2cN92GB8XiS1ipIaqp0T0zLk6JEMhjBgSJZyANvULBZ+jbYdTb4zmL3wiNN5ZbMjDEMy2eHL5j4A0UrdqiPsZY5BzkVDCBPpvcAwZDU+44TSaTwhqAw9JAeqvPUAYFaSI1VKZDWxYMPCaWyxqAL+ahT47l8vEk2wJjXD4tXSaW1BIrYN42QK4IMxKwagpj4kJmQ8mtZfbhYJ4dKCqvYvbdag4U48Jm+mxmWf/eBBHQorDy5tUF50CxrhAh3r0cHBfQIvBLo2kernYmE8q6YuodHBbQIt0iJXzurR3up2gOkiAOLYVejhbQItUaaGMOLbElFhN7EYYmYV8x5xLWQoou3IzW041OFonWLIOW54UZ4PHCaI2u5W9WZVD2YzNz5gwR6bsw3dPF6ZyWltQ1kJruIlguZ9Ly6WPR3aI2aiSDXm3O5qCmIpA+6Vg76gNLaaRb6lGb6el1apg+jpvW6Yfh6a4d6iC56o0J66z2ZOs9NayuatKtotzlvtg16qk260Q5N4K+iXWTtiXzJ4fpap3+6rkWpbom6So2nJjW6yqyaz4ta8A2N8PltS3/3bvFhq13ZSGPZuxcc2xoQ2zJHueRTiPLvmzXlWvkS5O2Hm3iwujE3hDQDu3oHWzuEJ+VLmDVphDWbu0zee2KwGvOrizahjjeDm3Zvty0JusspMHUzm3wAO7LPi/fVondNmwl2+vkdtDlZuzmbjIH8Dyhgi7vFZ+8lm7E1o4KcxsDsFOJ6F5LwFNKcN5Hve2QzuxIYBe4a0G7ZF5D/W6gtmrxpgRUaQAd04MmvcvkPRLu7W7is27Ahp0WYAEX8GWkDDs09qUkmI1QjWA8arom0AMHcNX62gToZub9/pG/qpLIAUVAosdRZUxDAkWx2IONYF8/cACc02464DBZQYaB/7Pt916wWnjoEfAAdUZfSyAkrAgHtWBWfwHAZkorqlgWbzECbhw8BFdrchZxyt6jEsfNqLBgZ63GNuClqEDyXvRyMDgmsyAaDlMEhfoX2uRxQwmAk7maNswELdIiEwgBYh7uSgCjzyECfu3WevIMZlIL20sGKi/uEGfrEc+FEofByNBXGvXzfE0aQFA7G64CxsvaN8cYt/4YrAEZOxeik/FlNGFc4ewJJ6gbuBuKh1sHOTDTVt9UEF/rP+Zv83B0e8FXoqrQkOw8m4yXrcB0zyhQTsemO8/zsc2FPGsDeuyp4RHaZoDAzhmPY4AEO5v1/I7u410MBndwKMT1z3j0Jf8oY0nviZ/1P87AA6jIM7HI8i84RDc39ikqASAXcmW3hFNFQcvcnutppRwcD8m4gr5CwWL3hXj+aDEWonoPctIO97FsqxOkYsgoWxSU+JxxBOhiBjghnc14X9ad99tybsL2oXKU85AR9SDCcz0P1hwp2HYN+dUaedieCeFGL5JJ+QEg9WN9kUG9hR2P+Z4t7WM57YlDdpaPzB4C+qBXXeL2mrlm+Ht3eKVPcKYfv6FPdKv31Claeq1XH+puD21X9PeeeSi5b5j3+uwCe06t8pyd9yH2S1h98qkrlaeLurWw8UMqlbBPe+Va+58X+1q/7SGWgjaABFoCisMjvHJohDT/n1pVKddM7nu1x/qnN4I9biljH2L8FICGdQLdS0nmEYczcBzJn3ysKnsdDnxO5irN18MPJYJ4PIKNCtG2mgeslffTj+jKL2wjYGVX5nTkdfcNztZwpcA7E/05TkQ97Hrdj+9wC3xefnAeH+Iwfc7nyaS76kGFBBpDZFlMZXvnv12u7utp+et9owhljvnENoU4fF7xxyZPj2qpKfofvoJrXn9b7ogD9w8gCACGxKLxiEwql8ym8wmNSqfUqvWKzWqbpMHAsw2Lx2RmQFBOQwVCtfsNj8vn9HrR+7Hr99czX832JzhIWGhIJyFh9GBy6Cjo94gVKFlpeYnJF9BGFBCS/wlaFhn6REl6ipqqWrRpJEKyGgs1KmtkWoubqyvXuuuLRKt7+0tcbOzUe+wbnDus/Az9mxxdG1AggJ2tvc3d7f0NHi5ewEltfq46jZ4qsen+Dh8vP09fb3/vrri+z2+p3g8woMCB/P4RPIgwocJUBhc6fAgxIp2GEitavBgNn0aNDx5s/AjSHsaRJEtOGSAupcqVLFumHGAypsyZQ2AetEkzp86IOAf23Ak0qMCfAYkKPYo0mtF+S5M6faqr6T6pUKtaJUUVXdarXLse2moOrNexZOuIVVo2rdo/ZwEkIAAXrgEFCrIkiMAkQoIlBvZeabs2sOAqbRUIaMAA2wFsWf8IFGBSgMARx0PuYgE8OLPmJZgpDxEQoUFkAAcUEEBDYMECyQAEOCgQwYBoyQQQCChQF0Dq1UMiO2BNwIGAxARKfy7QwC8UzJubO+/8+PiBBAx0U1gg4ACDA9oPABhQV/X06gS2G2CQoHt3AL6jF3CgAEFxyqHdOpDC3Ln+wdCJMP6uW3QQoNEaBAC2RiBMnmEz4GcGjraddgEOQRkFBhC2X4YaItHfZwlOiKCHB/6nYHTaiDgaBA1EYKBnlOWX34YyctVhiAB6lgACve1lE4kgIpBAjjuyJ9l5DFxYG4WP4VYZfjM+qV+NPnrWGgK21STijRQUcGWVXY4GwIpEFID/G2UJkPmek1CumVmMfGxXhptszqmTnHYo0EAadtLJp0l7RtVnoF39mQuhgh76kKFi0BUGd00oimikN8WpxX9aMMoEpJJuChBRqSF3oQG3RZDbawvsVdptLaJU122nGqEAct6VdloRoM1W2QJppsokABGQeV9rix0AV2uv5XmEppwuq9UR6QGgoq9oxAqAAwsYoJ0B5RFwHncDEJAABAvYV4QC15ZnHXa2FjAeaQgcYEBk5SVw3l73dfvdNYuhAR4AC+R2B7MCx0SUAeIi8JiFEy7QADYMwOWeZDbFp4ByQ/DG3lvR2fohBNfcJsCCqP1KgcT+8ZtlwAOvjBFRCECg/+1jNlFWAARxxdybyRRGkFgRYMq78clYHhYXsSa6BiSRB4bYI4Eqsww1T8leSK181T4mwLgAYOvZaANcSO/VRUCA13kgcoxleRe65RmQoG1tNU6MNZ1s1HYneoQCDCD3WI6qRRcBwu92LZkACETggOAWy2blfVQKfWB8XP625ZUGILxA3ELTbYSyd3++SlZr43nI41p4DnrqWDWhN5lrF2J6FqirTvsls59ye+26f4VQ7rv/LojvoAgPfPFm9W588r8Qjwnzyj9P6aTQTx868tRfj7v12G/fvEvefw9++M5zT/4TIZ2PfvrqU1R+++6/D3/88s9Pf/32349//vrvzxt///7/D8AACnCABCygAQ+IwAQqcIEMbOCGggAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38913=[""].join("\n");
var outline_f38_0_38913=null;
var title_f38_0_38914="Palmoplantar pustulosis - plantar";
var content_f38_0_38914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmoplantar pustulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDpjH8+eg9KSXAQg8ipnXHfjsaTy9w+euGx72nUytmH465PNSBCyEMMkcVakgC7hjAPP41VDMj7DnHpSsN6jfLPln5Qear+W25jtwK0Yl+X5qaY+TxQZNamRLAXGAMD1qu0RDgcfiK2ljOSrDg1DNbAnKgD8aBMzzF8uOR701kYrtbBB/Wrip2Yn6VIsIZSeaBJGP8AZFY5K89qZNbFiq4BA7YwK6D7Kvlggkn0FV5bVnTIA4PagGtTCa2CAjG0ntmoFtdzbWJxjityWLLDIA+vSohbneGxj0xQTyoyo7dVV0IG3+VQXFq6tlDnA456V0KRgSA7Rzx0pl5aAOCMk8jr/OmieVXOWj04SSFyqkH8xUhsAYxv4Vv7w61vWdsQrjbn5vSp5LQvnfwAOAefyoaL5Tg5tLZJyE4HfJp9hG8FwEGwMTneVxj2xXZxaeHLEoGxyc/1FZ+oWZWZScBAcAAYxUNBa+hizW0i5mZQ7LyWJxmtTS4BLEqSfIjgn7uAD6VYhhjByfvjvjOKh3ujJlmO35c+lFx8vMRXWm2xxtibd3BBArndb0WJgDt2k+ldR50wkIXf5Z4znmqt9cyumAMqp4zQkpF+ye55hJbvZTNncYxxkDOKvW88csZV1JX1xW7rke8hCiRs3JdQc/n3FZVlaD7SiSKXAO0rnbuFDRDhYry24CkxEbf7vY1HC6I+JYtv+0DXV3tnp0L+QIpRsXLNEwbJ9OazLfQftqB4rqOKRiR5cwIwO2W6UNGdye0hUoGiKupFWzb+WA233qnD4c8QWUmUtS6DkPE4YVPBrLq/lXsBLKcNgYx9RUSKjboWUeNjjqe4NXUaOUKgiCmm26WdxhgSgI9MVfWxBGYn3j1BqE5Gziit/ZkLkt5ec9ciqV5oMbKTD8p9BW1DFdRDJJZadJeFWAmg4HUirdmZs8+vNKKNtYbWHfGDVVQ8DBW3Zz94V3l/HBdqxAIPauWvYWt3Ifpnr6UJWBF6zEzxgLIrA9RVkWLE7imzH8Sn+lU7UJ8qyjaP4ZE/rWtFcXFty6C4i9ehFFkMuWYMUYDuHA/iB5/EVcjmMR3A7kPYdPyqK2bTb7GybyJ8fdfimXUU9mu4BZefvoev4VSMpGtG6yjdGQp/uN/Ss7UbRJWIkQox6Ed6gg1KPhVIjk9HHytWpaXH2wGNgrMP4D/Q0yU7HNW5ns7kwyHaM8EmtdLgocngnqCeCKXUoIpR5Nwu1x91iMYrLnMka+VLwR05osJu5rPOknMZzjtTWYkcDOeprKsLny7ghhx0IPf3rXHAJAypoC5B5eMEjjvVa8iUBuBsPSr7LhSF+YEZ+lU5yDGQADmgDBurFGIKD8qz59OAycHJrcdWDcDgdahcfNtI3L6+lAHMSxtbnGG2n2pryrIgCY49a6W5gEkJGPyrDNismQvysKQGVNCrEhsE+pqhc25jUlP0rYu7WSPPHNVFYcpKAD70J2Bo+pFQ4BYYB4/z+Yp4UfxDg/zp52AbWPTp/n8qax3kDHUZGP8APqK3aOt6sglUt2zjpUUsKlgcc1abHOM9c1GxJGSRkGpHqiuw2KRUZDA+oqyUzye9RYP4Ck0IYAGFNHzcY4FSHGMGkxtbaBkmmTYjNsrjpg0nlbVwBzV2DAfGMj1p7xjkjNKwihjbH74zTURs98GrBj5AOal2gAYptAZ8kRwwHCnrUaQqTkjgcYq8y5bjJ9hSNGOMH8KSBrQovDkgJ25xTJ4zwT0q2yAev4VFMSflGT3NVYjqRxRKuHxjPanXMe7oB6datJGHRcAZqOdGQc9uaNjayM6EGN2U5GTg+4pLqFHK+noelDkl++M8mnSsTgHjgcYotctU7lCW1Jk2QqucYGTjNZJlCzskvyt0wSAa3LohvukK69McdK5zVLFbzG92353A96icX9k1hT6M1reNJPkHQjiq11bxxqBxk8807TDIhVHcEoMZPWn6ukrwKbZlEg6bhkUnorj5LO1zD1C2WcblHOOlYE1rtuAUPXOcnGK61o3k8oYXfjkjpmsi+QRSkuDjPJxxQ5aakOGtjKPzNvLFWHBINPguZo3cmTG7g7j978KnntoUcuq/Iw5Ga5zVGnsbnyXjLwEgg1PNIn2aloddp+qXunozWlwdp/hJyPpiuZ1y7F1rs17K8wmnAZwPug4xgD04rSsOSEcsu6orqOBLgpPjzOxIok7xBYdJ3SHabqcYVY5mZcHggV1Gr6TLZWy6jp2o27q2DJFHKCVPriuPOlXCsHhwyHkYp0cc8TETEgDsB0rJR1uS6et0zftdZ1FTuKCZB1yv9a2I9UTCm+tHiL/xDkGsaxu2e2KrJ5QPG0IMNVpb6MsI5UVj0wapLuzN05PZGzNZ292heIlTiub1TT5EyrqXXrWpbskfzRPLHk52qeKle6aRiJVUp64wfxqmhRg09TiIJHtZDHwYz/Cw4rag3Oq/Z2Az/C54P0qTU9OjmBMeN3YdKzLbzrSTY+SnoaWxTi73RqhIZsrOvluO4FPNtNEmVdmQfxIelLDKsqDehkUj6EVJErq2YJN6nrEx+ai1zJt3Mq9Fz5Z3ot1H7cMPesy2v7iCYSWkjHyzko3UD0roLhlZjw8E3o3Q1galbkSebGfKuB3Xo9NIOVM7aw1e21e0EcxxIRgq3Wq+pQGCJRMC0Y+5Kv3h7H2rgkuz5wb/AFMoPbgGujtPEDtF5Nwu4Y49Kd7aMzcbFC8meCRWDggHqK29O1ATRKS2QOMelc9qoVsyW4ATPK1S0y5ZJCgPfoDTFY7qOTY2CcKeh9DSS4ViRx3NZcNyTGp3A49etWDP5i/ITnuKAC5bOWJx3yO9VY2SXcOARUrnEZVWOD69qzxuWXAwCfyoGWzlQRjiqexRLnGBmleVsFWOcHGR2pqEHI3c0hEtxEjopxWTqGkiVSVXB65rWjk2kBuRVv8A1kYKgUMD2xlxkOvTrz0/zmljTIGePl/+v/jUzAHOfz/DH+FNfK42EcH9K6GdXNcjPAxgZH+f6UhU45HbI/nTkXOM9e/P+fSpQyYGBnA70rA2VWQqCRyOmKikQ7SR0IqxKcMR2HFRgls4HFICpsJDZHNAUgHPf9KulVxkD5qhnj3EcYNIFqRwgqw571bVSMjqetMRMDjHHFSrnC7cdaLjaGyoAM45phjZsAdPWrHDYBHOelLxnA5HegLWK3lgjAXpVWVSJN1aTkDsMiqVwcYzzmhCCN1RW348psB1PeqDAFmBIx7cVLK3ybeiiq7kkgjvVBGGtyWGVVXv1xmllJkG0Hk+tVWcKOSevFSiUJDubhzkfMO1BtyGTLIyOFGD3wOR9Kzb26mdmjU7GIyDU8rsbh2H3ec4HtUckUYkR+F565pPVaHbTgluVrEXTxZmxuX7309aZcuEj3jkDNbNpseQowJGDkDvVKe3iVWXP50rcq0Jk1cpWE8b/OMgH271dkkAjx95Sc1RniaKMCEDdngHvSXayTWQVV2knJHrU3aQmlLVFgrJFMs0bpLH14/lU09nHOqMEBQAttPr6Vi6X51tcy+coWBiSq/3fauqttktqWUE/wAJHYGopvmRlUg4s4fXB5DR/LuRuwHT2qcWrahpqzbFwoyTitfWIEWGUCNFUkDJPf0qtPCUhRYwyxKuCP6596mLfM+xi5XdjKjt4Aykl/MU9R/WpZ9OS/dS2RIo5wKtlCbPARdwfaG6GooEMcqOGbk8cVLktmaRk+hQijlsm2yqwU9BVuSOOVQ+3IPU1tahCkoWQpncuc9f8mqEunuqgCaPd1AUnBFPmtoJ2auyhbwRq/PytnP1rSjt4J4vL8lRL/z0zVRYN7MjqQw6jpWjCvkWgkKk7Thc01JFKyRCtu0akE8CqcqXK3AIO6P1rRtbiO5JQMCwqc45GQvv6UuZNaMpRKMU8UknlSbd47dKhvrJZYyyDjP3W6irZtYmuPOfBccbh6VeUxY2n7w560+buTKK6HJiGa1b5csp/hY1YHlyABdyP14NdDJbxS8AA/0qnNpYXPHXpimn0Rk4IyZGkCbZlE6DueorPuLYyRkoSV9DziugEHl5SbJHY1XnttjgpxnnNapEOKOG1KNgw3Llh0NVbWY7iEJU5xiux1DTzcIVG0EjggcGuL1LTLm3nJUFZF546MKTig9ndGg87AfvM46AjpVCYSRyia1IOOSBUulSSOrJKM4HKEc/UVNJbsg8xQHi9R2qbWM5Q6FrT7xZwGViJP4krYS6Urt3bX7NXJNbyLIJrfkjk44q1b3vnECQbWHUCjYxcXHc6u3uI5HKXDbXx26NUN5D8geMjd3XuKy0mEigg/OOx71Yju+Nuck9zQySgWlWXBJB9Ke0+1s8Z7069Usu9RkiqJYvkHqP1pDL63gLAZyfWtS2mKqMHOa4iXzIJS6swwa0rLU9wQMxyKBH04s3KjPfIpQ/PPOf5dKqKcLjHOcdelThsqA2M9cVvc6rWJFK+XyfmH+f6GpAo8sAelVty7wPfH8jV0KVjBB4x/UighuwyeMSZYcc4/SmInOOwq3GmIfm+8cEfTpUJAIyMf407E8/QhK4dsjijy9/VfwqeNcfPJkDHWmglgWXpmk0aRfYYilTk4yaCMOSMnHTNSJhyo78GnuDnCjPPNTYtPuVoVJJ9e5p5GcketTBcA4x/jTZPu4GKaB6lS4c7SQPqarsem6pJcnJz0OMetMz+7B2nrjnoaBqNipKwLHJ7CqZZmkwin5mwD2PFPvpAZi3Kjt6VQklkEkXkgmIgiTjofX8qnmsbwhoX1h813ywEa8sg9R61lNcPIwZwzKo6Z6jmrbyusT+W23eMMR3B61lSmRE3jkKSAp7j/OafNpcuEdW2IYvL1PzOdki4xnvipJLbdG3GXXHy9DnuPyqG0upBCb6RWYhjHhewxn+Wa0HfMIljkcruGMLgHvkUlNOJdSTWiHWlpJG22KRJRt3MOjL3xz7VDqsaiVJP4SASE53D2qwt+HSG3tUtUcuN0pxvI9CeooZVlidFUhcbozjsTSpy57pmEZSk7yMSOA3Kp8hDkjgHoauHy/MEDAK+dpOeM0+VTHG+cgnjj1rm5rq9h1n5kzbkFQ3bfiplLlNYpybN2e0E0EsauEJU/OvPNSaLH5Vm6TqWD/dOcEc0tjcyP5W8ZO0Kybe2OefWr9vgKyIfkPQH+VXFX1C7tYxtdTbEZEwSFPanPbMul2kjxnLxhgvr6VsSWDamfs8bRJJtYkudo6Z61n2ds1xpiiScjyHMeC/THIx7c07XMZ2djIayVdxfedw4Ud/Q1V1KaaC2jtYEMoLb1bGCvqK3pIfMtCQSGVMnI6MODV2CKOW7j8xAI8cDOTnHc9/XFc84JkRlZlCAM9jDGRg7Q5Ujkk//WqoYirct8+cEMOgrfaEeYdqsmOoY8/hUF1ah2fKDefTvUTKuc5qrfZZInZx84wee4q9pMsdwn2eUlUZTggZ5xxSXumLfxRBmClSQNwx9P8ACsyZZLaAzR7hGh2Pg9DU3tq9ikrq3Uu22lJbXLSEMu4/katyQtNGw2YkHQgZzUuj6gL+1jUnc8fy5K84q+6hWDADipsraFqT2e5lXUUaRxwlSJjyzZ7VmzWkpkVo3PynoO9dPf4mGDhigAyBg1n7lgbOMNnPPrWTdnZlQloQQzAYHRgO9SJLvJwDntUF0iyXMkqZw3OMYDfT/Cs2W7deVbjPWtVVUdxez5jceEFelRNbrtPBxioLK/8AMXaGDMByCOtaccrOo2riuiM7mMqbi9TFNuyNwNynrVTUNLWaLO3jHpXRypxnbhqjKCTgAGtExeZ51caWYZdyjBB4Ip8MRKlhw2PmXHBrs72wBBIA9ayJbTY2QOc+lS2I5qSz2uWjAAPVazNQtG3GaH5XXt612j2xdT8oFZt1YnGcfpRczkk9zkorlpB8udy9U6FfpVmO4Em4Kdsi8nNO1bTHD+fb/JMnOR3qlFeJcnbcjyLpeNy9DVWvsc04uBqw3SkBCCre9K8ayAsg+buPSqLSkny3ULJ1U44P0NK162/58o44wBwaViUyxJAkgYY+bGOawNQt5baXcuePSukhkjuEOwgSAVSuj1WVSWoTsG59KkbmOOvB49SDmpJCFYc5B4NQwt8mD7ZP/ASf604glwT0NbJHU2OUF+f4uv1rUgRpIlPbJ/OsoFVwc5z0Fa+nBmQKOTkkYoRnPYnuowgCofugDPpxVQxOyCVsAZAA/rVuUFX+YZYHgduv/wBamgbnYkf7XBpmKZWnLMFGc9jgU5LcrxgluuBzxU6IckAEBiOnepf9TEG5aU9FHvkYoLUyrFDvkwjAHHLdgM1IEVAETO0nGSamlUQRxxhiWcbm+vp+FVppMjA6A0jRNse44w2MdDx0qvKDjA7095cqAcVWuJguCoZiBnBFFjSCdyC4QM20E569apXMmAF3YVRwPc1JLch/mZVAxjArPvR+8dQSpXjJOKl7HRGPcgnZGJWUkADC8dT2pRA8durAFo3Y89sYx0poiZkiQzKQwDhlOce36GpL24DSSBSPLizGpA4OD1/GlHVmm7sinciSYpEvKs3JA4H1o1ayee1cW+FaJTjB9KcJwWWNgcnoR0rSdlWxIiQCRic/NjI4x/WtOVNGkrpqxR8PqghuYJwoDorEHr35H+e9NKG3iPljkLmMkZ2+vFNsXbzm81Pn7NnpzV+H58dN3XNCjzRIqRs2zm3sWlvPOCIsm7c2wYHXt7VstKyu3lj5M446Ae1NdW+0EEbecAdM/jVl4Nu6J+h4wPUcVEY8q0FKSSKU8BLHHzI3Ttmq5txJEIQEPz5BI749av3ISJxEu7YOFGO9J5GCX7nr6UktSUytZho4goY5P8OOQKltIn3SHGSp359u9T3M8FrYJ5khWfdxwOB6UulSi4uFERLGT5RtGSa0jvYcW2mydrhvLjgQ/KRj5Ry31rnoG+yX08JI8tx3HQit+Z1WZC67QrgNx0GeaztYgSGSaEKGYtkN6jtVO1roTig0yaM+dbyrh3XcjZ6EdRUtzbbFikVy2Tu3qeAwPSqmmqTd25TGSSuT9OlaU0JAZCAm1ifc1z1Y3iZyik9C0VjIDgHzGIYN6e1QXCFwJOfMB9On0rQsbYS23lCV+AWULyT7VBEY3lVJAUB67eorJRuEdbmJ9mllkKQoGOPuk9vSqENvLZyzLcqPJCkPE4xvB7V2EmmS28rKgOcZ564rF1yYfaTbEEM2NhYcD1I/L9aztrZkc6vZGLpKLYXJ8rMcTHkH0rflhd0Vwx29c+3rWVcDbO4KkKvTI6VLExZFUNJsHcHp+FHJbY2abtJGgsO6J1Eu1iNgYrjb/wDrrPhsJJ3EcgyQcbgOg9c1fZ5I1DBEcEYDDgEf40+Fp3kRYykcB+9x1/8Ar0nTvuZ8ziUL7T5bRdgUyqzYVEGSD6/Q+orMvPD7rbefkjJBC44FdFqSXKKqWlxIVBJjYDlQeoI7VQtru6jJhmjEwzgiTJBz29qz9mm7F05zeqMCHTtsiyIxDDjNbVu+wAFVxjuKnlj2BDEgCuMEYzzVcqwkKsrKTxkjGK1iuVWNZS59yZmDRsRkepHeo0jVQVByPUdKlRPlG0g56io3Vt3IyBx0rVOxFraIdLCCvPJA/Osq5t8qeDnNbCjCjPfk/WoZU+ZscCm9SFHUwmtgDknpTLi3Bj71ozRjknmoHXB+tJESRz89opzlevrXJa5pH70SRDY45r0WaMbSWFZ13arKp9DVJkOPc87gcyJ5U4PA/wAkU24DIB5uXjPCy9x9a3dR0zb8ybsg9KzHUoMYyp6qe9UpKxzzptbGZFK0Eu5HPX1rWWb7UAxHzAZz61QurA7RJAdyf3e4qp5z27Bh0FFrmWqPqlUyGweST+v/AOo1JtDAkEgN69s//WqGMnAXd8o5YgdfX8+lXIyGGGAB9Pfv/hWp1sfEqs6llyPb6/4Vq25CwKVOGYnA/EVnIdqbhjJ4/H/OK0s4KRspOxAv4/5zTRjOQ92YoGIwx55+lQ52rkk5zxmpJXDnAJCeh9aYAu33zz7UGS1LEBC4J5J5BPQCmRsRLvJ5X7v1oiGEOARjimyK7MTnGeRQVFXIriXYp6lj8w/HtWNqN+0AIUZKgBgD1NaM2+NGbq2Mp/WuJ1C7f+0CphYF8gNjNKTsrnfh6SkzoUuzJFvzVaSWQQCXdjc2BzjHrVK0cxHyy+T1AqSfnmdyqt1AX9an4lobNJbCsxW3eRSSw+8vUD3qnqFwxv2DY8qQbxznJqzaOk8MsUfVAWd8nhfU+1Z2Pt6qRxGrE7scntk01e9kEXd3LUSqJAY9nTPFXLSJHhf7WAE5NVrKARyDbyUOWYntU8twHRwQFTIJwc7qtR6sb10RQs03TFACIl6se1TTBZJWmG4ZPAHpU3nhB5ar8rdcdqmQwStt3/KMnnrn0qla1jbmstSgkwhgCMQWkmzk9lA/qasiMxykvnBJwO9VTbbLgO5yx6+nXt9K0UUOhklyVwW4HFJLQipt6kLSP523b+6HfGf/ANVXjHiKNgWUkHIPIwP5VXhb5ypQBSM+hq5IjeUjqNwxxz0pR7mEinImx1lmGAPukU/5ZY2kRg5J3MewqtqBd7dwAyjOznv9KdYQeVB5cjckZqXvsU4+7co6pYm7xgbyDjGOoq/o1qNOCtNERxuGScjHTBqS0idbvDEhRg4q1dCVbr7Nck4iGAmeAKXJd8wpX+Ez9VUPbPIJt7kZ+b7wP17imazE4ht5XHzlBkj/AD9atvHH5IUJkk4JXgkU+aEtC0KqWUHcc9Rj1q9bD5tjC0tC93GpbaRIuD2B7V0uoRFpi0kRQ4APbJx1rnkJjnDFcEMDj3Brrrwl1EkyHe4+bfz+VZtXM6j95NFLS91pJG0o+RWGCDj681obRa3UzhXI5IZuflNZdxLctBHEuwwh+QVJ28c1pyvugiJ5yoBwMg1hHczs73Zp31tPeRRNGgefIKPwAcDpn6VyHjHS7hBFeR5VFZQSeq5OAT+NdcjK8TWzu0OwblI4A6EVleIZTe6BOLhAkqyBsJ0Yjv8ATitnTTWplBSUkjz+9vJDemJQZZZDtGOp96kguQ4MbgpLGO/8j/jWqbOGS3lW4twomBywODgjsR0NNudIaN4VigmZlQAyA7uB6nvXJNyvY6lNbEOoTtHpUZiT96hyQDwQfWqFprExP2PyyxcZBUZwc9K6Ge6jtbeJ1+VwQGBHO0dP5mpbuN5NKhnEarh8xsBwDjtiqs77kqUeWzRU8xtofbIJ1XDADg+9UBciaUb4n2k9Sf1rWttRZC3mnzBjDBhkH3qvflROrwRt5RA+UnI6VUVdcyHBWdrDzdSQXECyKAefMAA4Pt7Y5qnIXLmTcWLMSSf04qbU0ZLOCS3QuikgkDnPvRbgTQxvhvM5zkcfhSad9TSK6iomfmwAfpTXiB5ycHIzVyJCByAKGQ46cdaoGZ5TaNucionUk1feP86rODu4AwaBXsUJU5IxxVZ49xOCdvYd60ZwFwccVW2qzZXqOaht3E7PUpNbkjJIx71VkgxgZBzWq6Anr0HrVeRc8gcY9O9UnchnOXluCDnk+nase4sUHzMpB+tdXcQhjljgnsKozQcYwPejYmxxskL28nyjgnkVUvrAlTLCqkd1rqru1DHGBz6VSWJkGw8impdzJwuj3JGIQHHPGV9+w/CnQ7s4PJ6cf57mqkbN0B+XBwe+KvQH5wMYHX8B6f0rpuNovwxbmRc85Az+PJ/p+FXnlCu23Jz/APqqiJApUYx2I9PUfyFThizsGHIPQdM00zCaJUB3biOMVIrcZHekVT3APpTmJYkkAZ46UGVySJ+xyAemKljXed2MqnJz69qghy5AHQHBrTSJY4gpznqQD+VOKuDdjJvFaVGyeB3HHNchq1srzKyg9ecdq7m7UY5HQdK5rUMICchQB1pSjdWO3DTdzl9WK2stv5Bw0q5Oc/Kf/r1Pp/mXN6fPI8lELl+y4HT3qO9tzO+QzGI4bGe/rVQyFg0MZO4dcdqyiuWWh3cjcdNyzcLI87RwNhZMhwOh5zj9Kt2+EthCOVzuPrTbT9zCzTMCSBGuOw/zxTJB/pJYZVFGMtW+i1ZKj9kuMiuhKEIG745AqvFJDASZGMuRtU8U93Mto5BAKnOQMYBPQVX07TWkmfzJNyHlT3/KiTbskCWm5Zt0idthBaRzlVq9Fa+SkpYBZAQBnkCqkxCuSoVQoA5qSwvGnYjYFKcLn+L/ADmmlZ6jkm1dFSeGd7iNVIMW4k56mtldogLCMLHkqi+g7mqtyJOJIEG0Y69s9Ktug+xISCpAJfj+tCVrkSd0imm5sgRrITgrtNaNsu5fuhvXjp64qlMRaW0bry8p4A7Vf06JlthJM6jOR7+p/wAKlb2Mqjdroq6rBnCnlV5HvnvUcKN5YBUdMZNXNau/MjiCAKCTk9ieP0HSqRZyxjQ4yM//AF6F5hTlKUVcs2dqP3hJ+YnLHBOO1LdWHkhXlkO5+cDt9antC6pg5xjaT2zUF00pclpDlAX/ABpy0Vwlzc2jGRR4dY5AAcgg+uSKfeSQJBNFcJuWRvmI7jp1pdKhmvJVRlKknALnA/P8arXakFlbjDFeuaL3jdA7N2bM/V4z50csZwjx5HHeuqspxe6XE78yKm1sj04rF1O0aK1CZy8Zw3p+dWvCMkh0yXfsCrL94ntioatL1FP4RsIAMwVd6od/XBxg5+vFTaRcGWO4jVYwo+decDHTj8xVbU5msZX2fMr8fL159Kr2t5EmppJHlSQAwI9eDXNK8ZWGot3Ols2DKGKgzovyNnrg9x34zVjV5IpY44o1R+MghcdR92sy3jMRD9Sfuk+n+TVy4Tz4Q8eyJidx5Pf/AOuK64bEOCvc5k24j3xYzsOVPt2pzSSpaoolfy89jWrcWlywG5owU7E88845/H8aSBYljEjwlwp2vtBzjqG9KmUL6IuTTRgOJJ/3U6pJCpyDtAYjuAf1rYtZIgqwXfmmHGzO7jaOmB6is++vg17sVNvRQCNufrU5jln2BVJZTjGc1mo22BxbSuR39pDIjSWkmYwdrbxzVQQiJUV8qMdD1xWokbz280QULjkD/aFOs7Izru+XK4bLnoff+VPlaQ4txWrIrlFkVFkQoqD7q9z6/lSLagAiJlYjsPSi5SZRuByQeQ3Bx2I9aVSY2QhckY596W5SVtiNoivbk1HKMDGOOlXJ8GQ46GomVTjjBrMooMjHORgDvUbRcZHTt+VXXGBx/Oq7j5CSckdBRYlmfPDnvwareRgnjnvitMnPA6dQDULghgcfWk0QZxjwOe9RmPrxWhIoLHkY47Ux4gqA7lO5sbR1HvSSsDMmSEBTx81UJY+TnOB6itqVRkg8ccYqjPHjp271EtwMmWEBd23Pt6VTktw6nAx71syqMZwBn0qBoeeSSCM/SpFY723OYwcH3zVy2fDZfOexP86rxnaoHIHWrMTcFmGMdq7jGTuXEc7gDjaP0/z/AFq3aMRKQDjP6Vn2vLDdn1rRtwd2AAACOfWmjKVi35uR/s9PpQXxkYAbvmn24znI6HvRLGG2hOWzjFMx0JNPCmXnqefyq8o4Y+pzVWJFt8gZaQD73b3FOknESfvOwzyKuKsJrmehHfsQn3q568jjkxv5zx1q/dXUcyt8xz2wOKxbtm3884FNndh4OO5WngRQ23gHrWUNPXzXI+VzyTnrWt5LMMkn/wCvVC5triO4D7S27gKaymrWdjui2tLlPUnLbFjT5UGB9R1NOgzd25W4LbFycrycjtQJfNaaNUxIF2nmr2j26woyyso2qXJ7YA7/AOetRzO5U3yR13KolDywwwKiQRDpnJJ961JIZIXiMcQZGXJbOCB/nNZ1vYobtmzsjL8A9eT3rdmcSS7EGIwBwOBj0raCfUUraWMu8Q3EJ8oY9MU/TIZbdUDf6wAs5UdB6A9+Kv5KyxqqgYGCcdfU1D52yVdrOWI+de2M9Kcld3JlJtcpZPlyTGRZGZVBLIR93A4XPtUcMx3RjcAp655wPerEJKRkJAsTSklpCPujrx+WKo30bwTukUobB+ZlGB+AppWMYpPQmhjSW78mFhKNzBW7YHf9Ku281tKpt0cZ2EEkc/l71V0iMwTiQY3EMOTjkgj/ABoazSxkZ3ZHcn5yT29B71EpW1ZE2noSvZNNaSrcKGYDKEdBjrVBFYyxxhGOzg5PIFX5LmOaJljBDMc4Cn0zSafJCxZsb8cEk5GD61PNfYUW0rmjZRuumzOPlQtt5HXHBArNuJCsshblCP1BraMqtbmBQAiAuBnnjqB+BrFaJzKWVC0fUev/AOqiT5o6mcHe/MZ2iwzQTgMzlcnlm5OTnpU+oyutyZIyFZySSO31qVDw5JJce3FVZnZIWOAWPCk9qlLljZHQtXc6RrcXmli7KgNND8wX7ufU+9Z3he2zBMjSEMkuQp4HI9fzrc8N7p/DMKLwjEo2R1BNZFtiy1C6t2GQTuBJ9Dg/zFaON2mYK75okWt2mGfPJ6gDn8qxVG2UFkJOOw71paxujmI8wgD5hg9vSsOXUBbbmZ0yzYTe459veueq4p6m9PmSsdlYFZ7fymZA4HfGfp/Kr5jjhMYgLbQ5LDr1AI49M5rG8MtHdyjz1J3kodowQcZzj0wK6f7KWYiCTe6gA7e+PTv0raGxhKajKzMy7txK26XDNztHqeD/ADz+dLG5CkpyhUqcnaSO2fw4qxceZLt8wDA4xjGPf+VRLCXIIA3ngADv1/xolHsJ2tqYuuWImtoGZifLPyyHkke/+e1ZCDylkVNySjIDDpj611GrWrjT2G/pgnb0rCsQjTY5GDkBwMVl1sVSk3GzZLZSGKWNtxLE4PvV2NCk8xUnyyOSOoyM1myAxE7yCQex6VvqyT2aCAjDKAwxye4/UGtU9C5aEEVjFJhvMKDB3Ej7p9vXNMOkuswXzUYj5hsOd3sKmgdlZCpyV4wee/GB+NXooTM29FKFck+o9/z9KW4nKUephSI5y7YY5xmo2Q4OcE9Me1bUsGGJC8jkjoB9Pas+4jkUg8ZNZvQtTuZbjB4GPSowNwAbHPFXZ1ymQCGzncapuAr7twyBnNSxtkTw9cDHfGc1AygKcEg9PrVrBbIB6jOOlMlQhemD0NJiRRbkYx19KjZOTjIq1Km0YH3utVyDnrjPbNS2DRTdcrlv0qvLGGUg96vbCzAAdO1QSKcH5T1rNsRRa0k8tDHGZFdtijBwzeg96ivraOKfy4hOm1QJFmXDK4+8MenpXXyLBqemacqanDZtaoUaKXIAbJPmKR3P58Vj+JbiG91EtDI0wjijjadhtMzKuC/40pKyuQndm2iHHB4B61KgZWxwcdv6U1G2qe3oas24A3Fh+VdyRm2PhHylyQWPA96twMc9Rgc49PeqQK7OSevbvVuIYj4we5NMzlqX4pPu49Py96uWoZQbjPAO1fc+tZtuPNkVRw2cemPetCWVEQKn3VH+TQZNdiyGzHggAkc1l605IO0AAkZHvTmvB0HJ9KrPLDPIqhbiMthSSwK/yzWkdUa04OD5mirNEYbR5H2lyy4Cnkde1U5P3oVyvAxkDtV68EVpPLdXbjyocjgHJ+nuawbS6lgt/OlX585C9cZqedJ2Z30U5K5ouuYCchSDn3zVOa/dsRsqhyMbupq7aDzbZmbCEj7zVmaqC5JjUqkahVJ6kgdaq99jSEVKXKyrBDtlLAZJ4J71bt7UK7SKxZgPlXPA56kVjWk9wDI75zjjj9as2XnNMm0lyB0Hes/d6I2qQZtQwfa72C3UhcLvllf27/TFX4whJSHLIJCctjO0CoY4bi3hLOUZXAy4HIHZR+NSWskVvYXMz/vZCy7V6bsn5vyrWPuuxyt6aBLGyB5CSXdtqkdAKovLLMhD5V1ON2BnHpSvfs8j7omSTup7H2pkwUoJAdsinPtmplJN3QleO5ct5jIkcUoYryOTxgnkVm38sgDvuGUbrjqfQfpSzvKsokAwhPzLnoPalvJI5p3lQIY+pCjA6dqXNdDslJF/QWjuURp2LydGJGNpz0H0H86dlXiZnB3ZwGz2zwPrWFompoouIie5k9eox09OKv8A2jzI4zKQNxxgdAajfRkuk1JmvpSTC4xLxEjAAn72D1P86NVFvp0skMSr585DPgHC+wqnbXs0dqJR1XODnkqeP5ZpY9k99G82SXYP83c5/wAOKWy0M+Vxld7F3RX8tJ2mZtpGxQeM54/IVnfbJBENhIdeCzHIwD0FT3U5eRYicRKDjkkA7j/hVW8Uix3xZjVmILYxnvim9EHIm/UhnuXhdmRSQx7ds0XMm63b5eSucegFUpmkuLYbSVI9uCKmtFlcurZyRlSKlS5nY3SSVzs/Ccnl2ENqzncpc5U9tucH8cfrUOoaeq3i3KPuCuEZQOobv+dTWcLpqCvGURSCGwcjJHNXb2IjaYCJHRNrBRycMCOPWtk9LHFzcs7rqc3rgVyixkZY4JPGK8/1TS472Rd4fdG+4FewwRj9K9M8VaeyaU9wFUFHxx1ZexNcdbbly8MTHec5IyBXJiIqctTqoT0ujX8NqbSGOWXcJGxzn7q9D+YJruLOUIsrSKrKVG0r35xkfl+tcdZzvLZAONswyoOeg6j6V1elMXsI5CACinJYZJO7kY/KtKSXToc9ZX1ZNFNE748sKMHrzgH3p8VvIjt5YbIJ+6eRVUOkcwZeWY5KHoOKu2koj52ktgkd+3SuiOpm9tBuoQiXT7hWVcqhkGCfT/6xrzvUZWiCsA69Tx3BxXorybfkVVDkKwUc56/41yuv2Ycqyx+WAFVh155/wrKtBNGmGVnqc/Y3HnkBMksCefpW/osgj3QsWDAZT+dZVhapDKhZRsBzV8MI77fH9xSdv+7/AJNZ07pe8zqnrobRiMbBtoyoxnbwQM8/lV+It5f7xVVJDyP6e3NRWziaKMMGdgyjd3wQR/I09WAtkLqMhcDv2rU5ZNvRiEA4Z8jt8wzx0qpNGshcRo7MOSMcYqyqbmyXHzHv05ppB24JJZRgkVIkYhdwjLgEZxgjoMVnTIozkfQjoea27qPaxOFIPtis64hBzjkHnis2mbJmaxRsFiw6j/JpS67GBPHXipJrdW4U4PY1AYC0eM85z9axbaZSFLxyIMt865qsdhYAnAPOanW3TdnBX6VGyR+YeSP61DbYMqvtB46deDUY+cfLVooFJAwR1+op1uyQ3SSvDHIqHJjf7p+tAjbgOoppOnf2PNZW8flnzUaSMMz7jlju9Riua8RLdSX/APpzxSXO1QWRlIxjjleK2H1K25P9i6afT5D/AI1i6lMlxctLHbw24KhdkIwowfeqm1YzimnqjbUYcbuFqbb/AHePSoJMjBXk9TT4pcjDnk9fau3oQyUff4xx2q5Acx7feqgAHXr04rSsYQ4OTtycscZwvrVbktFq2jC20jMcbjsHv/8AWFQ3BONxwEHYd/c1LI6l8IuET5V9AKrXbq6jJwOnShjhHW5HbwvcuyIfmbpx2rUtVgsYmeT5plBAIOAMjmsyG/islZo/mnUYIU9MiqNw8ssigpIdwBYk4wD604s1cHN2bsiC7uzqUmwJGkKPuK+uO5/GliEbwSPF8/zYwVzmj+zwheVzgY2hRxxTtNdAsp8xREpAHHVs1m5W0aNLpRtEu2L4tWM2CFBx+X86x3RWBBGB3B7VavbuSLUI/scZcrg9cZJ7nNQ27tNLNJKi43E7R0NXTdm0y6bkveMeZAoOzKxnJJ9QOn61d0i2EMvmj5iR8o9yOv60kk6NMuyMHd1Ve1atsqKVRyUDqSpx19P1ppo2qVbRsya4HmRwwkArtG4BskcYxmrKrFLZwrGUaVRt2jomBgZHfpkn3qrpMAt7wTzsTErZI25z7VeNx9nmkSGEpGTuIIBYeh+uDVJq1zkk+kTMmh8x432Ih5YjcSWGeprPkwLwxzsDsP3V7mujuora6j823cGdMlto7ep9KzTDbmUtO+WJLswUg9OmfxFS4p9BxnFogngkYA52x9TkdR3rNNs99eTixiOZAdkYPI9Ov4mtm6kRo0kXKRKSChbJfgd/TvVKwXF87Q5AUAsQOAO3+fespJ30HFtamJougOupySThjGpyzdflHJ4rXaRCZY4QxjEpRGwPug5JA9yf0ojvVkmubG3ildpHEW8Hau7H3SfTGenpUiWrR2bMEw5PPqCcUox3saSnKWshZt7wgOux1ONoPXHCgfmc0Bi9vHLHkAuzgA7SF7DP60gtXit4m8wkM5BBPIx7/jV2CFZbd0cbYo42O3HcDC/q1VGNiE7ISG3VbWfcTu8oNuzx94dPzNR6oJjotsNwyrNgenzc/jU9kGkjkLLuRVUHd/Bl8Y+pCipTDCzWsErKr7sMpzz3NKorrQlytJGDpyb4JxNuUIo+YDoe341rWCeWiSbQwfALH0ByfzqoYGkvriCMNDEXKonpg9/WtpA/2NQQPu7hx0Azx/OilGyuOcr/ADHWs5gdHdSwkl27epHpWtu+0TLKBiM9S3GD0rJ0+L7RKVcAoSzfTj/61b8cKPGkYOJOgBH+fb86Gm5XWxjVVmUdWcXFo0exXiIVyrEjPJz/AF5rjnie2uZFRv3ecooPb/CuwvykMjxFwWY/LgdV6/gc5Fc3qfmRy7WK+UsZRlK85x1zUVYa8wU1y7E1lZSSIqxPy7HIY101mY0jEREm8gJxx/npXNaKzJxGY38pQThuo9ee1a7RXXlCaTCYO0HI9TTp6CneTsy7H5hvpElh22oUgEHoRnOfrjrSrKI4FZI8S5+XDdBjqagmuhHGPtMhcEBjt+Xjt+NVYZ3zNHGACuWDZyCPb61cfc0EoNmoLjzYSI8q6/MCD/P2qK9iS406Q9Jk2nafQH/CltZNq7YgWOCDkfhirrDepicL864DdfUf4VsndD22ORjhP2gRkhSTtOfypHdO7ZYcgkc5wB/jV+/gkW6ZmXDj7wB6kYrMx859c55rmkrM2vzGxpMpOORuGBjpWsIt3yjjAB6+1Ymnv5TKOTnn/wCvW+DlVbPG3mqjsYT3Km0ZCZCjPH/1qVWKjYvzZHJomXGQ+Rzkf403KjCgjBqhFW8xtBHOazTuQDacg9OM5rblVScDlgck1SngVCRhgc4qJIuLMmaPL5XcBxUDAFjz9K0xECv3SAT37c1E1soclV+tZyRakjKZG+bLHntiq0kTMxXvxW2YlGcAA+hHWq0sQ2g4GcYyO1ZOBSkZHlnIzyc+lSc85xtHXFXJI8Y4/MUwQgAEjk/lS5QbuVvs0sm1II5HdztG1SdxpdRhhEe2O3uIpo8LKJTnnHPGOK6e2uY105DA83mxW5twojJWNmPMm76Via/LHcXn7sysI41h3uNrOyjBJFaOKSMlJtkUZLEkE7KsquCuQB/Q1EihMEcHrn/61Txqr4LfkOv0roJuTW4DnDYKg/5zWpFIojKRnMeev94+tZvRBtYe+P8APQVatlCR9Oc9D2NUnYTRIzAZA+7+lQJsndlkOEXrtOT+FSzxkqzAjkZPPT3o0myjG5ipy5xxwcetNamkWoxuZwgMczSxKQm7gE8VJHORv8zIXuOpal1a4jjleGE4TcSzdewwM1UEilSBk5+9VqPQ0S51djrnUodjll29lRhn+VQWQjkRkCFYUj81v9r2plxArTqcdBkmrEUKojBh1wB61Dg5PUrkithjSySu892EMr42IMAKoHAqG7YxW6BNu8nB9qX7MpcuzEuuTuz3psTiTIMIbn5T7+9F3sbJditBbxq6sxxg5xVzUrW7mkiupZtsSgIhA4A9BT7GwWOSWS5PmZHyrnGTUuordXNooWRhGvLDPAAPANJR92zRMp6o1dNt3j0m5bILgKQSfm688VR1G9WxnQmEKyjBcnJJ9an04507bIT5ituLZ/h7fmaqmzN5d+bNhwWycnjcema0eqsjCFud82xq2lyZlW0XGJCAFHB3HnOfSnPapbW0gYjZKSd/XPriq0AjguFkypVRn03U28vlunjO4hY+FUDAx9KDJq793Yx3t4nchZHRnwVVG4+v/wBar1naGeCQhpWVBwvJGeOtUvKkHJPK9CR15NW7Ak2TEny3ByrDqx+lRd9Ubzk7DraAeV5eBhW37guD+QrXns2a1YFkKB8hV4KkcAmq1gVfMZG9l4x0zxVuaTMEROckYPpkfz61rdW0MJSexk3rb2ijVGCLnnHGc81Fc4E8awsjEABtvqCT+Par82GuZViX5WPCHkc1XtbHyLqRiqru7dWXioknY0TJYyLaARspYSLGWAHcEmoNTQedE3zFyM7SvueM+/FaDDZ88YUFCCG6t+tUNQvGkbMrfKBx65PP8qUoaAk27kECudTYTFA43bucjgetX7V/NiaFU5xu9wADWVDKgAERzuOCducLWnpbIt4VPIKk5bv7U1aw5bGpbwpFDGVH7zGT+VbcEQlijLDcSw5J79P6VRt5YY1QuikHnB6mr8dxHKNwUbRIAQelTF62OacmzK8SRrHFaXDsoQ9SOcCuc1CUK5R13Mwxj8ODWx4os3/snzdzhJGEgHp/nNcukpWFGdN7ITtz3pVIM3pU24J3EsFMd2CD8jDBJHfrxXS+asCKEBbjdtfkDnn+XSsK0mzcR7iuVJ6d/wD69annpJOjSKuxWzt9/wDJrnUuXQJe8yWaJLvTndgvmIAdgXJYY5x9KoRu0FwxijkKMPuuOBWxE7RwrGuVdVyQPUj9aYMEnzB8u7pjqcVpa4RfLdE1u7xL+9+V8gqf73fitKBxKWZChcAnJHT2rOxudWI3DoD7VPCQFP3lT1XufStFKxDWlyHVXLqAE+dS2SOAc4H8hWIyHc3bnIWumvQJYAu3ATH/ANc5rBukwzE4AHOP5VlJ3ZUHoIrjK4bBHqK3LWQGIYBHbNc8mV3IcFgexxk1rWzlYiobIzt5H+feiLsKSuXZPnYDqc8+xpu0hjuAwOlRRsS2MfMfennPUAccYHetCR7EMpAXAI61WkHUMuQf1qYAErjKt6U5hheTnjP40BsZ/kukg2kbWHc9DQwAJBUfN3qdlZQjA54pCQVG4ZVTyQvQY7VLC5VljQHaclSeD3GaryW/zkKRgnGTWhtXaw3EkHg96gYGRRs53DkA9MmlYpSM6WLBYEZYjrjvmoJBsLBxjB7DqK1GjEicDPO4du//ANaq0qK8aHnzF9O4xmpaHc0bUedpRhguYY0FsUMTyBP3m7O73471ja5KlxeYSQSukSo8q9HYcE1t7JVsLI22nwXSshDyGDed2T8p9McU3WYIfsl0RawQtCIgGjUDDMMsnHXHWraujKMrMwA5PXIxx05oVMYAzilGzktgYHQ9h2/xpVGWIDEe/fn+pqi0WYhk4UAjt/n61agUgc5JJ/T/AOuaqx5UAHJ+g6/5PFXLdyM5Bz2x+QFCBiXRaND8uWU9D6+n4UyG4eOESAFI8n75+9780TsrZTAIIIzjsOrVJEqTRlpF5xgKecD0FWtrFfZ1Of1BvtCs+1FLsSSeo9h+FJbgJEFBJ471ev7dpG/d8nqBjtWfPbzFflJUYycnmqi7nVTkpRsTOT8vzYLGpycxp09Mjv71h3Es0MW5G+bpkjJ/D3qfTLnzoVy2NoOc0cyvYtw0uaNwPMgeOJV3nA5HSoYQIY3VyEJxnHtU0ckQwGkUuxyu31z1/Co3tlM6s/lyKRnAPzHnpzQ0t0K6WhbeWOQAkgHaMYHTjgfrVOK6W4mmt52kaFCrSiPoB0C56Zzzj2pX8uQushwCDnn73tSWlmsEwRWYK5DOnTnHBpSTb8jNpbs1bJkSwlUSKEQrlCfmfJ/p/WpZnVVxDJGGI24wAMEc1U1GSO1jAyBtXluOT9Ky7a9Z7aQl8KpIBI5IpSavYxUHJ8yNKztIjJG80pZV+Yrzxxxj1NQpiacqGZIlOG4ztH+NS2cyyQrclXCbArSdBmmyTrz5AGSpXcvX60+XrEpt3OSu9Rv4/EFv5Ks1iww0UQy5A5yfRq6yCaAWm8eZuJOwAcn29u1QR6S+2GXycMpwNo6+v9BW2bYxDEEaxShtkpx/F7+3GKzje7TCrUg7JFWGaVZXa4Vo5wAvlqB1q3e3XywvuXIU/Ljgc9zWbcmaS3ZYi8kskuWx1PTAx7cmopkmigDOV3Mo4HUEjoferuiEuZ3NKznLTojjncCG3cDnn9Kswogkklk5Ibdg/wAR9D/Oudsbe4SaMPKWctyPSuqtYEix5/O9sKzHC59D6k04vuVVioEDwTPE+9uP4Tk56dMfjWbJboLxTdgeXgkbe/1roHkRQGjmEgUZyTjOOv69Kw7mF5N+7AwM8dc0SnoRTqN6EaRq/lrGVQuNrKDnbg+tTXsDwuZUIJQ7dy9zVETtDaS7UG48BscitC11SK6sVhlxG6N8w4JkB7/hisHO+xE+ZO62Nu3TNuGkVt5OQoOD9TUu9mYLEm1R0B4xx/hVTT/3fmSKrhXPy7hg7fXP0q9LLAuzfuDg5I6Z44FVF3ZN9QvbB7vTXhByRhk7jgdM1xN4qW7fZ2GSvzZxyTXay3rJGV3kKRnH9a5i6VRciV03lsn5jxzn/OKdSRVOU03fYy7LYYnEx3fNuTsR+NaWlsjqhfdgnpjNZitLvAjVQ7qVII5wT09q09MkWP7WM/NGQFx0B75rGnJdUaS2NOScKzuoJIzyP6fpQ2/buYDOSRn9ajWSBLIbskljuG7r6Gqzy+ZlFOItv49c/mTRJtPQmN2aNmRMGADKikcDnJHrV92GEji+4O2ec+9Z9sECGOLiMjBwSOOv41bUNtDKCOeo56VSFJak33ozwSSOg61lXqbhySRnGc9Ow/r+VbBOE+ZSC/Oceh/Ssy9BMZXacdcD1Pb8hTaFFmbGmXAwBwRknJ4NadsuQD155zVHgPIOuDuzjvjOPzNX7cqq7A25fU+nOP1pJFNj8Y5BOQeeKkO4E569famhccgNnBwVHpSN5ihSGycc1YiQSBFGV5B6Gm7yfnVz06A1E+QV3Mc9Rz39KY7nYGxgdM+mP/r0wsWHJO0kZA5/z+NQhvkJ6g8Y9h1NR/Mcld2wcfU//rqF8iQkZw3ynP4UBYcoC4OSRgYHuxpjMElK98ZBHtwP1odnDuQuTg7QOxqFyoUhCMA7efYf/W/WkGxOcorYJG1eo9QP/r02QDZ1IZSfpgAD+tRM+MZB2j34xSKzJJjKqAwyT65zSBGvaxwJabfIldmt2nysxQE5wVGPpWVrWxLwLbL5cEkaSKpOeMDrnvVyKeG0sbNpJ7zds8xfL2hUOTwM/rWdqs6T3hkV5pMhVDS4JJxls47cimyI3uVFTdGw2/d5bngn/wCtwKcI8AMzYznqc7j6/wBBSBiVPQDBPXgAf4fzNTtdA6eLdogsiuHVgPmGeNo+vQfnVJXG20KH3bQrBR/FgZOehI+nT6mpo8SHCMVIH4Ljgn6DpVWNCOoAflcFuAR1x/sr69zVmA7QVQkL0yRnp1b6DsPU0ikJO5DYJBxxg89Og/DqaW3mAXAbLHgDOD9ce9OeP5TwNxA4zyPRfcnqazJARM5RwrqcqxI5NNaGiV1Y6BLU7lYyLG5HcjisWaCSSaSRBvAJbPQEetNSeSSJPMdZCrZLtgn6+/pTzqyLviZd4duNy8fTFEXHm0MFzxehg6lbyxMDKpAzlcenrinWccK25bOOQPQk/Stq/nheH/WIrn+8OR7Vz90QzqsX3uMtj71OUkmddOvzrlZZMiQguEwMZ3E5py3M8ixbYSYjgO0Zxj8fWplijkjVVOT1Pr9aS/xYskEO9ZwpYs2QM+wpzVlc1k4vRCTkvtjkhERb5xtPTsKs2nll1yzEhuQDnAH/ANesmxvnmbzbgM0qnkMOMdv8atJOk+ZSpQcfKBjJzx/9elCStdEcmli9qUUc7yqJXKHGC4H4/wD1qgtraKIy/KxXyySXGVX1NWrOMNbNNICHA4x356VcvNLumth5Y2iTbvXGC3fA9h/OqlFPUyc1FcpkM/2zTlIQhYVy0SEgc9SB064GKbZu6JAyoATzt6+1WryJI4vLi2nGM445x0/Dirlk2I1dWRQMYG3IyPX2o5X0E5Wi7G1cTrFD5UjLvRFCpGclwDuA/Pr9KpiSKK4mN28m6Q5fYAQw6kf41Xsy93exGU7pJT8wXj8qW80+eS4aVzItsjEDb0AHr/KhrQ51FJ2bKDRJCrPGWkmLEqCSBH6YxVeOJvMhE8mGwW3HpkdfxzgVpPCI0aaZCIs4HIGDjA/U/kKz5pYo5QsTqyqpAcfxDPWoduhvGVzQt/lncn946nLHtk8Z/M0SK1xPB5jkIpwrBgRnBzx69KoW0b/aQkTEqxHJPXr1rWtrdPnP2fzWXB+9twOnalJ3jYU3YijkeGSd2coVQ7ircYHRQPrilyk8CspIdhgqo+70A+vc8VfmgYRlXtYolT5cFs7cfQ9agaaG1h4kRJQCCY4wMLjjbkcelZ07x3MlK+hR1Eq4kSCEKzZZVUZ46D9BWXpSG1u7f7VujMjYU55OOvFTarcWzs0kf2liFG0bsc4HH0zms21uWjuIio2puzJj7x9Oaltc1zeMW4tHayTT3ErR285VGOfLQE7QPerCRuUGQzDpnIyB/n0qlPeKZXk3ktjaB046VLGI8x7vklKgALnO6tW+pjqkXZIg+2MJHycsSx9OlY99EGby1jU55GWIJ9T+Qq08SxvGEZy4wdn93uf0FNeMtz5gJZTgDrk8Dr7c0L3lsOK6swT+7uY3WGJWTLKC5Oeh5qXS2YiSJ/L/AHmTksR15q5qHluCwiby1zk7hwM8DPr/AI1Un8sEFflYHaFz0H1+uayaszVO6NNIUO0DLLjPykYz60wQxYAOBJnBUnJbvz+JqeyQfKHAIO7lQMcHAH5n9Ks4hjwsCgAEj5hz1wP5E1SI5raBAy7QBuJAx7D/ACakDOjNuAz25605GKqVKqjcHHHGfX8MUyN8kfd49B096CL3JVfzAS4IzkYFVpiGGCDySC3pkc/kBUoBYNnBB5+XtUN44YEIpxjd16D/ACKroCRUByxZzgldwX1yeB+QqxaoFkVSAFK5OT6f44qCNVaZWlJ4ODg9MLk04szN8wKsSDyeOaSRTLnmMrlSdpPHFEpZFPJLAYIHWmTknZKSoXGeed3Bp6N5kaiLdubAz159/wDGmhFWVnByQO2c/nSSEAdRjPbJHHNLOMhi/XJGSCd3Ymqs+EHRz2wDjFMtakxnBOA+7PT602STJJJVcEDHUn0/Sqz+Y6nZhcr9TikVwSGBzySSTxxx2pXCw8zYJKZOQxPso/8Ar1CCpTBZlQE47c4zTZFDEYyQzcAjCgZqJ3BfLkBcHJHuaVwJ2kHlAjdjqc8k8VHLLlVznGCcenvUZkBBIA3FT97jHFNSVEkWRkSVEH+rbgN/Wgk34bm5awshaahZ24WLDwuy53ZPzHI9MVi6rJM12TPPFcOABuiIIOeg4wOKe+q2mdh0mzbBJ6t/jWbfzpdXJMUKW6kY2Jn+tNiitdi4QFQEv8gPHHULxn8T0FSB9rJuGHTJyO7EEkn35FQKF2/LnavX356n6mlz8gVyd5PBz0Gf5k1YJFhdsabeMKAoxznHb6A8mno4J+YYPAHPIIPU/wCetQRvkfLt65H4ngfTvUsThscAAKArH07E/qaVh3sWdwfo21RkAgfdXuT6sfWs7UUKsVRG3AcjoQPStRFEaHdwxUfLj24B9h1NUbhFZe79SCeMepPue1MuEtTFe4kiQsifOxGCwzn3x2FTpIWdWhIaY8rntSNAXYqq7iODzjHtx+tLbKUcKwALZXc3QcHGB+tY8vvXNJJP1MyW+aeaZZ1BP3QFXgUsQlWZXnULHnCBeAf8amIgjR0A3KT8jueVB6e/PPFTx3ohspoJoWlXgRhR90+tTyqT5k9UTKy+FF9HFt5Hlr85baQOcnqCf5fjV+3C3iea0ys+/LKcAgD/APXWJNqEVxbCCK3MchwA2/Jz3zSRwi0VnlXYDzhTnBPvW8feVmZqLe+jL9zaNbqhwoLPuXAB5Bzz+NSRWqrgv90fM2BVG1u8TjEasc4GCSD9alv72UwyEfwDoO3ua3hFRWpqlP4S4Z/L2CMlXGduMfrniq/2pxMp+0z79vVmACjrwap2F20qGaW33BAPkz1qn9oaa7dmGwAEgBc/QVlVl2H7M3HlAt2cuQjLuGTliT0/z6UmlyqqMxY7CSMMeD3rE+0srxRttUL6Dp7n1Na9uYxGoU5Ljcd3c04XauyHBqOozU9RECs4iDP22jpSWFw95bl51SBBgkf3fQetPa0yT5rYB/Oh4YxEIxnOeMDk/Wjlle4KMbDJLmOJnEar5ZxuK+3vTb4CeFPs0eCQOR/nrmmopt3y6RuoO0g+vpTxcBiwUIgU52qeKSV7pjWj0J9ORoVVpcNkYJb1/wA9q3o7RZY0lkJUDgBT1Pb865qGV5btxK0nTIwMjPpXQ2kiqUjMiRsv3stgD2zUS8jCte90StaviRYZkLAE4ByxAOP6k1TubHzgNx2jPyk8D8PWrl/eQ2m9YQszY2bdwC9Ou7uMelY80sjgPdXaEdf3Y6Cod2Zwu3cqvbjfKsmOAwUHjkH19MZNZ1mFN1FuI2eYCQf4ua1Hkimil4LIAQH7/lTYPKjlSR8l0GUUnoe2cfWhRe51xm7amm06xri4UFi5PAyR7VcuJPOi3GMRKgONzck+orK5Cvuc/e3fjWha3kTRRwzrvPp0OfXJ7VcuXqYTXUihaKB2Zyz5GC3GFB9OvPvVlA8bvIf3mOS2ODkZPPtjFZk1xuj/AHZ3Jnbvxg//AF/Si3lKrh/vd8Nkc9qnm6GiTauWLj5U8vb90bm3DnnBIx9cVmzkGUkcYCj5unSr0pcrlmLAg4BGfX+pquYC0u3A3ABiPw/+tUvUqLsadhtV+oBAJIx/dXP88VdnfYAMgLwpPfIzz/8AW96zrN1zkL8mNwyOwI4/OrkrLvAYggcEAZzgZz+ZAoMXuTo5w2/A3HJIHXmopyqjC53Kcn86SItvcSbckEkEdDnHSo5QWX5Mkd+3NG4LcsB2Yck5/M/So3P3lYYQ9Qq84UZP59KgQkA7evQ89hTZCzruOAjDBx71SZVhrMY0AYhmxyo9zkj+lBnYtIQADvLjBz/nrWfPIVm2ISRkHI9qVH+bbkksRgnsfWhMdjU3hkjXOcYH/wBanJIAWKBlYc5B7Zqr5m4uiEsA+RnGfrUMcx8xsqAe4NFxWLRYoQH3Mx7e3WqlwzqoZec9akEjbmIAJJwM9qicnJCqDk5GelMYofIJcLuHOW6D8KieTdjcQ+MYGOPemyEKxHRcZ5GTUBlXphc9CwGTSY0OlkDgdCcY4PH0FRmRSPnGT0AA6YFRyYyN5GwgFfQU5iqwoXyCf4jxxQhsRvmDcZI4Y+lOheKOVWnUyoAd8QOMjjv2qIqsk/ysx7gY6/8A1qjEmYmJkwOpUnO4ZppEnSQWMV1AJrXRGkgYfK73W0sPx96ytYgjt9RMJi8g7Bui8zdtPX739KsW95HJDZrcrcASwPZMVXchyflK+pBPT2rL8RTK2pGMLJiFUhZpF2vIyjBJHaqdrGcb3LLSlMKMZOAP5AfzNJI24EqxxkAYHQdB/U1AzEsxPDjOTnpnk/pxQu8qWPBPB9j/APWFWikWATsxkc859M8D9Mmrdrywxnaccen4fkPxqpCQyEqOOeW6k9AP5/rU9vtyxfop5Pc9yR/Ie5pWuDZdyxO3l8rwM9WJ/l/PFMcMVBHJJ3AY7np+fPPYUuXLMAfmz0z0PTA/QfgamkIMJCljjoB3z39s4wPbNISdjIlQwkyR48t8AgcDAPJ9cZzknrVHUCLklgzgk8Ejlvr7e1acwAGQSQwyw/hIHc+w6D86oTkAEFdoHOOnH/16yqLqjZPqVElEISNUD3UrYDkf6s4xn+uaypLK5t3Ecjl8915I9jWpb332KQtHhpD1BGdvoBVqG9h88TT/ACMWyzLyc9c/hWNNO+o7yjqkLodhsiNxKE2gZBc4GaNQngzHH5ke9my6q2QBUsWoQzSmJZCUc7sOOnuSe5q5cafZxw+dIWZQAW2oCQe2RXSpRdmZe0SlzTK1tb8tsIORu9MVl3ULW8xREDbjlnBPIrqLe2insYpoX8p1GWV+C35/yqjLasZSJVGc4wDkZrdTUtDSGIjzalK3UrhwgIUcgcZqVLdPndCEAHI7jParItivK4YY6DtVZ45f9YyKAB34zTsjTmT1RRdUXLRoHxkikilltojIV3bvmCrzyfSp8r5IG7ludqkHAq7E0X2ceWSWTAbb1NJtbg6qS2K1peS3WJJVKleCvpUliF+1u25wwfd6ke1OleNIFeMbCzYJPQ9etMtMb22IcA5PoKylLsZyfMm1oQX6xOjgN5bKCxVRy+Txx6+3pRo9pvZ/tSgSREiRgcK2OTz7VZ3p5582LeGOS46j8Kg1udEsZobeIHzAxVuc8A9v1rmbcW2YuT2RYsL/AE6K533pcROwRFQjcxOeg7irmtfZ470RWsjtAyqxk2YIJ7YPtXnFha3Ud8JJJQ8nUO3OO9d7aXE8ot471AxCjDk4OD61VCrKUbSLqQ5He90PkntnieOIkkjGzvjoOTz61n7MlQoyBkFSf88VpeXbxecYGMgKhcnktk9qqR3YkYoIgjA4B5yfb9KptIiMrLREIjkEeHKhyAQAaimZg6mPIQgbuPfmpXg813kWQKqZ+Z+BiopwZTutwzLwBnuOeRTUtNTeMrmlNPm2VQuAGJ3f3qgRBLJkngtz7+30qm6slpsaXcVG/aD0HpVrTWYxspI9/XPYVkpOTGtmzThACRlywTAAIGSOpqQMiMCBtI7HqfrTxHwuACx4GeBnpVYgFs5HHA59P51ZClcnGTtVcAHAzUUw+Z2ADKxyOeo7UonAOEOARk54PsBTmZAOWYkYHI/E/wBBTJ1uOhYKVGTgEj69KfJI5ZI/lOcZx054/pVSORk8oYGe2Dk5B/xNJK+Hb02grgdcD/69DFbU1tPdXZznHOM+vWnTqQzcLgHdg8Y9qo6cQjNjbxySf6flVudkYcK5P3vbFJbEW1uQBskfKBjsKbcFSOQcjjAXge9MViGG0DHYN2p8zMq44KnLE00VczZyisfkJ9ScimLLJGG6EDoBzRdBmkLNgBs5+aoQSMhUZupIU5H1NBdzQhcgoGYKP4hnJFOlIHzZOTzjGP1rOgnVnJHbgZ5q6JA+dpUL1yTxxQJkygbQVK5xwx5NJ5nyc/Oo454qBWOCFYLnnIqLf9wM2eeoHHv+NUguEzhXYoBjr1yTUfmZwD869gOn0p0hR12/MvvtquqgoEDSEZJ288e4pNBcV5dsgLYKjocY6VG5G9i+7rznt/8AXpJpFQBZQcjAA6fgaY7gsuzaWPJVTnH1oGOll2pucnkjIBGMVVac+YBGu5gMgHJ7d6kmPDsEByOuce3H45pkcslt5c0cnkyg7g6sNy9smgDUk8jUtN09G1FrOS3j8spJEzKxyTuXb355+lVfEF2tzfRyRSb0jiSISSDBYgcuR2zWpFdLZaZYiXXdQtfMj8xYY4Q+1ckZznocVU8T6evkyXY1Fr2RFjaR50C5jf7rDBwR2pt6GalqQW7qgDSfP/dU9/r+P8qXe0nztyi9D6//AK6rgBlxz055/OrEZTy2D45OPr6n+laIrzLMRKEfd57Dt9f896tRNlsKxCqeD2z0zVFTntnnHHr3FTW0m4bFXoemevr+nFVYkvrIHkXgYGAAOuOw/wA9zSFy6kD5sgkueAO2f6CoIhuXcrhCMgk+5/z+FWBIvk5yc8HAHHH3V/qaLCRIVAyZHAPYYzj6j+Q96z5YlkO9c45J3HIA9T6/49KtxrGxVSWMZJy3AJAGT+tAkO1/MBz8rMgwOf4FA9PWlylKVjFWwAJcqytnI3cnnsff+VULyBw4Byyg44549q6u/uRKIUjURxxxbCf7zZy7frgVSnhyPmA5IY+3HC1lKmlsawq9WYNvbmGRTGvJ4/HHQfSnLfXUMwRHk25J3DkZ7k/yrWMEYUjcvAxyOc9zUrRI1sqiNVQEtnaAcduf6VHLZFOae6HR3kdwY0kMkbhcHC5BHvV6KWCbzGiuFWQY2iQY3L647d6x5I/kbIx9OCc1VkjOZeQFbGCSScDsKa0Rzyop7HU20EdwxMUiROF3ZLcEVzk90LqIqEw3IJyfWoLi7uY4UhZlAAHCjGB2H071UuZZHjZYWzz8xAxuwKpVGhU4SiyS4PlRlsNtQcVVtNRkMwV1ADHg4NI0stxBHDcsY1GASB+NSJb5Ty48nAJDHvms3Vd9DpTsrNF4XJlBgdXIyWweOfpVqx/1i7VkdWOWRF7Cs2GN4of3wAlOBgdxWhPcxwREQ7gWXDFW/ka0U09SW1ayRbvJraWMSLGRJuzjOMj0IqmNl68UECHDE7wTgAn09sVXWZfKSMEs5b5SxySD1qlL5i3zKEJLEhVHr6UpNMzjFG3NojOu63jyzMQgBHrx+NVmTy3Ks3mlTj5jjFKtwN5jlJt1QFmjcEYwOP51nXF2FHTzNvBf1+lTJpajpqTdmX1vhH/rOUU5I7nsKWe7WWBDHH5QQ8Oxxn15FZEUouXccIgJzkjPHYVOMiNS+HTk8jqMVHN2NXTSd1uX7m+jlEVpAm0sV3MGzk47e1ZzXElm7Rhv3m0Kx6kZ4IHpUkU8cRJgtlEgAG9vcf0qHyQswbl24/Kod5bEwhZ6k0N4sZYJGXDYIZuvHANa2mHPEi7tx492681nRQgtuY8jsf6Vp252NnOMDqR7VcU1uVKyRbuGbOUGByTuA5PWq3mYYBsr6+/fip2Yyfc6bTgDtVSYjHG1hyBx+ZrQyTJRJhNpUcnJ44qdSrRrn5VHf9aplh6jnPAHvUlvJlSxU9QGH9KBssMUTbg5bjJx1/GqryMdi5PH8Weg7/yqWeRSC+QOegHeqm9lwSoA6D8qGI07BxJPnYSgOFA6dM81duNwO4ZLn723p9Ky9OKLdIGbgdcdK0TcAZyoYE00tDNvUhkOJMKoz1zx1pjyK6kyb1PAyBUc+FkAUc565xiq08z+Vj5uD1NIq1yKZtrt82FPOCvNRCRC2Bux04OPzpkoJzk4xxkmoRINhywx+e78KSGy40nBLBRjsOM0ol65Hyrzj1FVhKVQFFUt0+Y5xVZpTltxwc/NgdKdxpGkbk7v4S2Oi9B9acZwGBjypxkAHr61lCZDwTwDzTFmXflumeA3/wBancLGnLcFyTu2n361VlI8nczSbyclc4Wq8k64wIznH3gajU5OXBUHqx5/P0obAa85EhYgcHPrStOCPlJTIyMfzqsZ9jDClsnBJ7+5qPzWyV4GeuakuxaEob5S2Qce350wTERsM5bjt796qK+CF/hJ6dqQT/vFc/cB5X2FIVjstNkiXS7Q6y+nNEVJthcRO0gTPfbjC5zjNZviO+vUkvrG7a3WOYpKJo14eMAbFX/Z9qrDWNOms4E1KzmkMC7I5IJQhKZJCsCD0yeRUfiDzJ7iGWSBY1NvG0MEbFvLix8oz3OOtXe+hklZ6loY2nJKjsDU+7YRnOO2evtVWKRU4Vs8Y5A6d6nWcPIOTkdOM5NaJjexYVsEBVDA9eP8/SrcT8kEAIeG45x3+npWfvbIBx/eAHIp8TsJRhiV6cd/eqT7klyNlG8NnaWIznoO/wDhT95jChc7RyfT1P8ASqi457legzSuSWbqyDsCef8AJp8xSLjzKu5AWbkKPfAyf1psc2whiAduWy3fA/xqorOAFOSfugg9CetPZyz4Yfu+AB7D/GpbHYn3hiuSdgBwR3/yaeDwPMYHncPTJqtvGxiR8wGTgZ68ChpFZwVI2jnPpUsETmNQ5LMWQNjr+ZoJRl2pvLMwLZ57dKhLrgDquOee9QSbv4TgHOefxNIaRakHzY2/NnnOPwpjgYySMAEf/XqASMoDFtwxu+npTzJwF3AjBxg45FJgyuVV2GTnPHr7UCNQxUg7OeenGQKeCoYso4UA0jSYBKDJBxk9+KVh3Yx4lZuEAYEnr70rRYySue2T7Uiv0Mh5JH6mpyACefUdOvNTy3DmZVkTnqQ3Tr04qO4O5ZMfKOOvpVx15DYJBJ61DcAFQqnBwMgc0ilKxkTy+XFgEZBwKlt7trfYVyASMnGSDUdzbea/Xj09KSOPyyuOABxmp1vYtpSRPeSLKWlIlYFMZc9/eqtguRl+QevHSpMFVPfcMD6U+NQVXbwTyQOMVTV9yoLlLCxBMrgqRxjtUmRhWz2xj0FCKu/Jzgn15qREAHTnvzRZBci2AcjqTn+lCgrJjByOufpUkkbIp4ByBjH50sUZkLs2N2Me+T7UKJPMTRR/MrMWwehJqdQV3F2AKnPT7x9KgjA2Al+p/u4PpSk52qgJbOOTx+FVYzbuXFkG0kblOCWYdAPTFNC7myM7FJz6YFUoZ2Z9rZ+8S3HvVlpwzHOfTnv+FMga0ZUkAZ75zjNOUFWG1f1oOFYkglh046U1ZFUE8N7HtQJslGGULnnOM/3j7VC8riSTO5T0Bx2zT9wC8DPoR1qtcvuRgGO3PTFJjTJrWZQWU5BHGS3Sr32gFQMbV65XuKxLdwrMcZI9utXHcLD5mAuTgY6cUiLFozfKNxxk5B61DJIfLIUqynOcj+VVDO2cA/KecVE0gL8N19RwaCuUW5lz8xbnOcAVRe4IY7lyPep5yCODx61nyEb2xnjvSKRoQTFgQFAx1FRySKv39xPbFVrdzuwvJJwadLIpJAUnk9aYXFdlYgDIPUknNNZ2BGOC3aoWYgHHY9abvLZGcUirkzzLH8gZST2BzUMly21lO4+p681E4QOBnnuetQSM3IViPxx+dF2GhYWY/dYnp0NNMn95tpPAzUJdBj5gWxyfWomlLHjnPWgaJ3kGwnK5UjGaS1eKa7jN80ot8/vPJxvxjtnjNMvRGpURy+aCo3Erjae496jsLWa/voLS1CtLI+1MnAB7k/hRbWwJpq5vK/hZeS+t4wfvLFx2qt4kv4bnUIJLHzxbRW0US+bjcQoxzjihrDRUj8t/ELl+7RWbmP8APqR71T1WCfS70WzyRXEMsayRSRnKyIRkMM+tXqjF7msrqwICj61LC6qDtH1wTz/npVXzAV3Bx/n3p6ltwBAII9qaZVjTDd8EbsHPSnxMVAOMnGefTtVFZm3nJLbjzmpBNg7m+Vuw/wAKq5JeiO3BLAkHOc5J96BKQcc54AxjJqj5/wDDyc04tkr0LDv0xTCxcMqZjC8NknJpuV3kA5HGD9KrK6r82BzirWqxfYrsIGzFsVlYd8jPFAX1sDyFF2M2Gxg+2aUlRDIvIyAcDtjtVTzC7HdzyAKFLgc9RxikUixGXZtjN04wKduyGBByMlcnuaqJIyjJ64/Wn7kPUHjof8/Skimyd2wNh4AwCM+lQyfKThskZx6UksyM37lywwOW9+tRBs4ILNnjGcYoYkyfJ2fKSykDIz2qushbCgk45x9aZJuwFB4bgnPA96j3MXLHCnPUjqaRV0XEZovmZTtyMH1qdG2qCAOck+tZxZnbAB2q3Wpo5BuVCCR7CgTLgf5CByccDt0pJFJUBRjcMgYqFXCy8IMA54PvVhBI3z7c8AHnoKLCuV2ADkyKM9SfamiIMcj2AGKsqxjJHBYjvxjmkfbyxwOeamw7lNoMrx2wOfrUkMKquSuQeBz3rYm0Z49OkunuLfCqCqK+5myfQdKzQeAwTgDJOe9PlfUSqX2ETCgrt54GfSpiVI+VQBz781TiUyttTGScdaWRikmF7f3uP0pWHclL4kHG04596kMzBc575Pr+dVTKG5IUknH401HBU5bke1FxFnzEMaY44GeOvNMnkJGN4KjIH51XDqFHIPQVFK+OpwOe1FwsSx/KoCggHuas+YfLJIHXrWYJsckYxUqTFo8EjPpQmG5b85k6uc0wSZJzjGex61VMylxvG71BOM1Eko3Nn8qQW6mmZQANuTnpQzMyMQfwqilzkYYncOhqSOY+X8oye+aCWOQsPm3HOc4pVlXAbIIA4z/hVSSUhsr06VH5gRWPWT1HQUgsXPNDDBJH9KruzBz2HqDTEfEbse4x1qCSU8YzjsDQO5OXPQsSBwPpVZyAgPPJ65pPMbBJ+UCmna2DuHsaLCuTWzojId5DZzups0u4/veuck46/jVZZCruQQQPWldsDcc89qYLclZhjrkf3c9KryTE4JaoGkZeVPPvULSMBnAwevNBZZLA9+vTPSojIWzwfeqxlLFskD0GKiLnPTJ/KkBZLKOCcH0FRLMFJGQKrtIQcZz9KiZ+SNwwaCkXJJAq9eM0/S764ttRt7iyVjcxPvQBdxJ9Md/pWW0h24zkU+zu57W6jntnkS4jYNG8ZIYH2oA61tSt3BeXwgTIeSEedUYnr8vp7ZrN1O/u9UumN3a+Q6qqJCiGMRIOFAB7AV0OoXHjbUZ1u4LXWLaN41LxxuQC2OWVeCAeuMVyep3V/wDavO1EXTXSkK8k+4tx/Cc+lXuc7a/pnQF4wm7DKPQYJ/CpIpV6IwJOM7hWdbsF29Wx3z2//XU3mjGRwo/HH40kzQvxklmJOMnJ4496cZNzAr29aqQygIBuZsrjg1KJW4J9u+KadxdSwJAzHOOO3apVYcjquOoqmZAMjahI6nGaVG8w+i9yB2qxPUnZgw5ACj0GaJLmaURrM7ukS7EDY4X0H51E24Iqke4Xp69aaRg8g8DgA/zoDQtRzbJAW9ckH/PWpHl49R7HkVSztHzYwSDkHnFSgqc5ZeRxk4xQG5MJAwOVA5x/Wl3qoJwuAoxzVV5AOC3fIwOnNQsxPU847ikxoseYpGGA5bscAVI03ynbjnPT6VVUArjHGOuKHcEcds0iy7HImCJPTqOBRBNGk371A0W7t1qmWGzHfPJpcDABzk0xWLLzPI+1RiHd2PWnqRExUqD7nvVWKQx+xHpRLdMQqtsLHPI6jJzigC/G/BbICqMZPFWYbtplZHkWIhBszwHx7/SsRZDwD+VPMoLbmUtxjBpXsDjctmcSFQcg/wA6m3qJWyQcc474rMWYBQQMEnrUsUwJbJO7H50rhYvGUKUdshWyNo44qpJ8zEFiVzkY4pJ7lXWNcKNq4bP8Rz1qKOfc+AACCfpQ3cmKJ1O1e45Az3AokfLkuTUO4k7QcelLJJuBJznFIq4yVjvyCQOSAaVmIUDp71E0gGADhsYB+tMJAzgggdQKVguPMo/hGOeopsk24kN68A1CZXU4GB+FRNI6go+PYYoC5a8xTnAI56VJE4XG3AwM+5qmhAUsAc9CetSRuhO6Qlew5ppCuSscnAOScc1FvBb5gQR6VFK583GMjtUZlO7DZI6+9IVyfzRwO30qx5pXGBkHpiszz8HnKqPTvTTMN/XH+9nigLl+V8DPXPeq5kwx7j61A0wIIPWoJZGxjGOeaBmqtyGto4dg8xWJ355wccVXkkByc4b3qkJWjyfXpSGQ4O7GKGQSGXnnO4nBqYFBGcnnH61lmX5/cdxSmY4OTzSGi8JssORgdgKaCCCN2AfU1USTOeRzTZJwMY64pj2LMzALgtx71Tkf5jnJ9xUc0rEj5ieO9RSSKMHJyaB3JBIAMnj+tI8q7c87h27VA06EAY5z2oaRQMjHP50h3HGQEjtn1qKTq3Xj1pfMUr2x6Ec0zzEJGWxjtQPmGGQYIJ5PGK0vDeqR6Zr1jeXCNJDbyByo649RnuOtYxYrJxjnvitbwzNaDxDph1NojZCYeZvGV+rf7OcZoRMpaG09pp1zdtcr4xiIZt5MsMwm69x6/jSeJ/Eb3OsKtvNJLbJAkBedcNMQuPMI7ZqW71V769utD8YTW/nE4t9QgCH7MxGRynDRnIyO1UPiEix6xZQbopHh0+3R3iYMrEJ2I6ir22Od76liMhiGJbaPzanpt+6xwT05/pWerlTtzjjoTzzT/tHOQAxHGM9f/rVJ0mnGcByGDbSeOmamSQbdoHOMcH9ayUlO4hycA8nOOfaphPucjIyRz1/AU0xM0fO2g/MAPzp7T4VV29ecjpWWZFBKo2fcU5bgLznJ9apMVjUFwduMnOactwCMdx1FZnnBlIDHA6570pfIJDY6U7isaZlWQEjhs8KP51ETljnj39aoiQADDcDg4p6zsWwpwKLjsXC2OnTpx607zMPllyOnWqCT5xk9Owp5l3x5I596Q0WnYM2EGM8cnml3bcEjjpxVVZlJ478E56U7cNwAx9WouNFtJAOgz7GhnZzkgKPY1TdyT0C/SnF+oORmlcZo6ZazX14sFttLNnk8ADHJ/KqInRydhLDJwSOtM89wGETOgIwSvFRIqoo2njgChtC66lhZckjkZ9qQybnxzt/KquX3cNkegpplZWz2PQetTcZfzt2rxj19DSu+1iAwOe4FUlny3zHt0pBJ8xxzxzk8UXGX2Zhyo46miKQZyB83p6CqiZY/TtSO7pIQBg+3FFxF95WA5wAemKQSZVzkZx17is5pwrBuVOOp5oNzu5LfpTuItKyu2Ome/TNDug3BSDGOKz/tLsoCjB9aY7EhjnOOwoTCxd8xSBtQ/MfWo2mO/lc4PU1UWc7T2B61HLPgYyNuKCWrF1rjdnOQSeg6U1JOdpJPNUFmwvQ89DSpMA2ASWPrQI0JLl2bG75l4561G7OrDcRnr7mqgkAyWzknjBqP7QBgkkn0oAsvJhvnO3HoM1XluRuAQ5471WmnOOcknoKzbqUBgNxB7j0pMDY+0Bgdz8+9Ks+Tx/Oue+1nu5wKtQ3fGCMnPWgGazTN06knrUbS56knFVTPt2kck9ADTDcHfhc460CJmm284yPSmmZSpYNwO2Kh8xmJ4qnI2MggUgLy3fqTSi4WQ8HHvWO0y49OaRZGZfkyR3plGu77iQWyF96gMmTu4z9apmX5Bg0nnqpx07UAWjMMEnIpDKm4ZbGaqh1xwT60hkAUYGT3pWGWXYA53H61EDubO449fWq7MDyc/TNRlyRgfkaALWXbIz070+BDK0cEIeSeVtqoBncT0A/GqkZfadvXr1rW8LXqWviayluZfKiVihlI4jLKVDf8BJB/CmS2X5NDt7eRbWbWdNg1FD88W2RkVu6mUDaPfsPWsxraTTruS3uomiuYHKuuc/y4IPXPpXYC3ltvFOn3LzXKS2sEdudOjtHdpAq4ZEYDY0bnJ3E4+Yk1zniyVBqEMcbI8lraxW0rK24GRRzg9wPu5/2aq3Uxk7ksLF8b+cHHNTsdgTHc/lRRUR2Oh7j1JKLye39aFdiCSecE/jmiigOhPgFVHrgU9xgL70UVQPYTPCj1IpATxyRk9qKKCBxclOeakilZTxj16UUUDJASZAp6f/WpIj+9AIBGM0UVQDI+v1P9asI2CMAUUVJYCRsFu4PFPLEnJ60UVIiPeWJJOcHFRzOQOKKKYxNzbCcngdKiZiWPbntRRR0CJOyjC8c4zTkAOc80UUh9ByTudyk8YqAMT1JNFFWT3I5mO3PGc4qIzOScnoKKKllITzGAyDzT42JVs0UUhIjk6e2M4qpKxz+FFFN7CjuMcnaeTTY3JGCe9FFDJZJkrGzDrnFRSsSG9sUUUgRWmkZQuPSqO4ycsck9aKKBFS4G2TAqWPK4IJoooGiyGO8DPUdacXIQgUUUEsHdgq4NRR/NGXPJ5oooDoZ9wcZ+tPhupYopY0bCvweOtFFHYHsIpO4c54p0gA3AdM0UUFMVGOzGeOlPChicjtRRQBDKdrcVCrkZOeRRRR1AdbndMM1Lcf6xh0AFFFBmyzHqmox6ebWPULxbYqQYROwTH0zioZEX7LA3c5zRRVIh7n//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple brown macules and pustules are present in an erythematous, hyperkeratotic plaque on the plantar foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38914=[""].join("\n");
var outline_f38_0_38914=null;
var title_f38_0_38915="Echinacea";
var content_f38_0_38915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echinacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Martin Wall/herbslides.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38915=[""].join("\n");
var outline_f38_0_38915=null;
var title_f38_0_38916="Phenoxybenzamine: Drug information";
var content_f38_0_38916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenoxybenzamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/35/23092?source=see_link\">",
"    see \"Phenoxybenzamine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/58/19364?source=see_link\">",
"    see \"Phenoxybenzamine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dibenzyline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F209104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha ;",
"      <sub>",
"       1",
"      </sub>",
"      Blocker",
"     </li>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F209085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pheochromocytoma, hypertension:",
"     </b>",
"     Oral: Initial: 10 mg twice daily, increase by 10 mg every other day until optimal blood pressure response is achieved; usual range: 20-40 mg 2-3 times/day. Doses up to 240 mg/day have been reported (Kinney, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Micturition disorders (unlabeled use):",
"     </b>",
"     Oral: 10-20 mg 1-2 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F209096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/58/19364?source=see_link\">",
"      see \"Phenoxybenzamine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pheochromocytoma, hypertension (unlabeled uses):",
"     </b>",
"     Oral: Initial: 0.25-1 mg/kg/day (maximum: 10 mg); increase slowly to blood pressure control",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F209086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dibenzyline&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F209069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     GI irritation may be reduced by giving in divided doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F209068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic management of pheochromocytoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F209101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Micturition problems associated with neurogenic bladder, functional outlet obstruction, and partial prostate obstruction; treatment of hypertensive crisis caused by sympathomimetic amines",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6091405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Phenoxybenzamine may be confused with phenazopyridine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F209102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: GI irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Inhibition of ejaculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F209072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenoxybenzamine or any component of the formulation; conditions in which a fall in blood pressure would be undesirable (eg, shock)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F209057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: An exaggerated hypotensive response and tachycardia may occur when administered concurrently with compounds that stimulate both alpha- and beta-adrenergic receptors or in the setting of pheochromocytoma. Discontinue if symptoms of severe hypotension or angina occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstructive atherosclerosis: Use with caution in patients with obstructive cerebral or coronary atherosclerosis, since a marked reduction in blood pressure may induce ischemic symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory tract infection: Can exacerbate symptoms of respiratory tract infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be at higher risk of adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Not recommended for long-term use due to case reports of cancer in humans.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F209079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, (may worsen hypertension). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6091406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate animal reproduction studies have not been conducted. It is not known whether phenoxybenzamine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6091408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F209073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Dibenzyline Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $975.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F209065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, pulse, urine output, orthostatics",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dibenyline (AE, AU, BE, BF, BH, BJ, CI, CY, EG, ET, GB, GH, GM, GN, GR, HK, IL, IQ, IR, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Dibenzyran (AT, DE);",
"     </li>",
"     <li>",
"      Fenoxene (IN);",
"     </li>",
"     <li>",
"      Lition (TW);",
"     </li>",
"     <li>",
"      Seton (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F209056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces long-lasting noncompetitive alpha-adrenergic blockade of postganglionic synapses in exocrine glands and smooth muscle; relaxes urethra and increases opening of the bladder",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F209071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V.: &ge;3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 20% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hack HA, &ldquo;The Perioperative Management of Children With Phaeochromocytoma,&rdquo;",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2000, 10(5):463-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38916/abstract-text/11012949/pubmed\" id=\"11012949\" target=\"_blank\">",
"        11012949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kinney MA, Narr BJ, and Warner MA, &ldquo;Perioperative Management of Pheochromocytoma,&rdquo;",
"      <i>",
"       J Cardiothorac Vasc Anesth",
"      </i>",
"      , 2002, 16(3):359-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38916/abstract-text/12073213/pubmed\" id=\"12073213\" target=\"_blank\">",
"        12073213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kinney MA, Warner ME, vanHeerden JA, et al, &ldquo;Perianesthetic Risks and Outcomes of Pheochromocytoma and Paraganglioma Resection,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2000, 91(5):1118-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38916/abstract-text/11049893/pubmed\" id=\"11049893\" target=\"_blank\">",
"        11049893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Te AE, &ldquo;A Modern Rationale for the Use of Phenoxybenzamine in Urinary Tract Disorders and Other Conditions,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2002, 24(6):851-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38916/abstract-text/12117078/pubmed\" id=\"12117078\" target=\"_blank\">",
"        12117078",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9764 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38916=[""].join("\n");
var outline_f38_0_38916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209081\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209104\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209085\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209096\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209086\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209067\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209053\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209069\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209068\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209101\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6091405\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209102\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209072\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209057\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299865\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209062\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209079\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209063\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6091406\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6091408\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209073\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209065\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038765\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209056\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209071\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9764\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9764|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/35/23092?source=related_link\">",
"      Phenoxybenzamine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/58/19364?source=related_link\">",
"      Phenoxybenzamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_0_38917="Liotrix: Drug information";
var content_f38_0_38917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liotrix: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/14/27877?source=see_link\">",
"    see \"Liotrix: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/38/22118?source=see_link\">",
"    see \"Liotrix: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Thyroid Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Oral: Initial: Levothyroxine 25 mcg/liothyronine 6.25 mcg once daily; may increase by levothyroxine 12.5 mcg/liothyronine 3.1 mcg every 2-3 weeks. A lower initial dose (levothyroxine 12.5 mcg/liothyronine 3.1 mcg) is recommended in patients with long-standing myxedema, especially if cardiovascular impairment coexists. If angina occurs, reduce dose (usual maintenance dose: levothyroxine 50-100 mcg/liothyronine 12.5-25 mcg)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F189139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/38/22118?source=see_link\">",
"      see \"Liotrix: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Congenital hypothyroidism:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     In newly diagnosed infants, begin therapy with full dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 0-6 months: Levothyroxine 12.5-25 mcg/liothyronine 3.1-6.25 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 months: Levothyroxine 25-37.5 mcg/liothyronine 6.25-9.35 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1-5 years: Levothyroxine 37.5-50 mcg/liothyronine 9.35-12.5 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years: Levothyroxine 50-75 mcg/liothyronine 12.5-18.75 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years: Levothyroxine 75 mcg/liothyronine 18.75 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: Levothyroxine 12.5-25 mcg/liothyronine 3.1-6.25 mcg once daily; may increase by levothyroxine 12.5 mcg/liothyronine 3.1 mcg every 2-3 weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     [levothyroxine sodium 12.5 mcg and liothyronine sodium 3.1 mcg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     [levothyroxine sodium 25 mcg and liothyronine sodium 6.25 mcg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;: 1 [levothyroxine sodium 50 mcg and liothyronine sodium 12.5 mcg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;: 2 [levothyroxine sodium 100 mcg and liothyronine sodium 25 mcg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyrolar&reg;: 3 [levothyroxine sodium 150 mcg and liothyronine sodium 37.5 mcg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Replacement or supplemental therapy in hypothyroidism (uniform mixture of T",
"     <sub>",
"      4",
"     </sub>",
"     :T",
"     <sub>",
"      3",
"     </sub>",
"     in 4:1 ratio by weight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid-stimulating hormone (TSH) suppressant therapy used in the management of thyroid cancer (levothyroxine is generally recommended for this indication); prevention or treatment of euthyroid goiters (eg, thyroid nodules, subacute or chronic lymphocytic thyroiditis [Hashimoto&rsquo;s], multinodular goiters)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diagnostic agent in suppression tests to diagnose suspected mild hyperthyroidism or to demonstrate thyroid gland autonomy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Liotrix may be confused with Klotrix&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Thyrolar&reg; may be confused with Thyrogen&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased, cardiac arrhythmia, chest pain, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, fever, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, hyperhydrosis, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Changes in menstrual cycle, increased appetite, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hand tremor, myalgia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic skin reactions (rare), diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to liotrix or any component of the formulation; uncorrected adrenal insufficiency; untreated thyrotoxicosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated; contraindicated in patients with uncorrected adrenal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution and initiate therapy at a lower dose in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated; initial dosage reduction is recommended in patients with long-standing myxedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly as these patients are more likely to have compromised cardiovascular function; lower initial dosage is recommended. Suppressed TSH levels may increase risk of atrial fibrillation and mortality secondary to cardiovascular disease (Gharib, 2010; Parle, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infertility (unapproved use): Use is not justified for the treatment of male or female infertility in euthyroid patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight reduction (unapproved use):",
"     <b>",
"      [U.S. Boxed Warning]: In euthyroid patients, thyroid supplements are ineffective and potentially toxic for weight reduction. High doses may produce serious or even life-threatening toxic effects, particularly when used with some anorectic drugs.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13842638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Management: Take once a day on an empty stomach 30-60 minutes before meals.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Liotrix has not been found to increase the risk of adverse effects following maternal use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes. To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13135918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12976275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous thyroid hormones are minimally found in breast milk and are not associated with adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thyrolar-1 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 (12.5-50) mg (mcg) (100): $76.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thyrolar-1/2 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 (6.25-25) mg (mcg) (100): $60.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thyrolar-1/4 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 (3.1-12.5) mg (mcg) (100): $54.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thyrolar-2 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 (25-100) mg (mcg) (100): $89.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Thyrolar-3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 (37.5-150) mg (mcg) (100): $109.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F189110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     , TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T",
"     <sub>",
"      4",
"     </sub>",
"     remains low and TSH is within normal limits, an evaluation of &ldquo;free&rdquo; (unbound) T",
"     <sub>",
"      4",
"     </sub>",
"     is needed to evaluate further increase in dosage.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F189113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     TSH: Age 21-54 years: 0.4-4.2 mIU/L; Age 55-87 years: 0.5-8.9 mIU/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     : 4-12 mcg/dL (SI: 51-154 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     T",
"     <sub>",
"      3",
"     </sub>",
"     (RIA) (total T",
"     <sub>",
"      3",
"     </sub>",
"     ): 80-230 ng/dL (SI: 1.2-3.5 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     free (free T",
"     <sub>",
"      4",
"     </sub>",
"     ): 0.7-1.8 ng/dL (SI: 9-23 pmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Thyreotom (CY, EG, IQ, JO, LY, SY);",
"     </li>",
"     <li>",
"      Thyreotom Forte (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The primary active compound is T",
"     <sub>",
"      3",
"     </sub>",
"     (triiodothyronine), which may be converted from T",
"     <sub>",
"      4",
"     </sub>",
"     (thyroxine) and then circulates throughout the body to influence growth and maturation of various tissues. Liotrix is uniform mixture of synthetic T",
"     <sub>",
"      4",
"     </sub>",
"     and T",
"     <sub>",
"      3",
"     </sub>",
"     in 4:1 ratio; exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores and stimulates protein synthesis, increases basal metabolic rate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Liothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ): ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Thyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ): 40% to 80%; T",
"     <sub>",
"      3",
"     </sub>",
"     : 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: T",
"     <sub>",
"      4",
"     </sub>",
"     : &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to triiodothyronine (active); ~80% T",
"     <sub>",
"      4",
"     </sub>",
"     deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     : Euthyroid: 6-7 days; Hyperthyroid: 3-4 days; Hypothyroid: 9-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T",
"     <sub>",
"      3",
"     </sub>",
"     : 2.5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: T",
"     <sub>",
"      4",
"     </sub>",
"     : 2-4 hours; T",
"     <sub>",
"      3",
"     </sub>",
"     : 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (major route of elimination); partially feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Helfand M and Crapo LM, &ldquo;Monitoring Therapy in Patients Taking Levothyroxine,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1990, 113(6):450-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38917/abstract-text/2143640/pubmed\" id=\"2143640\" target=\"_blank\">",
"        2143640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson DG and Campbell S, &ldquo;Hormonal and Metabolic Agents,&rdquo;",
"      <i>",
"       Geriatric Pharmacology",
"      </i>",
"      , Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parle JV, Maisonneuve P, Sheppard MC, et al, &ldquo;Prediction of All-Cause and Cardiovascular Mortality in Elderly People from One Low Serum Thryotropin Result: A 10-year Cohort Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 358(9285):861-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38917/abstract-text/11567699/pubmed\" id=\"11567699\" target=\"_blank\">",
"        11567699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanders LR, &ldquo;Pituitary, Thyroid, Adrenal and Parathyroid Diseases in the Elderly,&rdquo;",
"      <i>",
"       Geriatric Medicine",
"      </i>",
"      , 1990, 475-87.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sawin CT, Geller A, Hershman JM, et al, &ldquo;The Aging Thyroid. The Use of Thyroid Hormone in Older Persons,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1989, 261(18):2653-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38917/abstract-text/2709545/pubmed\" id=\"2709545\" target=\"_blank\">",
"        2709545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts NB, &ldquo;Use of a Sensitive Thyrotropin Assay for Monitoring Treatment With Levothyroxine,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(2):309-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38917/abstract-text/2644903/pubmed\" id=\"2644903\" target=\"_blank\">",
"        2644903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9564 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-581423BC0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38917=[""].join("\n");
var outline_f38_0_38917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709014\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189131\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189132\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189142\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189135\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189139\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189136\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189112\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189095\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189114\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189147\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189140\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189117\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189099\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299608\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189104\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842638\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189107\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189120\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135918\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12976275\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422261\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189110\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189113\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189121\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189098\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189116\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9564|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/14/27877?source=related_link\">",
"      Liotrix: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/38/22118?source=related_link\">",
"      Liotrix: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_0_38918="Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy";
var content_f38_0_38918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38918/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38918/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38918/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38918/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38918/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38918/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38918/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/0/38918/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate specific antigen (PSA) is a sensitive marker for prostate tissue, with serum levels elevated in approximately 95 percent of men with advanced prostate cancer. Due to the sensitivity of serum PSA as a marker for prostate cancer, serial PSA measurements are routinely obtained to detect early disease recurrence in men who have had aggressive primary therapy for localized disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=see_link\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring PSA after definitive treatment of localized prostate cancer leads to the identification of men with a PSA-only (biochemical) recurrence. In this situation, increases in serum PSA are not accompanied by signs or symptoms of recurrent or disseminated disease. Many of these men are relatively young and otherwise healthy, intense interest has been focused upon their management, with particular attention to survival and the impact of therapy on quality of life.",
"   </p>",
"   <p>",
"    Management options for men with a PSA-only recurrence after radical prostatectomy include external beam radiation therapy (RT) to the prostatic bed with or without treatment of the pelvic lymph nodes (salvage RT), androgen deprivation therapy (ADT), a combination of salvage RT plus ADT, or observation. Most of the available data regarding these approaches has come from observational series. Long-term results of randomized clinical trials will be required to define the optimal approach.",
"   </p>",
"   <p>",
"    The use of salvage RT for men who have a rising PSA following radical prostatectomy for early stage disease will be reviewed here. Other topics relevant to patients with a rising PSA include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33544?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20983?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1656?source=see_link\">",
"       \"Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=see_link\">",
"       \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81457419\">",
"    <span class=\"h1\">",
"     DEFINITION OF BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All prostate tissue is removed during a successful radical prostatectomy. Postoperatively, detectable serum PSA using standard immunoassays is indicative of residual prostatic tissue, which presumably represents locoregional or systemic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most widely accepted criterion for patients who have undergone radical prostatectomy is that of the American Urological Association (AUA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/2\">",
"     2",
"    </a>",
"    ]. According to AUA guidelines, a biochemical recurrence is defined as a serum PSA &ge;0.2",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    which is confirmed by a second determination with a PSA &ge;0.2",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33544?source=see_link&amp;anchor=H5#H5\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radical prostatectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF BIOCHEMICAL FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of a PSA-only recurrence can be highly varied, reflecting heterogeneous tumor biology. Biochemical failure by itself does not necessarily predict death from prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33544?source=see_link&amp;anchor=H81453304#H81453304\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Prognosis after biochemical failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This heterogeneity is illustrated by the experience at Johns Hopkins in a series of 1997 radical prostatectomies performed between 1982 and 1987, in which 315 (15 percent) developed a PSA-only recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/3\">",
"     3",
"    </a>",
"    ]. The median time to the development of radiologically detectable metastases after PSA elevation was eight years, and the median time to death after the development of metastases was five years. Men with a Gleason score of 8 to 10, a PSA recurrence less than two years after surgery, or a rapid PSA doubling time had a significantly greater risk of developing metastases and dying of prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SALVAGE RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with a recurrence following radical prostatectomy, salvage external beam RT can provide long-term disease control if the recurrence is encompassed within the treatment field and a sufficient radiation dose can be delivered to eradicate the",
"    <span class=\"nowrap\">",
"     residual/recurrent",
"    </span>",
"    cancer. The success of salvage RT depends upon dose and treatment volume (ie, prostate bed with or without pelvis), in addition to the localization of all clonogenic cells to the treatment field.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial retrospective studies that attempted to define patients who would benefit from salvage RT relied upon biochemical relapse-free survival (bRFS), rather than cancer-specific survival or the development of metastatic disease.",
"   </p>",
"   <p>",
"    Numerous studies have analyzed the factors associated with biochemical relapse following salvage RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. Factors associated with an improved bRFS included a positive surgical margin at prostatectomy, a low PSA level at recurrence, and a long recurrence-free interval following initial surgery. In contrast, a short (eg, &lt;6 months) PSA doubling time, Gleason score &ge;8, a history of lymph node or seminal vesicle involvement at original diagnosis, and a persistent elevation of PSA following RT were all associated with poorer bRFS in those managed with salvage RT.",
"   </p>",
"   <p>",
"    Although these studies have been used to define patients who were more likely to benefit from salvage RT, these analyses were retrospective and did not include a control group that was managed with observation rather than active intervention. Thus, the factors identified in these studies may have been prognostic for the development of biochemical relapse and not predictive of improved cancer-specific survival in response to treatment with salvage RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Impact on survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three large retrospective single-institution series provide conflicting data on whether or not salvage RT as a single modality can prolong survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 2657 men treated at the Mayo Clinic who had a biochemical recurrence following radical prostatectomy, 856 (32 percent) received salvage RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/11\">",
"       11",
"      </a>",
"      ]. On multivariate analysis, salvage RT significantly reduced the incidence of subsequent local recurrence (HR 0.13, 95% CI 0.06-0.28). However, salvage RT did not significantly decrease mortality compared to those not receiving salvage RT following biochemical recurrence (5 and 10 year survival rates, 92 versus 91 and 70 versus 69 percent, respectively).",
"     </li>",
"     <li>",
"      A study from Johns Hopkins analyzed 635 patients who had either a biochemical or local recurrence following radical prostatectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/10\">",
"       10",
"      </a>",
"      ]. At recurrence, patients were managed with observation, salvage RT alone, or salvage RT in combination with hormonal therapy in 63, 25, and 12 percent of cases, respectively. Cancer-specific survival was significantly prolonged in patients who received RT, with or without hormonal therapy, compared to observation (96 and 96 versus 88 percent at five years, and 82 and 86 versus 62 percent at 10 years).",
"     </li>",
"     <li>",
"      RT appeared to prolong survival in both groups in a series of 4036 men who underwent radical prostatectomy at Duke between 1988 and 2008, irrespective of whether the PSA doubling time was short or long [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/12\">",
"       12",
"      </a>",
"      ]. This cohort included 519 men who had a biochemical recurrence and were fully evaluable. Salvage RT was given, either alone or as part of a combined approach that included ADT, in 219 of these patients (37 percent). At a median follow-up of 11.3 years, multivariate analysis demonstrated a significant decrease in all cause mortality both in those with a PSA doubling time less than six months and in those with a PSA doubling time greater than or equal to six months (adjusted hazard ratios 0.53 and 0.52, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the limitations inherent in these retrospective studies, these results provide good evidence that salvage RT shortly after biochemical relapse can alter the natural history of prostate cancer.",
"   </p>",
"   <p>",
"    Careful surveillance and early salvage RT following surgery (eg, while PSA still less than 1.0",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    may be an appropriate alternative to immediate adjuvant RT for patients with high-risk primary prostate cancer managed with surgery. Immediate, postoperative adjuvant RT and early salvage RT are being compared in the RADICALS trial sponsored by the Medical Research Council in the United Kingdom (NCT00541047) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33943?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Adjuvant RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dose and treatment volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that study the optimal radiation dose in salvage RT. In 1999, ASTRO guidelines recommended that the dose should be at least 64 Gy for salvage RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/14\">",
"     14",
"    </a>",
"    ]. More recently, a number of retrospective series report better outcomes when doses above 65 Gy are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether RT should be limited to the prostate bed or should include pelvic irradiation is controversial. In our practice we recommend small-field RT for two reasons.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial (EORTC 22911) observed an improvement in biochemical relapse-free survival but not overall survival at 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/18\">",
"       18",
"      </a>",
"      ], while a second trial (SWOG 8794) observed an improvement in both metastasis-free and overall survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/19\">",
"       19",
"      </a>",
"      ]. The results of these trials are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33943?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Adjuvant RT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of more extensive pelvic irradiation was assessed in two trials in men whose prostate cancer was managed with definitive RT. In that setting, two large randomized trials (RTOG 9413 and GETUG-01) failed to show an improvement in survival among men who were assigned to treatment with prostate plus pelvic lymph node RT compared to treatment limited to the prostate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. However, these trials used RT to for primary therapy of prostate cancer rather than in the salvage setting. These trials, as well as other data addressing the extent of the RT field, are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=see_link&amp;anchor=H17#H17\">",
"       \"External beam radiation therapy for localized prostate cancer\", section on 'Whole pelvis versus prostate only RT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of elective pelvic irradiation in men with a rising PSA following surgery is being addressed in an ongoing multicenter trial (RTOG 0534, NCT00567580), although only in the context of men who are receiving ADT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/13\">",
"     13",
"    </a>",
"    ]. That trial does not include an arm with RT to the pelvic lymph nodes without ADT. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Salvage RT plus ADT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salvage RT after a previous radical prostatectomy is generally well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a multi-institution database study of 959 men who received postoperative RT (81 percent as salvage and 19 percent as adjuvant therapy), the five-year rates of late grade 3 genitourinary and gastrointestinal side effects were 1 and 0.4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SALVAGE RT PLUS ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of androgen deprivation therapy (ADT) to definitive RT benefits men with high-risk clinically localized prostate cancer as well as those with locally advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=see_link&amp;anchor=H3126101#H3126101\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'ADT with external beam RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=see_link&amp;anchor=H2956464#H2956464\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'External beam RT plus ADT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two large randomized trials being conducted by the Radiation Therapy Oncology Group (RTOG) eventually should provide important information about the role of hormonal therapy in conjunction with RT in the management of patients with a rising serum PSA. RTOG 9601 (NCT00002874) and RTOG 0534 (NCT00567580) both include patients with persistent elevation of PSA after radical prostatectomy as well as those with a rising PSA after radical prostatectomy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In RTOG 9601, there was a statistically significant improvement in freedom from PSA progression with when adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"       bicalutamide",
"      </a>",
"      was added to RT compared with RT alone (57 versus 40 percent) and a statistically significant decrease in the incidence of metastatic disease (7 versus 13 percent). The actuarial overall survival rates at seven years were 91 and 86 percent, respectively, which did not reach statistical significance. However, there were too few deaths to permit a statistical comparison of overall survival. In addition, the trial used bicalutamide monotherapy, not a GnRH agonist, an approach that is unconventional in the United States.",
"     </li>",
"     <li>",
"      In RTOG 0534, patients are randomly assigned to RT alone to the prostate bed, RT to the prostate bed combined with neoadjuvant and concurrent ADT, or RT to the prostate bed and pelvic lymph nodes with neoadjuvant and concurrent ADT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38918/abstract/24\">",
"       24",
"      </a>",
"      ]. The trial does not include an arm with RT to the pelvic lymph nodes without ADT. RTOG 0534 is currently enrolling patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33943?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Concurrent ADT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the available preliminary data from RTOG 9601 and from observational series, it is reasonable to recommend short-term ADT (four to six months) with salvage RT for men with very unfavorable risk factors at the time of radical prostatectomy (eg, PSA&gt;20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    Gleason score &ge;8, seminal vesicle invasion, low volume metastases to regional lymph node).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADT ALONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ADT alone, intermittent androgen deprivation, or antiandrogen monotherapy in men failing radical prostatectomy for localized prostate cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=see_link&amp;anchor=H3#H3\">",
"     \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\", section on 'Androgen deprivation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The routine monitoring of PSA after treatment of early stage prostate cancer has led to the identification of men with a PSA-only (biochemical) recurrence. In this situation, increases in serum PSA over pretreatment baseline are not accompanied by symptoms or signs of progressive disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men who have a PSA-only recurrence following radical prostatectomy and an otherwise favorable life expectancy, we recommend salvage RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although there are no randomized trials that address this topic, this approach is well tolerated and appears to extend cancer-specific survival compared to management with observation alone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dose and treatment volume'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Impact on survival'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men receiving salvage RT, we recommend a minimum RT dose of at least 64 Gy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), in keeping with the recommendations of a consensus panel convened by the American Society for Radiation Oncology (ASTRO). Based upon recent historical series that suggest that higher doses may be beneficial, our practice is to use a total dose of approximately 66 Gy while minimizing toxicity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dose and treatment volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment volume is controversial. We suggest that outside of a clinical trial setting, RT be limited to the prostate bed and not include the pelvic lymph nodes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The RTOG trial 0534 is currently assessing whether there is an additional benefit from more extensive RT fields, and patients should be enrolled on protocol whenever possible. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dose and treatment volume'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Salvage RT plus ADT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of ADT in conjunction with RT is uncertain. The role of ADT is being investigated in RTOG 0534, and patients should be enrolled on protocol whenever possible. Outside of a clinical trial, we suggest limiting the use of ADT to men with very unfavorable risk factors at the time of radical prostatectomy (eg, Gleason score &ge;8 or preoperative PSA &gt;20) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When we do use hormonal therapy, we use ADT before and during salvage RT (four to six months total). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Salvage RT plus ADT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=see_link&amp;anchor=H3126101#H3126101\">",
"       \"External beam radiation therapy for localized prostate cancer\", section on 'ADT with external beam RT'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=see_link&amp;anchor=H2956464#H2956464\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'External beam RT plus ADT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For elderly men and those with severe comorbidities, observation in the absence of overt metastases is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Natural history of biochemical failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/1\">",
"      Ravery V. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 1999; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/2\">",
"      Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/3\">",
"      Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/4\">",
"      Pazona JF, Han M, Hawkins SA, et al. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 2005; 174:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/5\">",
"      Buskirk SJ, Pisansky TM, Schild SE, et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006; 176:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/6\">",
"      Ward JF, Zincke H, Bergstralh EJ, et al. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004; 172:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/7\">",
"      Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/8\">",
"      Macdonald OK, D'Amico AV, Sadetsky N, et al. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE database. Urol Oncol 2008; 26:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/9\">",
"      Wiegel T, Lohm G, Bottke D, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Int J Radiat Oncol Biol Phys 2009; 73:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/10\">",
"      Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/11\">",
"      Boorjian SA, Karnes RJ, Crispen PL, et al. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol 2009; 182:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/12\">",
"      Cotter SE, Chen MH, Moul JW, et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 2011; 117:3925.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on February 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/14\">",
"      Cox JD, Gallagher MJ, Hammond EH, et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999; 17:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/15\">",
"      King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008; 71:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/16\">",
"      Bernard JR Jr, Buskirk SJ, Heckman MG, et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 2010; 76:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/17\">",
"      Tomita N, Kodaira T, Furutani K, et al. Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy. J Cancer Res Clin Oncol 2009; 135:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/18\">",
"      Bolla M, Van POPPEL H, Tombal B. 10-year results of adjuvant radiotherapy after radical prostatectomy in pT3N0 prostate cancer. Int J Radiat Biol Phys 2010; 78:s29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/19\">",
"      Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/20\">",
"      Lawton CA, DeSilvio M, Roach M 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/21\">",
"      Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007; 25:5366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/22\">",
"      Peterson JL, Buskirk SJ, Heckman MG, et al. Late toxicity after postprostatectomy salvage radiation therapy. Radiother Oncol 2009; 93:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38918/abstract/23\">",
"      Feng M, Hanlon AL, Pisansky TM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2007; 68:1417.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on September 14, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6952 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38918=[""].join("\n");
var outline_f38_0_38918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81457419\">",
"      DEFINITION OF BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY OF BIOCHEMICAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SALVAGE RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Impact on survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dose and treatment volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SALVAGE RT PLUS ADT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADT ALONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33943?source=related_link\">",
"      Pathologic stage T3 and margin positive prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1656?source=related_link\">",
"      Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=related_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33544?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20983?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_0_38919="Ticagrelor: Drug information";
var content_f38_0_38919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ticagrelor: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/27/8629?source=see_link\">",
"    see \"Ticagrelor: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13159402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13159403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brilinta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12911320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Brilinta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12911322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent;",
"     </li>",
"     <li>",
"      Antiplatelet Agent, Cyclopentyltriazolopyrimidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12911370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute coronary syndrome:",
"     </b>",
"     Unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI): Initial: 180 mg loading dose (with a loading dose of aspirin [eg, 325 mg] if not already receiving); Maintenance: 90 mg twice daily; initiated 12 hours after initial loading dose (with low-dose aspirin 75-100 mg/day or 81 mg/day in patients with UA/NSTEMI as recommended by the ACC/AHA [Jneid, 2012]). For UA/NSTEMI patients managed medically, continue ticagrelor for up to 12 months (Jneid, 2012).",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends a maintenance aspirin dose of 75-150 mg/day. Safety and efficacy of therapy beyond 12 months has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Duration of ticagrelor (in combination with aspirin) after stent placement:",
"     </i>",
"     <b>",
"      Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI.",
"     </b>",
"     Those with ACS receiving either stent type (bare metal [BMS] or drug-eluting stent [DES]) or those receiving a DES for a non-ACS indication, ticagrelor for at least 12 months is recommended. A duration &gt;12 months may be considered in patients with DES placement. Those receiving a BMS for a non-ACS indication should be given at least 1 month and ideally up to 12 months; if patient is at increased risk of bleeding, give for a minimum of 2 weeks (Levine, 2011). A duration &gt;12 months, regardless of indication, may be considered in patients with DES placement (Jneid, 2012; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Conversion from clopidogrel to ticagrelor:",
"     </i>",
"     May initiate ticagrelor 90 mg twice daily beginning 24 hours after last clopidogrel dose (loading or maintenance); patients who are in the acute phase of an acute coronary syndrome, especially if determined to be clopidogrel nonresponsive, may be considered for administration of ticagrelor 180 mg loading dose followed by 90 mg twice daily regardless of previous clopidogrel exposure, taking into consideration the administration of other antiplatelet agents (eg, GP IIb/IIIa inhibitors) (Gurbel, 2010; Wallentin, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     In general, conversion to ticagrelor results in an absolute inhibition of platelet aggregation (IPA) increase of 26.4%.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12911371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12911373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Use caution; drug is thought to be nondialyzable.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12911372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, undergoes hepatic metabolism; use caution. Use is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13168279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brilinta&trade;: 90 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F12911391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brilinta&reg;: 90 mg",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13135647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM264220.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM264220.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12911378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Missed doses should be taken at their next regularly scheduled time.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12911323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used in conjunction with aspirin for secondary prevention of thrombotic events in patients with unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14941561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients with allergy or major gastrointestinal intolerance to aspirin, initial treatment of UA/NSTEMI;",
"     <b>",
"      Note:",
"     </b>",
"     Dual antiplatelet therapy with another P2Y",
"     <sub>",
"      12",
"     </sub>",
"     receptor inhibitor is not recommended in this situation (Jneid, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12911330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     As with all drugs which may affect hemostasis, bleeding is associated with ticagrelor. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents which alter hemostasis and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequencies as reported in PLATO trial versus clopidogrel:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Respiratory: Dyspnea (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Ventricular pauses (6%; 2% after 1 month of therapy), atrial fibrillation (4%), hypertension (4%), angina (3%), hypotension (3%), bradycardia (1% to 3%), cardiac failure (2%), peripheral edema (2%), ventricular tachycardia (2%), palpitation (1%), syncope (1%), ventricular extrasystoles (1%), ventricular fibrillation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (7%), dizziness (5%), fatigue (3%), fever (3%), anxiety (2%), insomnia (2%), vertigo (2%), depression (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising (2% to 4%), rash (2%), pruritus (1%), subcutaneous or dermal bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (2%), diabetes mellitus (1%), dyslipidemia (1%), hypercholesterolemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (4%), nausea (4%), vomiting (3%), abdominal pain (2%), constipation (2%), dyspepsia (2%), GI hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (2%), urinary tract bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Major bleeding (12%; composite of major fatal/life threatening and other major bleeding events),  minor bleeding (~5%), anemia (2%), hematoma (2%), postprocedural hemorrhage (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Puncture site hematoma (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (4%), noncardiac chest pain (4%), extremity pain (2%), arthralgia (2%), musculoskeletal pain (2%), weakness (2%), myalgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (7%; mechanism undetermined), hematuria (2%), renal failure (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Epistaxis (6%), cough (5%), nasopharyngitis (2%), bronchitis (1%), pneumonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, confusion, conjunctival hemorrhage, gastritis, gout, gynecomastia, hemarthrosis, hemoptysis, hypersensitivity, intracranial hemorrhage (including fatalities), intraocular hemorrhage, paresthesia, retinal hemorrhage, retroperitoneal hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12911326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, angioedema) to ticagrelor or any component of the formulation; active pathological bleeding (eg, peptic ulcer or intracranial hemorrhage); history of intracranial hemorrhage; severe hepatic impairment",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Moderate hepatic impairment; concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir, atazanavir, nefazodone)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12911327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding:",
"     <b>",
"      [U.S. Boxed Warning]: Ticagrelor increases the risk of bleeding including significant and sometimes fatal bleeding. Use is contraindicated in patients with active pathological bleeding and presence or history of intracranial hemorrhage.",
"     </b>",
"     Additional risk factors for bleeding include propensity to bleed (eg, recent trauma or surgery, recent or recurrent GI bleeding, active PUD, moderate-severe hepatic impairment), CABG or other surgical procedure, concomitant use of medications that increase risk of bleeding (eg, warfarin, NSAIDs), and advanced age. Bleeding should be suspected if patient becomes hypotensive after undergoing recent coronary angiography, PCI, CABG, or other surgical procedure even if overt signs of bleeding do not exist.",
"     <b>",
"      Where possible, manage bleeding without discontinuing ticagrelor as the risk of cardiovascular events is increased upon discontinuation.",
"     </b>",
"     If discontinuation of ticagrelor is necessary, resume as soon as possible after the bleeding source is identified and controlled. Hemostatic benefits of platelet transfusions are not known; may inhibit transfused platelets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperuricemia: Use with caution in patients with a history of hyperuricemia or gouty arthritis. Renal uptake and transport of uric acid are inhibited by ticagrelor and its active metabolite and the risk of hyperuricemia may be increased. However, reports of gout did not differ between treatment groups in Platelet Inhibition and Patient Outcomes (PLATO) trial. Canadian labeling does not recommend use in patients with uric acid nephropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory: Dyspnea (often mild-to-moderate and transient) was observed more frequently in patients receiving ticagrelor than clopidogrel during clinical trials; resolution of dyspnea was observed within 1 week in approximately one-third of patients.  Patients with new, prolonged, or worsening dyspnea should be evaluated to rule out underlying disease. Ticagrelor-related dyspnea does not require specific treatment nor does it warrant therapy interruption.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends discontinuing therapy in patients unable to tolerate ticagrelor-related dyspnea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with platelet disorders, bleeding disorders, and/or at increased risk for bleeding (eg, PUD, trauma, or surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients who are at an increased risk of bradycardia (eg, second- or third-degree AV block, sick sinus syndrome) or taking other bradycardic-inducing agents (eg, beta blockers, nondihydropyridine calcium channel blockers). Ventricular pauses &ge;3 seconds were noted more frequently with ticagrelor than with clopidogrel in a substudy of the PLATO trial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use is contraindicated in patients with severe hepatic impairment. Use in moderate hepatic impairment has not been studied. Canadian labeling also contraindicates use in moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Creatinine levels may rise during therapy (mechanism undetermined); monitor renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants and platelet aggregation inhibitors: Use with caution in patients receiving either anticoagulants (eg, heparin, warfarin) or other platelet aggregation inhibitors; bleeding risk is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin/other NSAIDs:",
"     <b>",
"      [U.S. Boxed Warning]: Maintenance doses of aspirin greater than 100 mg/day reduce the efficacy of ticagrelor and should be avoided.",
"     </b>",
"     Use of higher maintenance doses of aspirin (ie, &gt;100 mg/day) was associated with relatively unfavorable outcomes for ticagrelor versus clopidogrel in the PLATO trial (Gaglia, 2011; Wallentin, 2009). Canadian labeling recommends a maximum aspirin maintenance dose of 150 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Strong CYP3A4 inducers: Avoid concomitant use with strong CYP3A4 inducers (eg, rifampin, carbamazepine, dexamethasone, phenobarbital, phenytoin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Strong CYP3A4 inhibitors: Avoid concomitant use with strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, nefazodone). Canadian labeling contraindicates use with strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Surgical patients:",
"     <b>",
"      [U.S. Boxed Warning]: Avoid initiation of ticagrelor when urgent CABG surgery is planned; when possible, discontinue use at least 5 days before any surgery.",
"     </b>",
"     Discontinue therapy 5 days before elective surgery (except in patients with cardiac stents who have not completed their full course of dual antiplatelet therapy; patient-specific situations need to be discussed with cardiologist); restart ticagrelor as soon as possible after surgery. When urgent CABG is necessary, the ACCF/AHA CABG guidelines recommend discontinuation for at least 24 hours prior to surgery (Hillis, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Premature discontinuation of therapy may increase the risk of cardiac events (eg, stent thrombosis with subsequent fatal or nonfatal MI). Duration of therapy, in general, is determined by the type of stent placed (bare metal or drug eluting) and whether an ACS event was ongoing at the time of placement.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F12930100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (weak), CYP2C9 (moderate), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12931836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: May enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily. Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Ticagrelor may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Ticagrelor may increase the serum concentration of Lovastatin.  Management: Avoid using doses of lovastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Ticagrelor may increase the serum concentration of Simvastatin.  Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13159404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12911324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal mortality and/or abnormalities were observed in animal studies at doses greater than maximum recommended human doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefits outweigh potential risk to fetus. The Canadian labeling recommends women of childbearing potential use appropriate contraceptive measures.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12911325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion into breast milk is unknown; use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F12911385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Brilinta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (60): $284.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12911386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of bleeding; hemoglobin and hematocrit periodically; renal function; uric acid levels (patients with gout or at risk of hyperuricemia); signs/symptoms of dyspnea; may consider platelet function testing to determine platelet inhibitory response if results of testing may alter management (Jneid, 2012).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Brilinta (AU, BR, IL, KP, MY, NZ, TH);",
"     </li>",
"     <li>",
"      Brilique (CH, CZ, DE, DK, EE, FR, GB, NO, PL, PT, SE);",
"     </li>",
"     <li>",
"      Possia (EE, PL, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12911349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Reversibly and noncompetitively binds the adenosine diphosphate (ADP) P2Y",
"     <sub>",
"      12",
"     </sub>",
"     receptor on the platelet surface which prevents ADP-mediated activation of the GPIIb/IIIa receptor complex thereby reducing platelet aggregation. Due to the reversible antagonism of the P2Y",
"     <sub>",
"      12",
"     </sub>",
"     receptor, recovery of platelet function is likely to depend on serum concentrations of ticagrelor and its active metabolite.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12911351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of inhibition of platelet aggregation (IPA): 180 mg loading dose: ~41% within 30 minutes (similar to clopidogrel 600 mg at 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: Time to maximal IPA: 180 mg loading dose: IPA ~88% at 2 hours post administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of IPA: 180 mg loading dose: 87% to 89% maintained from 2-8 hours; 24 hours after the last maintenance dose, IPA is 58% (similar to maintenance clopidogrel)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Time after discontinuation when IPA is 30%: ~56 hours; IPA 10%: ~110 hours (Gurbel, 2009). Mean IPA observed with ticagrelor at 3 days post-discontinuation was comparable to that observed with clopidogrel at 5 days post discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 88 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &gt;99% (parent drug and active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4/5 to active metabolite (AR-C124910XX)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~36% (range: 30% to 42%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Parent drug: ~7 hours; active metabolite: ~9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Parent drug: ~1.5 hours; active metabolite (AR-C124910XX): ~2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (58%); urine (26%); actual amount of parent drug and active metabolite excreted in urine was &lt;1% of total dose administered",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannon CP, Harrington RA, James S, et al, &ldquo;Comparison of Ticagrelor With Clopidogrel in Patients With a Planned Invasive Strategy for Acute Coronary Syndromes (PLATO): A Randomised Double-Blind Strategy,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 375(9711):283-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/20079528/pubmed\" id=\"20079528\" target=\"_blank\">",
"        20079528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaglia MA Jr and Waksman R, \"Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(4):451-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/21242480/pubmed\" id=\"21242480\" target=\"_blank\">",
"        21242480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurbel PA, Bliden KP, Butler K, et al, &ldquo;Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 120(25):2577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/19923168/pubmed\" id=\"19923168\" target=\"_blank\">",
"        19923168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James S, Akerblom A, Cannon CP, et al, &ldquo;Comparison of Ticagrelor, the First Reversible Oral P2Y12 Receptor Antagonist, With Clopidogrel in Patients With Acute Coronary Syndromes: Rationale, Design, and Baseline Characteristics of the Platelet inhibition and Patient Outcomes (PLATO) Trial,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2009, 157(4):599-605.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/19332184/pubmed\" id=\"19332184\" target=\"_blank\">",
"        19332184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James S, Budaj A, Aylward P, et al, &ldquo;Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(11):1056-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/20805430/pubmed\" id=\"20805430\" target=\"_blank\">",
"        20805430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James SK, Roe MT, Cannon CP, et al, &ldquo;Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Intended for Non-invasive Management: Substudy from Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2011, 342:d3527.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/21685437/pubmed\" id=\"21685437\" target=\"_blank\">",
"        21685437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahaffey KW, Wojdyla DM, Carroll K, et al, &ldquo;Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      2011, 124(5):544-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/21709065/pubmed\" id=\"21709065\" target=\"_blank\">",
"        21709065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallentin L, Becker RC, Budaj A, et al, &ldquo;Ticagrelor versus Clopidogrel in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(11):1045-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/0/38919/abstract-text/19717846/pubmed\" id=\"19717846\" target=\"_blank\">",
"        19717846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16784 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-110.170.48.130-F96105F60D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38919=[""].join("\n");
var outline_f38_0_38919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13159402\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13159403\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911320\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911322\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911370\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911371\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911373\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911372\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168279\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911391\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135647\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911378\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911323\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14941561\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911330\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911326\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911327\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12930100\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12931836\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13159404\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911324\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911325\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911385\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322904\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911386\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276713\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911349\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12911351\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16784\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16784|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/27/8629?source=related_link\">",
"      Ticagrelor: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_0_38920="Food-induced anaphylaxis";
var content_f38_0_38920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Food-induced anaphylaxis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38920/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38920/contributors\">",
"     Hugh A Sampson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38920/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38920/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38920/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38920/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38920/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/0/38920/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food allergy affects about 6 to 8 percent of children less than five years of age and up to 4 percent of the general population in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/1\">",
"     1",
"    </a>",
"    ]. Anaphylaxis is \"a serious allergic reaction that is rapid in onset and may cause death,\" a definition developed by a consensus of international experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/2\">",
"     2",
"    </a>",
"    ]. Food is responsible for up to one-half of reported anaphylaxis cases presenting to emergency departments in developed countries around the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Food is the leading cause among identified triggers of anaphylaxis in children and young adults outside of the hospital setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review unique features of anaphylaxis caused by food, the characteristics of patients at risk for such reactions, and the foods which most often induce anaphylaxis. Differences between food-induced anaphylaxis in children and adults, and important issues in the diagnosis and management of this disorder are also discussed.",
"   </p>",
"   <p>",
"    Aspects of anaphylaxis that are not unique to food-induced reactions, such as diagnosis, acute treatment, and pathophysiology, are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18778?source=see_link\">",
"     \"Pathophysiology of anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=see_link\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of the use of skin testing and in vitro testing to diagnose food allergy is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF FOOD-INDUCED ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food-induced anaphylaxis refers to a serious allergic reaction following the ingestion of a food, which is generally rapid in onset and may progress to death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     IgE-mediated anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common form of food-induced anaphylaxis is that caused by the ingestion of a food to which the patient has IgE-mediated allergy. Symptoms typically appear within a few seconds to two hours after food ingestion and arise from massive mediator release from mast cells and basophils. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Signs and symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    IgE-mediated food-induced anaphylaxis accounts for the vast majority of reactions in older children and adults. The remainder of this topic review refers to IgE-mediated reactions, except where specifically noted.",
"   </p>",
"   <p>",
"    Anaphylaxis caused by food exposures other than ingestion, such as physical contact between food and skin or smelling of food has not been convincingly demonstrated. Inhalation of",
"    <span class=\"nowrap\">",
"     steam/vapors",
"    </span>",
"    from cooking food (eg, fish and shellfish) rarely induces anaphylactic reactions. Intimate contact with others who have been eating the culprit food is a rare cause of food-allergic reactions. These and other issues in food allergen avoidance are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Food-dependent, exercise-induced anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variant of food-induced anaphylaxis is food-dependent, exercise-induced anaphylaxis (FDEIAn), which refers to an IgE-mediated food-induced anaphylactic reaction that develops only when exercise is undertaken within a few hours of ingesting a food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. If the food is consumed without subsequent exercise or if exercise is performed without associated ingestion of the food, the patient does not develop allergic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/4,8\">",
"     4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most patients, FDEIAn only develops if a certain food, such as wheat, seafood, or nuts, is eaten in association with",
"    <span class=\"nowrap\">",
"     exercise/exertion",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In others, however, the ingestion of any solid food in association with exercise may induce reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypotensive reactions in infants with enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with food protein-induced enterocolitis, a form of non-IgE mediated food allergy, usually present with chronic illness, characterized by diarrhea, vomiting, and failure to thrive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/10\">",
"     10",
"    </a>",
"    ]. These symptoms improve once the culprit food is identified and removed from the diet. Reintroduction of the food, however, may precipitate acute vomiting beginning approximately two hours after ingestion, sometimes accompanied by diarrhea, lethargy, hypotension or shock, and acidosis. There may be an associated peripheral blood leukocytosis and thrombocytosis, which typically peaks within a few hours of allergen ingestion. Therapy involves fluid resuscitation and supportive care.",
"   </p>",
"   <p>",
"    Food protein-induced enterocolitis is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of emergency department visits and hospitalizations for food-induced anaphylaxis have been increasing in developed countries, particularly within the pediatric population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Obtaining absolute figures on the prevalence of food-induced anaphylaxis is difficult, however, because there have been no universally accepted diagnostic criteria, presenting symptoms are frequently misdiagnosed, and there are no central reporting agencies in most countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/2,15\">",
"     2,15",
"    </a>",
"    ]. The following represent estimates based on limited data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodes of anaphylaxis (from all causes) occur 50 to 2000 times per 100,000 persons, for a lifetime prevalence of 0.05 to 2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the early 1990s, it was estimated that there were approximately 150 deaths and 30,000 visits to emergency departments in the United States each year due to food-induced anaphylaxis, based upon extrapolation from a validated survey conducted in Olmsted County, Minnesota [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/4,17\">",
"       4,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Utilizing the National Electronic Injury Surveillance System, it was estimated that food allergy accounted for about 125,000 emergency department visits per year and 3100 hospitalizations in the US [14].",
"     </li>",
"     <li>",
"      The CDC estimated that there was a 3.5-fold increase in hospital discharges among children less than 18 years of age with any diagnosis related to food allergy between 1998 and 2006 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CAUSATIVE FOODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any food can cause anaphylaxis in a susceptible individual, although in the United States and Germany [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/19\">",
"     19",
"    </a>",
"    ], peanuts and tree nuts (walnuts, pecans, pistachios, cashews, and others) are responsible for the majority of severe anaphylactic reactions, followed by shellfish (crustaceans and mollusks) and fish. In other parts of the world, foods that are prominent in the regional diet are leading culprits, including sesame in Israel, and seafood in China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/5,20\">",
"     5,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional observations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Milk, egg, and sesame are more frequent culprits in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/4,21,22\">",
"       4,21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fatal food-induced anaphylactic reactions are most commonly induced by peanuts and tree nuts, based upon a few small series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/21,23\">",
"       21,23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"       \"Fatal anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wheat sensitivity is one of the most common causes in food-dependent, exercise-induced anaphylaxis, although shellfish, celery, other cereal grains, and a variety of foods have been implicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Certain mammalian meats (specifically beef, lamb, and pork) can cause anaphylaxis that is delayed in onset by several hours, sometimes waking patients in the middle of the night. Although meat is not a common cause of food-induced anaphylaxis, awareness of its unique presentation is critical to identifying the responsible food. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36072?source=see_link&amp;anchor=H25949260#H25949260\">",
"       \"Allergy to meats\", section on 'Clinical reactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anyone with IgE-mediated food allergy may develop food-induced anaphylaxis, although most food-allergic individuals will experience lesser reactions without ever developing anaphylaxis. Several factors are known to place certain individuals at greater risk for anaphylaxis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The concomitant presence of asthma (although the severity of asthma does not appear to be a factor)",
"     </li>",
"     <li>",
"      Allergy to peanuts, tree nuts, fish, or shellfish",
"     </li>",
"     <li>",
"      Past allergic reactions to extremely small amounts of food (ie, extreme sensitivity)",
"     </li>",
"     <li>",
"      A history of a previous food-induced anaphylactic reaction of any severity (most victims of fatal reactions had relatively mild reactions in the past) (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Fatal reactions'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food-induced anaphylactic reactions occur when sufficient food allergen crosses the oral or gastrointestinal mucosal barrier (or the respiratory mucosal barrier in rare cases of inhalation of steam or particulates containing food allergen proteins). Once food allergen has traversed a mucosal barrier, it circulates throughout the body and cross-links food allergen-specific IgE antibodies bound to circulating basophils and tissue mast cells in the skin, gastrointestinal tract, respiratory tract,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the cardiovascular system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/24\">",
"     24",
"    </a>",
"    ]. Activation of these cells results in their release of a variety of proinflammatory mediators. The pathophysiology of anaphylaxis is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18778?source=see_link\">",
"     \"Pathophysiology of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis from food or other triggers usually progresses in a rapid and uniphasic manner, although a subset of individuals experience biphasic reactions or protracted reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Biphasic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biphasic anaphylaxis is defined as a recurrence of symptoms that develop following the apparent resolution of the initial anaphylactic event. Biphasic reactions have been reported to develop in up to 20 percent of anaphylactic reactions and typically occur within one to four hours following the resolution of the initial symptoms, although some cases have been reported up to 78 hours later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Protracted anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protracted anaphylaxis is defined as an anaphylactic reaction that lasts for hours, or even days in extreme cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food-induced anaphylactic reactions provoke signs and symptoms similar to anaphylactic reactions induced by other causes, although gastrointestinal symptoms tend to be more prominent (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Gastrointestinal manifestations may include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nausea",
"     </li>",
"     <li>",
"      Abdominal pain or colic",
"     </li>",
"     <li>",
"      Vomiting (large amounts of \"stringy\" mucus)",
"     </li>",
"     <li>",
"      Diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other signs and symptoms, in order from mild to severe, include the following: pruritus, flushing,",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    periorbital edema, conjunctival injection, rhinorrhea, nasal congestion, cough, wheezing, dyspnea, change of voice quality, sense of choking, tachycardia (or bradycardia less commonly), dizziness, hypotension, sense of impending doom, and cardiovascular collapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Evolution of symptoms during reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms that present when a patient is first seen may be quite variable and not immediately suggestive of an anaphylactic reaction. In most cases, however, a careful history and attention to the evolution of symptoms should enable the clinician to make the correct diagnosis.",
"   </p>",
"   <p>",
"    As an example, a six-year-old boy with a history of asthma presents with wheezing and cough since arriving home from school, although his mother states that he was well that morning and she received no calls from his teacher during the day. He then begins to vomit while receiving nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    . He has never had any problems with albuterol in the past. On closer examination, the boy is flushed and has scattered urticaria on his neck and in his axillae. Further questioning reveals that he shared a candy bar during the bus ride home. The mother then recalls a previous \"asthma attack\" a few months earlier after he had eaten trail mix, although she did not make a connection between the two events at the time. The evolution of this patient's symptoms should alert the clinician to the correct diagnosis of anaphylaxis, possibly triggered by peanuts or tree nuts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differences between children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants and young children experiencing food-allergic reactions, gastrointestinal and cutaneous symptoms tend to be most prominent, and shock is less common than in adults.",
"   </p>",
"   <p>",
"    The frequency of presenting symptoms in anaphylaxis differs somewhat between children and adults, with children manifesting cardiovascular symptoms less often and respiratory symptoms more often than their adult counterparts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/3,19,27\">",
"     3,19,27",
"    </a>",
"    ]. In infants and very young children, cutaneous, gastrointestinal, and respiratory symptoms were most prominent. In these series, fatal anaphylaxis was primarily due to respiratory compromise in children, in contrast to cardiovascular complications in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Factors affecting presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, it is unclear why a specific food-allergic individual may ingest a food allergen on a number of occasions and experience only mild symptoms, whereas on another occasion, a life-threatening reaction develops.",
"   </p>",
"   <p>",
"    There are several factors specific to particular incidents, however, which are believed to impact the onset and severity of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/21,28-30\">",
"     21,28-30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The quantity of food allergen ingested: the larger the dose, the more rapid and pronounced the onset of symptoms",
"     </li>",
"     <li>",
"      The composition of the food containing the allergen: fatty foods tend to slow absorption rate and delay",
"      <span class=\"nowrap\">",
"       onset/prolong",
"      </span>",
"      onset of symptoms",
"     </li>",
"     <li>",
"      The concomitant ingestion of alcohol, which leads to more rapid and pronounced symptoms",
"     </li>",
"     <li>",
"      The concomitant administration of NSAIDS, which may increase gastric permeability to food allergens",
"     </li>",
"     <li>",
"      Accidental ingestion: in one series, 87 percent of patients were aware of their food allergy, but ingested the food unknowingly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FATAL REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 1 percent of anaphylaxis cases (from all causes) prove fatal. These reactions typically progress rapidly, with symptoms appearing a median of 25 to 35 minutes following ingestion of the allergen, and death ensuing in less than an hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/30\">",
"     30",
"    </a>",
"    ]. A more general discussion of fatal anaphylaxis from all causes is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatal food allergic reactions are most common in adolescents and young adults, although patients of all ages may succumb [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/21,26\">",
"     21,26",
"    </a>",
"    ]. Possible contributing factors among young people include increasing independence in decision-making, risk-taking behaviors, susceptibility to peer pressure, and ingesting risky foods at social and sporting events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/31\">",
"     31",
"    </a>",
"    ]. In an internet-based anonymous survey of 176 adolescents and young adults with food allergy, more than one-half reported purposefully ingesting a potentially unsafe food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, 17 percent both ate foods that \"may contain\" allergens, and did not consistently carry",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjectors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Features of fatal food reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals dying from a food-allergic reaction had experienced previous reactions, although these reactions were rarely severe, illustrating the important concept that the severity of previous reactions cannot be relied upon to predict the severity of future reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/21,30\">",
"     21,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous signs and symptoms were less common in fatal food-induced anaphylaxis, compared to reactions in which patients survived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/26\">",
"     26",
"    </a>",
"    ]. The reasons for this phenomenon are not known, although it may reflect the rapid development of hypotension in the fatal reactions, such that there was not enough time or intravascular pressure for the allergen to reach mast cells in peripheral tissues.",
"   </p>",
"   <p>",
"    Three reviews of food-induced fatal anaphylaxis comprising a total of 111 deaths indicated that 76 percent occurred outside of the victim's home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/21,23,32\">",
"     21,23,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Delayed administration of epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    should be administered as soon as possible in the setting of anaphylaxis. Delayed administration of epinephrine is believed to be a contributing factor in some fatal reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/21,23,26\">",
"     21,23,26",
"    </a>",
"    ]. In a study of 13 fatal or near-fatal food-induced anaphylactic reactions in children, six of the seven children who survived received epinephrine within 30 minutes of ingesting the allergen, whereas only two of the six children who died received epinephrine within the first hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ISSUES IN DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of food-induced anaphylaxis is made clinically, based upon a detailed history of clinical events, including the consumption of any food or drink prior to the episode, associated exertion or exercise, progression of clinical signs and symptoms, and response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Application of diagnostic criteria to food-induced anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have suggested that anaphylaxis is often misdiagnosed and underreported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Diagnosis has been hampered by a lack of agreement on the exact criteria that constitute anaphylaxis. To address this problem, the National Institutes of Health and the Food Allergy and Anaphylaxis Network convened two symposia of international experts who proposed a definition and a set of three criteria for diagnosing anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/2\">",
"     2",
"    </a>",
"    ]. These criteria reflect the fact that the pattern of target organ involvement in anaphylaxis is quite variable.",
"   </p>",
"   <p>",
"    The first criterion requires the presence of cutaneous signs or symptoms, in combination with respiratory symptoms, cardiovascular symptoms (or associated end-organ dysfunction due to low blood pressure), or both (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ). Cutaneous involvement is present in the vast majority of anaphylactic reactions, and the first criterion, therefore, will be used most frequently. However, up to 20 percent of cases lack skin symptoms.",
"   </p>",
"   <p>",
"    The second criterion incorporates less obvious symptoms, although it is applied to patients with known food allergy. This criterion requires",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    in two or more of the following categories: cutaneous, respiratory,",
"    <span class=\"nowrap\">",
"     cardiovascular/hemodynamic,",
"    </span>",
"    or gastrointestinal (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The third criterion is intended to capture uncommon episodes of food-induced anaphylaxis that consist of isolated cardiovascular symptoms. This criterion applies to individuals with known exposure to a food allergen (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ). Uncommon cases of food-induced anaphylaxis presenting as isolated hypotension have been reported in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/36\">",
"     36",
"    </a>",
"    ]. Isolated cardiovascular symptoms are rare in children, although hypotension may lead to nausea, vomiting, dyspnea, diaphoresis, hypoxia, dizziness, syncope, and seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reliable laboratory markers of anaphylaxis. Plasma histamine levels may be fleetingly elevated, returning to normal within an hour in most cases. Elevations in serum tryptase, which are sometimes detectable in anaphylaxis caused by non-food triggers, are usually normal in food-allergic reactions, for unclear reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Therefore, the absence of an elevated plasma histamine or serum tryptase level never excludes the diagnosis of anaphylaxis. The use of laboratory studies to support the clinical diagnosis of anaphylaxis is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of commonly encountered conditions that may mimic food-induced anaphylaxis in the emergency setting include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute exacerbation of asthma",
"     </li>",
"     <li>",
"      Foreign body aspiration (especially in the pediatric population)",
"     </li>",
"     <li>",
"      Myocardial infarction",
"     </li>",
"     <li>",
"      Acute urticaria",
"     </li>",
"     <li>",
"      Vocal cord dysfunction",
"     </li>",
"     <li>",
"      Scombroid poisoning",
"     </li>",
"     <li>",
"      Vasovagal response",
"     </li>",
"     <li>",
"      Panic attack",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these alternative diagnoses is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ISSUES IN PREVENTION AND LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and long-term management of food-induced anaphylaxis involve accurate identification of the culprit food trigger, education in food allergen avoidance, and preparation for recurrent episodes.",
"   </p>",
"   <p>",
"    All patients who have experienced anaphylaxis should be supplied with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    auto-injectors and trained in self-administration for treatment of a possible recurrence. Referral to an allergy specialist who is experienced in the diagnosis and management of food-allergic disorders is strongly recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/24,40\">",
"     24,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=see_link\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Verification of the culprit allergen",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is absolutely essential that patients with food-induced anaphylaxis receive an in-depth evaluation to identify and verify the culprit food allergen. Defining the patient's food allergies with certainty allows for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Effective avoidance without undue dietary restrictions",
"     </li>",
"     <li>",
"      Improved patient compliance with avoidance recommendations",
"     </li>",
"     <li>",
"      Reduction of",
"      <span class=\"nowrap\">",
"       patient/caregiver",
"      </span>",
"      anxiety associated with an unidentified trigger",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definitive diagnosis of food allergy is often not straightforward. It usually requires skin testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in vitro testing, sometimes followed by supervised food challenges to ensure that the correct food has been implicated. The techniques utilized in the diagnosis of food allergy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Allergen avoidance education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must assist the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    caregiver in food allergen avoidance once the trigger has been identified with certainty. Strict food avoidance is extremely difficult, something which is reflected in the fact that most patients experiencing food-induced anaphylaxis have known food allergy, but were unable to avoid exposure.",
"   </p>",
"   <p>",
"    Effective avoidance requires ongoing education, meticulous attention to food labeling, and avoidance of situations where foods are frequently cross-contaminated (eg, buffets), minor allergenic ingredients are often present (eg, Asian cuisine restaurants), or where food allergens may become aerosolized (eg, seafood restaurants). These and other issues concerning food allergen avoidance are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues surrounding the safety of children with food allergies in schools and camps, including specific forms for use in those settings, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=see_link\">",
"     \"Food allergy in schools and camps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Preparation for recurrent reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of food-induced anaphylaxis are common despite patients' best efforts at avoidance. The",
"    <span class=\"nowrap\">",
"     patient/caregiver",
"    </span>",
"    must learn to recognize the earliest signs and symptoms of a pending anaphylactic reaction and initiate emergency medical management without delay.",
"   </p>",
"   <p>",
"    Patients should be provided with a written Anaphylaxis Emergency Action Plan that specifies clearly what should be done if a food-allergic reaction develops again (",
"    <a class=\"graphic graphic_form graphicRef60439 \" href=\"mobipreview.htm?2/42/2722\">",
"     form 1",
"    </a>",
"    ). This should include individualized advice about when to self-administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    based upon the characteristics of past reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have experienced food-induced anaphylaxis should have access to self-injectable",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    at all times. Epinephrine should be administered immediately in patients meeting any of the three criteria that define anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Immediate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    self-administration in the setting of a food-induced allergic reaction is recommended for patients experiencing the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory symptoms: difficulty breathing, chest tightness, wheezing, repetitive dry cough",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Signs/symptoms",
"      </span>",
"      of laryngeal edema: sensation of throat swelling, change of voice quality",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Sign/symptoms",
"      </span>",
"      of low blood pressure: dizziness, lightheadedness, or presyncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, children should be treated if they display the following during a food-allergic reaction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lethargy or change in mental status",
"     </li>",
"     <li>",
"      Vomiting repeatedly shortly after eating, especially if these symptoms are accompanied by flushing or hives",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Areas of uncertainty",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are circumstances, however, in which the optimal advice regarding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    self-administration is not known. In such cases, the clinician is reliant upon clinical judgment and knowledge of the patient's past reactions. Our approach, based upon clinical experience, is described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a patient experienced food-induced anaphylaxis in the past and has a SUSPECTED repeat exposure, we suggest self-administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      at the first sign of symptoms, regardless of the severity of those symptoms.",
"     </li>",
"     <li>",
"      If a patient experienced LIFE-THREATENING food-induced anaphylaxis in the past and has a KNOWN repeat ingestion of the culprit food, we suggest immediate self-administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , even if symptoms have not yet developed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any patient with symptoms requiring the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    should be transported immediately to an emergency facility, preferably by ambulance, for observation and management, since up to 20 percent of reactions will result in a recurrence of symptoms (biphasic anaphylaxis), which may be more refractory to standard therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Time course'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Medical identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at risk for food-induced anaphylaxis should wear some form of emergency medical identification, stating that they are food-allergic and listing the culprit food(s) (eg, Medic Alert&reg; bracelet or other identification jewelry).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=see_link\">",
"       \"Patient information: Anaphylaxis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/57/29586?source=see_link\">",
"       \"Patient information: Epinephrine auto-injectors (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/57/15250?source=see_link\">",
"       \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/14/41186?source=see_link\">",
"       \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"       \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information is available through the Food Allergy and Anaphylaxis Network (FAAN), which provides helpful manuals, videos, and informational brochures for patients, including age-appropriate materials for children, through their website [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/42\">",
"     42",
"    </a>",
"    ]. Other sources of accurate patient information include the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, which are also accessible through the internet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated food allergy is the leading cause of anaphylaxis outside of the hospital in children and young adults in developed countries, although patients of any age may be affected. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Epidemiology and clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food can trigger anaphylaxis in an individual with IgE-mediated allergy following ingestion, or when food ingestion is also associated with exertion (food-dependent, exercise-induced anaphylaxis). Food protein-induced enterocolitis, a type of non IgE-mediated allergy, can cause hypotensive reactions in infants and young children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of food-induced anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any food can cause anaphylaxis in a susceptible individual. In the United States, peanuts and tree nuts are the leading culprits, followed by shellfish (crustaceans and mollusks) and fish. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Causative foods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for food-induced anaphylaxis include concomitant asthma, allergies to certain high-risk foods (peanuts, tree nuts, seafood, and sesame), extreme sensitivity, and a history of previous food-induced anaphylaxis of any severity. The severity of previous reactions DOES NOT predict the severity of future reactions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatal food-induced anaphylaxis disproportionately affects adolescents and young adults, for reasons that may be largely related to the risk-taking behaviors. Deaths most often occur in individuals who have had only mild previous reactions. Delayed administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      appears to be an important and potentially correctable risk factor. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Fatal reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Food-induced anaphylactic reactions provoke signs and symptoms similar to anaphylactic reactions induced by other causes, although gastrointestinal symptoms tend to be more prominent (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Diagnosis and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food-induced anaphylaxis is diagnosed clinically, based upon a detailed history of antecedent events and characteristic signs and symptoms. A panel of experts from different specialties has established clinical criteria for the diagnosis of anaphylaxis, which define three distinct presentations (",
"      <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38920/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Issues in diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who have experienced anaphylaxis should be supplied with injectable",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      and trained in self-administration for treatment of a possible recurrence. Referral to an allergy specialist who is experienced in the diagnosis and management of food-allergic disorders should be arranged. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Issues in prevention and long-term management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention and long-term management of food-induced anaphylaxis involve accurate identification of the culprit food trigger, education in allergen avoidance, and preparation for recurrent episodes (which are common). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Issues in prevention and long-term management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/1\">",
"      Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol 2010; 125:S116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/2\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/3\">",
"      Brown AF, McKinnon D, Chu K. Emergency department anaphylaxis: A review of 142 patients in a single year. J Allergy Clin Immunol 2001; 108:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/4\">",
"      Sampson HA. Anaphylaxis and emergency treatment. Pediatrics 2003; 111:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/5\">",
"      Smit DV, Cameron PA, Rainer TH. Anaphylaxis presentations to an emergency department in Hong Kong: incidence and predictors of biphasic reactions. J Emerg Med 2005; 28:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/6\">",
"      Simons FER, Chad ZH, Gold M. Anaphylaxis in children: realtime reporting from a national network. Allergy Clin Immunol Int-J World allergy Org 2004; Suppl:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/7\">",
"      Wang J, Sampson HA. Food anaphylaxis. Clin Exp Allergy 2007; 37:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/8\">",
"      Romano A, Di Fonso M, Giuffreda F, et al. Food-dependent exercise-induced anaphylaxis: clinical and laboratory findings in 54 subjects. Int Arch Allergy Immunol 2001; 125:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/9\">",
"      Palosuo K, Alenius H, Varjonen E, et al. A novel wheat gliadin as a cause of exercise-induced anaphylaxis. J Allergy Clin Immunol 1999; 103:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/10\">",
"      Sicherer SH. Food protein-induced enterocolitis syndrome: case presentations and management lessons. J Allergy Clin Immunol 2005; 115:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/11\">",
"      Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in the UK. Thorax 2007; 62:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/12\">",
"      Gupta R, Sheikh A, Strachan D, Anderson HR. Increasing hospital admissions for systemic allergic disorders in England: analysis of national admissions data. BMJ 2003; 327:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/13\">",
"      Poulos LM, Waters AM, Correll PK, et al. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol 2007; 120:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/14\">",
"      Rudders SA, Banerji A, Vassallo MF, et al. Trends in pediatric emergency department visits for food-induced anaphylaxis. J Allergy Clin Immunol 2010; 126:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/15\">",
"      Ross MP, Ferguson M, Street D, et al. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allergy Clin Immunol 2008; 121:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/16\">",
"      Lieberman P, Camargo CA Jr, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006; 97:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/17\">",
"      Yocum MW, Butterfield JH, Klein JS, et al. Epidemiology of anaphylaxis in Olmsted County: A population-based study. J Allergy Clin Immunol 1999; 104:452.",
"     </a>",
"    </li>",
"    <li>",
"     Branum AM, Lukac, SL. Food allergy among US children: Trends in prevalence and hospitalizations. Centers for Disease Control and Prevention, NCHS data brief, no. 10. October 2008. file://www.cdc.gov/nchs/data/databriefs/db10.htm (Accessed on July 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/19\">",
"      Hompes S, K&ouml;hli A, Nemat K, et al. Provoking allergens and treatment of anaphylaxis in children and adolescents--data from the anaphylaxis registry of German-speaking countries. Pediatr Allergy Immunol 2011; 22:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/20\">",
"      Dalal I, Binson I, Reifen R, et al. Food allergy is a matter of geography after all: sesame as a major cause of severe IgE-mediated food allergic reactions among infants and young children in Israel. Allergy 2002; 57:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/21\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/22\">",
"      Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol 2006; 97:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/23\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/24\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/25\">",
"      Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol 2005; 95:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/26\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/27\">",
"      Braganza SC, Acworth JP, Mckinnon DR, et al. Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child 2006; 91:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/28\">",
"      Grimshaw KE, King RM, Nordlee JA, et al. Presentation of allergen in different food preparations affects the nature of the allergic reaction--a case series. Clin Exp Allergy 2003; 33:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/29\">",
"      Walzer M. Absorption of allergens. J Allergy 1942; 13:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/30\">",
"      Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/31\">",
"      Sampson MA, Mu&ntilde;oz-Furlong A, Sicherer SH. Risk-taking and coping strategies of adolescents and young adults with food allergy. J Allergy Clin Immunol 2006; 117:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/32\">",
"      Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/33\">",
"      Pumphrey RS, Stanworth SJ. The clinical spectrum of anaphylaxis in north-west England. Clin Exp Allergy 1996; 26:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/34\">",
"      Klein JS, Yocum MW. Underreporting of anaphylaxis in a community emergency room. J Allergy Clin Immunol 1995; 95:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/35\">",
"      S&oslash;rensen HT, Nielsen B, Ostergaard Nielsen J. Anaphylactic shock occurring outside hospitals. Allergy 1989; 44:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/36\">",
"      Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/37\">",
"      Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study. J Allergy Clin Immunol 2000; 106:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/38\">",
"      Brown SG, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australas 2004; 16:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/39\">",
"      ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/40\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115:S483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38920/abstract/41\">",
"      Anaphylaxis in schools and other childcare settings. AAAAI Board of Directors. American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1998; 102:173.",
"     </a>",
"    </li>",
"    <li>",
"     The Food Allergy and Anaphylaxis Network. www.foodallergy.org (Accessed on November 05, 2007).",
"    </li>",
"    <li>",
"     The American Academy of Allergy, Asthma and Immunology. www.aaaai.org (Accessed on November 05, 2007).",
"    </li>",
"    <li>",
"     The American College of Allergy, Asthma and Immunology. www.acaai.org (Accessed on November 05, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2401 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38920=[""].join("\n");
var outline_f38_0_38920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF FOOD-INDUCED ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IgE-mediated anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Food-dependent, exercise-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypotensive reactions in infants with enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CAUSATIVE FOODS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Time course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Biphasic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Evolution of symptoms during reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differences between children and adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Factors affecting presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FATAL REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Features of fatal food reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Delayed administration of epinephrine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ISSUES IN DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Application of diagnostic criteria to food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ISSUES IN PREVENTION AND LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Verification of the culprit allergen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Allergen avoidance education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Preparation for recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Areas of uncertainty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Medical identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2401|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/36/21068\" title=\"table 1\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23228\" title=\"table 2\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36072?source=related_link\">",
"      Allergy to meats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=related_link\">",
"      Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=related_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=related_link\">",
"      Food allergy in schools and camps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18778?source=related_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_0_38921="Percutaneous interventional procedures in the patient with lower extremity claudication";
var content_f38_0_38921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Percutaneous interventional procedures in the patient with lower extremity claudication",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Julie M Zaetta, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Richard A Baum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Denis L Clement, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/0/38921/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/0/38921/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent claudication, defined as a symptomatic deficiency in blood supply to exercising muscle that is relieved with rest, is generally a reliable indicator of occlusive arterial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Classic claudication is a cramping pain that is consistently reproduced with exercise and relieved with rest. However, atypical leg pain is more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/2\">",
"     2",
"    </a>",
"    ]. The problem of claudication is almost entirely limited to patients with atherosclerotic disease who have symptoms related to the lower extremity.",
"   </p>",
"   <p>",
"    The general indications for revascularization in patients with claudication, and the indications for and outcomes of percutaneous intervention will be reviewed here. The roles of medical therapy and surgical revascularization for intermittent claudication and the management of limb-threatening ischemia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909632859\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of lower extremity pain varies with the vessels that are involved. The severity of symptoms depends upon the degree of stenosis, the collateral circulation, and the vigor of exercise. Most patients with intermittent claudication remain stable with medical therapy. When revascularization is required, the options are percutaneous interventional procedures and surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30201?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\", section on 'Symptomatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual relationship between the site of pain and site of arterial disease can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Buttock and hip: Aortoiliac disease",
"     </li>",
"     <li>",
"      Thigh: Common femoral artery or aortoiliac",
"     </li>",
"     <li>",
"      Upper two-thirds of the calf: Superficial femoral artery",
"     </li>",
"     <li>",
"      Lower one-third of the calf: Popliteal artery",
"     </li>",
"     <li>",
"      Foot claudication: Tibial or peroneal artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909615388\">",
"    <span class=\"h2\">",
"     TASC classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guideline from the Inter-Society Consensus for the management of peripheral artery diseases (TASC II) presents a scheme that classifies arterial lesions as type A, B, C, or D based upon overall success rates of treating the lesion using endovascular or surgical means [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/3\">",
"     3",
"    </a>",
"    ]. Type A lesions represent focal short stenosis of the iliac, femoral and popliteal arteries while Type D lesions represent diffuse disease and chronic occlusions. There are no classifications referable to the tibial vessels. Type B and Type C are intermediate lesions. The details of the TASC classification are reviewed in detail elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1031?source=see_link&amp;anchor=H909629056#H909629056\">",
"     \"Classification of lower extremity peripheral artery disease\", section on 'TASC classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519588553\">",
"    <span class=\"h2\">",
"     Lesions amenable to percutaneous intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, endovascular therapy is the treatment of choice for TASC type A lesions and endovascular treatment is preferred over surgical treatment for type B lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with type C lesions who are not good risk candidates for surgery may also benefit from percutaneous intervention. The patient&rsquo;s comorbidities, fully informed patient preference, and the operator&rsquo;s long-term success rates must be considered when making treatment recommendations for type B and type C lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and other guidelines suggest that the following issues need to be addressed when considering either percutaneous or surgical revascularization in patients with intermittent claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has not had or is not predicted to have an adequate response to exercise rehabilitation and pharmacologic therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=see_link\">",
"       \"Medical management of claudication\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient is significantly disabled by claudication, resulting in an inability to perform normal work or other activities that are important to the patient. This criterion reflects the variability among patients of the symptoms of claudication and of the impact of these symptoms on the quality of life. In addition, there may be substantial differences between patient and physician assessments of the quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patient is able to benefit from an improvement in claudication (ie, exercise is not limited by another cause, such as angina, heart failure, chronic obstructive pulmonary disease, or orthopedic problems).",
"     </li>",
"     <li>",
"      The projected natural history and prognosis of the patient.",
"     </li>",
"     <li>",
"      The characteristics of the lesion permit appropriate intervention at low risk with a high likelihood of initial and long-term success. Numerous studies have shown that successful revascularization can substantially improve the patient's quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need to intervene is more urgent in patients with limb-threatening ischemia, as manifested by rest pain, ischemic ulcers, or gangrene. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS INTERVENTIONAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloon angioplasty, with or without stenting, is useful for symptomatic relief in many patients with peripheral artery disease. Percutaneous transluminal angioplasty (PTA), results in a \"controlled\" dissection of the arterial media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/8\">",
"     8",
"    </a>",
"    ]. Advancements in catheter, guidewire, and balloon design, and the development of intravascular stents have resulted in a dramatic increase in the number of percutaneous procedures performed.",
"   </p>",
"   <p>",
"    Support for this change in management came from an initial randomized trial that showed no significant difference in outcome after a median of four years between PTA and bypass surgery for iliac or femoropopliteal disease and for claudication or rest ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term success of PTA depends upon the site and length of the lesion. Lesions which display unfavorable anatomy and which might be better treated surgically have one or more of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long segments",
"     </li>",
"     <li>",
"      Multifocal stenoses",
"     </li>",
"     <li>",
"      Long segment occlusions",
"     </li>",
"     <li>",
"      Eccentric, calcified stenoses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PTA has been traditionally limited to the treatment of focal, short segment stenoses or occlusions. However, with advancements in technology, PTA is now routinely applied to more extensively diseased segments to attempt limb salvage before a distal surgical bypass; it can also be used in patients who are poor surgical candidates. Since patient symptoms and outcomes are closely related to the anatomic location of disease, each segment of the lower extremity circulation will be reviewed separately. The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline recommendations for percutaneous (endovascular) treatment of claudication are summarized in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef69463 \" href=\"mobipreview.htm?42/14/43244\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data supporting the use of PTA for limb threatening ischemia are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AORTOILIAC OCCLUSIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTA of an uncomplicated iliac stenosis has an initial technical success rate of approximately 90 percent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65673 \" href=\"mobipreview.htm?8/28/8640\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Long-term patency is directly influenced by the extent of disease. A commonly quoted five-year patency rate is 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. However, the five-year patency drops to 51 percent when there is poor distal runoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/10\">",
"     10",
"    </a>",
"    ]. The threshold for percutaneous intervention in aortoiliac disease is typically lower than for infrainguinal disease due to better expected outcomes. The CLEVER (Claudication: Exercise versus Endoluminal Revascularization) Study is a multicenter randomized clinical trial designed to compare the relative effectiveness of percutaneous revascularization with stents to supervised exercise rehabilitation in a cohort of patients with moderate to severe claudication due to aortoiliac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its use in uncomplicated iliac stenosis, PTA with or without stenting also produces outcomes comparable to surgery in complex long-segment disease and bilateral iliac occlusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular stents can be employed, usually for a suboptimal angioplasty result (eg, residual stenosis of greater than 30 percent, residual gradient exceeding 10 mmHg, or significant dissection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/14\">",
"     14",
"    </a>",
"    ]. Although data in favor of this approach are limited, the use of selective stenting is supported by a study that randomly assigned 279 patients with intermittent claudication due to iliac artery stenosis to direct stenting, or PTA with subsequent elective stenting for a residual mean pressure gradient &gt;10 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/15\">",
"     15",
"    </a>",
"    ]. Initial hemodynamic success and complication rates were similar for direct and selective stenting, and no differences in outcome, including quality of life, were apparent at two years (",
"    <a class=\"graphic graphic_figure graphicRef58444 \" href=\"mobipreview.htm?23/15/23806\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/16\">",
"     16",
"    </a>",
"    ] or at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second trial evaluated the role of primary stenting after excimer laser-assisted recanalization in 212 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/18\">",
"     18",
"    </a>",
"    ]. Technical success was achieved in 90 percent; 1.4 percent had a complication (arterial rupture or embolism); and significant clinical improvement occurred in 85 percent. Primary patency rates (uninterrupted patency without reintervention) at one, two, and four years were 84, 91, and 76 percent, respectively.",
"   </p>",
"   <p>",
"    Some authors advocate using stents primarily when there is an iliac occlusion with an eccentric and calcified lesion or with disease involving a long segment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Although stents have been used successfully for these indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/13\">",
"     13",
"    </a>",
"    ], increasing the stent length decreases the primary patency, which is also a limitation of PTA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTA and stents have also been used for stenosis of the aortic bifurcation, although balloon dilation of the ostium of the common iliac artery can displace the plaque across the aortic bifurcation and either worsen the stenosis or induce embolization of debris down the contralateral iliac artery. One study of 20 patients described a technique of kissing balloons in which balloons are positioned simultaneously across both limbs of the aortic bifurcation and inflated in unison; this was followed by the placement of kissing stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/21\">",
"     21",
"    </a>",
"    ]. Stent insertion was successful in all 20 patients, symptoms were improved in 19, 12 of whom became asymptomatic.",
"   </p>",
"   <p>",
"    In our practice, we use a combination of angioplasty and stenting, depending upon the lesion morphology and location.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common iliac artery stenoses are first angioplastied. If there is a satisfactory result, we stop. If, however, there is a dissection or the lesion is elastic, a Wallstent or Palmaz-Schatz stent is placed.",
"     </li>",
"     <li>",
"      Primary stenting is the initial modality in the external iliac artery stenoses. This is because the external iliac is prone to dissect after angioplasty and the primary placement of a stent reduces this complication.",
"     </li>",
"     <li>",
"      Stent restenosis is a concern after stenting of a peripheral artery, similar to what has been observed with coronary artery stenting. Although the diagnosis is usually established with angiography, intravascular ultrasound may be superior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At present, we do not routinely use stents in the femoral, popliteal, or tibial systems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FEMOROPOPLITEAL OCCLUSIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoropopliteal segment is the most common site for treatable arterial occlusive disease. Balloon angioplasty is usually performed without stenting, as the latter procedure has a significant reocclusion and restenosis rate and does not appear to improve outcomes after intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/23-28\">",
"     23-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although contrast angiography is typically used to define the anatomy prior to intervention, it carries a risk of acute renal failure that is greatest in patients with renal insufficiency and diabetes, disorders that are common in patients with peripheral artery disease. In such patients, duplex guidance seems to be a safe and effective alternative that avoids the risk of contrast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incidence of restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTA for femoropopliteal disease has a lower rate of long-term maintenance of arterial patency than with aortoiliac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/30\">",
"     30",
"    </a>",
"    ]. One prospective study, for example, evaluated the effectiveness of PTA in the femoropopliteal arteries of patients with claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/31\">",
"     31",
"    </a>",
"    ]. The overall technical success rate was 88 percent; successful dilatation was somewhat higher for stenoses (91 percent) than for occlusions (83 percent). Two-year patency rates ranged from 42 to 58 percent. Loss of initial patency may be due to restenosis (which usually occurs in the first six months) or to progressive atherosclerosis at the lesion site or elsewhere in the same vessel. The smaller vessel diameter is probably the major explanation for the higher rate of restenosis at this site compared to iliac disease.",
"   </p>",
"   <p>",
"    Anatomic factors that adversely affect long-term patency include long or eccentric calcified lesions, occlusion instead of stenosis, and poor distal runoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Interestingly, repeat PTA has equivalent patency rates to PTA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/10\">",
"     10",
"    </a>",
"    ]. PTA may be particularly desirable in such patients; 58 to 90 percent have concomitant coronary artery disease and PTA preserves saphenous veins for possible coronary artery bypass graft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevention of restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of restenosis after PTA of the femoral artery is the same as that after coronary artery angioplasty, with smooth muscle cell proliferation and migration being the major events.",
"   </p>",
"   <p>",
"    A number of therapies have been tried in an attempt to prevent restenosis after femoral PTA. Only local delivery of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , which is still experimental, has been shown to improve outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Local delivery of paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The THUNDER trial randomly assigned 154 patients with femoropopliteal stenoses to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    coated angioplasty balloons, uncoated balloons with paclitaxel dissolved in the contrast medium, or uncoated balloons with contrast solution containing no paclitaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/34\">",
"     34",
"    </a>",
"    ]. The primary end point of mean late lumen loss after six months was significantly lower in the coated balloon group than either the paclitaxel solution or control groups (0.4 versus 2.2 and 1.7 mm, respectively). The coated balloon group also had a significantly lower rate of target lesion revascularization at six months (4 versus 29 and 37 percent).",
"   </p>",
"   <p>",
"    The findings in THUNDER were confirmed in the similarly designed FemPac trial, in which 87 patients undergoing angioplasty of femoropopliteal lesions were randomly assigned to either uncoated or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -coated balloons catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/35\">",
"     35",
"    </a>",
"    ]. The primary end point of late lumen loss at six month follow-up angiography was significantly less in the coated balloon group (0.5 versus 1.0 mm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloon expandable, stainless steel stents are not usually used for femoropopliteal disease, because they have significant reocclusion and restenosis rates and do not appear to improve outcomes after intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/23-27\">",
"     23-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized trials comparing stenting with angioplasty alone found higher rates of occlusion (21 versus 7 percent) and restenosis (50 versus 25 percent) at one year with stenting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the largest trial that evaluated clinical as well as angiographic outcomes, 141 patients (144 affected limbs) were randomly assigned to angioplasty alone or to angioplasty followed by implantation of a Palmaz stent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/26\">",
"       26",
"      </a>",
"      ]. The incidence of initial procedural success was greater with stenting (99 versus 84 percent). However, there was no difference between the stented and angioplasty alone groups in",
"      <span class=\"nowrap\">",
"       clinical/hemodynamic",
"      </span>",
"      success at one year (77 versus 72 percent) or two years (65 versus 65 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The composition of the stent may influence the rate of stent patency after femoropopliteal intervention, and three studies have evaluated the safety and efficacy of self-expanding nitinol stents compared to either PTA or steel stents",
"   </p>",
"   <p>",
"    An initial observational study suggested that, among patients with intermittent claudication or critical limb ischemia, the risk of restenosis was significantly reduced with a nitinol stent compared to a steel stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/36\">",
"     36",
"    </a>",
"    ]. This benefit was confirmed in a subsequent randomized trial from the same center that included 104 patients with severe claudication or chronic limb ischemia due to superficial femoral artery stenosis or occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/37\">",
"     37",
"    </a>",
"    ]. The patients were assigned to primary stenting with a self-expanding nitinol stent or PTA with optional secondary stenting. The rate of restenosis was significantly lower with the nitinol stent on angiography at six months (24 versus 43 percent) and on duplex ultrasonography at one year (37 versus 63 percent). This benefit was associated with significantly longer walking distances on treadmill testing.",
"   </p>",
"   <p>",
"    In contrast to these findings, the FAST trial of 244 patients with a single, short (mean lesion length of 45 mm compared to 130 mm in the preceding trial) superficial femoral artery lesion and chronic limb ischemia found no advantage compared with PTA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/38\">",
"     38",
"    </a>",
"    ]. At one year, there was no significant difference in the primary end point of binary restenosis as determined by intravascular ultrasound (32 versus 38 percent, respectively) or the secondary end points of target lesion revascularization and Rutherford category of PAD (",
"    <a class=\"graphic graphic_table graphicRef57359 \" href=\"mobipreview.htm?10/8/10380\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Endovascular radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular radiation therapy (brachytherapy) has been utilized to prevent restenosis after PTA in the femoropopliteal arteries. Its use has been limited by a paucity of data demonstrating efficacy when compared to no therapy, the complexity of the procedure, and the occurrence of late thrombotic occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Atherectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive role for directional atherectomy for femoropopliteal occlusive disease has not been demonstrated. Early randomized trials of the Simpson atherectomy device showed no advantage over balloon angioplasty. A newer, easier-to-use atherectomy catheter (Silverhawk) was evaluated in an observational study of 131 femoropopliteal lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/43\">",
"     43",
"    </a>",
"    ]. The primary patency rate at 12 months was 84 percent in de novo lesions and 54 percent in restenotic or in-stent lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INFRAPOPLITEAL OCCLUSIVE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few published data on the utility of PTA in the treatment of infrapopliteal arterial disease. Most cases are performed in patients with advanced disease who are not surgical candidates. Advances in wire and balloon design permit technical success rates of greater than 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Small vessel angioplasty is an effective method to preserve limb viability in a patient with a threatened extremity, as a two-year limb salvage rate of 86 percent has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the patency rate at two years was only 42 percent in another series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patency may be enhanced by the use of stenting. In a study of 82 patients (92 limbs) with critical limb ischemia or severe lifestyle-limiting claudication, technical success (residual stenosis &lt;20 percent with antegrade flow) was achieved in 93 percent of limbs attempted, with relief of rest pain and healing of ulcerations and amputations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/46\">",
"     46",
"    </a>",
"    ]. The one-year limb salvage rate was 96 percent for those with critical limb ischemia and 100 percent for those with lifestyle-limiting claudication who had initial technical success. Nonetheless, the goal of infrapopliteal percutaneous intervention should be limb salvage. Long-term patency should not be expected. Currently, no stents are approved by the United States Food and Drug Administration for the treatment of infrapopliteal disease.",
"   </p>",
"   <p>",
"    One group of particular concern is diabetics who often have nonhealing foot ulcers and gangrene that result in amputation. One study of 29 diabetics who underwent PTA followed by therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    reported that after a 12-month follow-up, 23 had experienced wound healing and avoided below-the-knee amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/47\">",
"     47",
"    </a>",
"    ]. The tissue oxygen partial pressure levels improved in all patients who eventually had healed or healing ulcers and, in contrast to the ankle-brachial index, served as a useful predictor of outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from PTA requiring some form of treatment occur in 1 to 4 percent of published cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/8,10,48\">",
"     8,10,48",
"    </a>",
"    ]. Because a larger arteriotomy is needed for percutaneous interventions, direct arterial injury can lead to groin hematoma (2 to 4 percent) or the formation of a pseudoaneurysm (0.3 to 2 percent), or arteriovenous fistula (0.1 to 0.3 percent). Complications directly related to arterial dilatation include distal embolization (2 percent), thrombotic occlusion (2 percent), and, rarely, arterial rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Femoropopliteal stents are prone to fracture, which is thought to be due to the dynamic forces imparted to the superficial femoral and popliteal arteries with knee flexion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/49\">",
"     49",
"    </a>",
"    ]. Systematic reviews have identified a cumulative incidence of stent fracture in the femoropopliteal segment ranging from 2 to 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The variability is likely related to heterogeneity in severity and length of stenosis treated, and type and number of stents deployed. The risk for stent fracture increases with treatment of longer lesions and multiple stent deployments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stent fracture is associated with an increased risk of restenosis and late occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/50,52,53\">",
"     50,52,53",
"    </a>",
"    ]. In one observational study of 239 patients, primary stent patency was significantly reduced in patients with stent fracture compared to those with no fracture at one and two years follow up (68 versus 83 percent, and 65 versus 75 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/53\">",
"     53",
"    </a>",
"    ]. Primary patency rates of stents with fracture compared to without fracture were also reduced at three and four years follow-up in this study; however, the difference did not reach significance.",
"   </p>",
"   <p>",
"    Late thrombotic occlusion has also been observed following endovascular radiation (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Endovascular radiation'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PHOTOANGIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy is an emerging treatment for atherosclerosis and restenosis after angioplasty. The administration of a photosensitive drug with subsequent percutaneous, endovascular light activation is called photoangioplasty. Texaphyrins are a class of photosensitive drugs that specifically localize within atheromatous plaque and are converted to an activated state during photoactivation with far-red light energy, which sufficiently penetrates tissues even in the presence of flowing blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/54\">",
"     54",
"    </a>",
"    ]. Photoactivation releases singlet oxygen, which produces a cytotoxic cellular effect within the plaque, while sparing the normal surrounding vascular tissue.",
"   </p>",
"   <p>",
"    In a phase I study, photoangioplasty was performed in 47 patients with symptomatic claudication and documented peripheral arterial insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/55\">",
"     55",
"    </a>",
"    ]. The procedure was safe and well tolerated, with 62 percent of patients showing clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909615712\">",
"    <span class=\"h1\">",
"     ANTIPLATELET THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For secondary prevention of cardiovascular disease, patients undergoing lower extremity interventional procedures for peripheral artery disease should already be receiving long-term antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), unless a contraindication exists. Antiplatelet therapy is",
"    <strong>",
"     not",
"    </strong>",
"    held prior to the intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=see_link&amp;anchor=H16#H16\">",
"     \"Medical management of claudication\", section on 'Antiplatelet summary'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of specific antithrombotic therapies on the rates of thrombosis and long-term re-stenosis following peripheral intervention continues to be studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/56\">",
"     56",
"    </a>",
"    ]. There is limited evidence to suggest that the rate of",
"    <span class=\"nowrap\">",
"     restenosis/reocclusion",
"    </span>",
"    following peripheral endovascular treatment is reduced with the use of antiplatelet drugs compared with placebo, but the available trials are small and of variable quality. In the absence of high-quality data, we suggest maintaining patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (&lt;325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    as prescribed for secondary prevention of cardiovascular disease. Whether dual antiplatelet therapy provides an additional benefit remains debated. Given the increased risk of complications and a lack of proven benefit, we do not recommend dual antiplatelet therapy following percutaneous intervention for claudication.",
"   </p>",
"   <p>",
"    An updated Cochrane systematic review identified 23 trials comparing various antithrombotic therapies including antiplatelet agents, anticoagulants, and other vasoactive drugs following peripheral intervention (femoropopliteal and above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/57\">",
"     57",
"    </a>",
"    ]. The side effects of drugs, particularly with respect to bleeding and gastrointestinal side effects were not consistently addressed. A summary of the results of this review is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (&gt;325 mg) combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      significantly reduced the rate of reocclusion at six months post-intervention compared with placebo (odds ratio [OR] 0.40, 95% CI 0.19-0.84), the magnitude of which was not seen for low-dose aspirin (100 mg) combined with dipyridamole (OR 0.69, 95% CI 0.44-1.10; P = 0.12).",
"     </li>",
"     <li>",
"      Low molecular-weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      did not reduce rates of",
"      <span class=\"nowrap\">",
"       restenosis/occlusion",
"      </span>",
"      compared with aspirin alone in patients with intermittent claudication (OR 1.73, 95% CI 0.97-3.08; P = 0.06).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"       Cilostazol",
"      </a>",
"      significantly reduce the rate of re-occlusion compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      (OR 0.32, 95% CI 0.13-0.76).",
"     </li>",
"     <li>",
"      Batroxobin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      significantly reduced restenosis in patients with diabetes (OR 0.28, 95% CI 0.13-0.60).",
"      <strong>",
"      </strong>",
"      Batroxobin is serine protease derived from snake venom. In contrast to other anti-coagulants, it does not affect the function of platelets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential benefit of dual antiplatelet therapy was investigated in a trial of 80 patients randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (500 mg orally), followed by daily aspirin (100 mg) plus placebo, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    prior to intervention, followed by aspirin (100 mg) plus clopidogrel (75mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/58\">",
"     58",
"    </a>",
"    ]. Primary endpoints were measurement of &beta;-thromboglobulin and CD40L, which are peri-interventional markers of platelet activation. The median level of each was significantly lower in the clopidogrel group compared with the placebo group (225 versus 366 for &beta;-thromboglobulin, 127 and 207 for CD40L). Clinically, fewer patients in the clopidogrel group required revascularization after six months following the intervention (2 versus 8 patients). The clopidogrel resistance rate was overall 30 percent, with both of the patients requiring revascularization in the clopidogrel group found to be resistant.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     Cilostazol",
"    </a>",
"    is approved for the treatment of intermittent claudication and is generally prescribed to improve pain-free walking distance, but it may also be effective for improving outcomes of peripheral intervention. In patients with coronary artery disease, cilostazol may lower the rate of recurrent stenosis and repeat revascularization after coronary intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/59\">",
"     59",
"    </a>",
"    ]. To determine if a similar effect occurs following peripheral intervention, one trial randomly assigned 80 patients with intermittent claudication due to a femoropopliteal lesion and undergoing percutaneous intervention to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or aspirin plus cilostazol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/60\">",
"     60",
"    </a>",
"    ]. Freedom from target vessel revascularization at two-year follow-up was significantly higher in the cilostazol group compared with the control group (85 versus 62 percent). The rate of restenosis was lower in the cilostazol group (44 versus 70 percent), and freedom from target lesion revascularization as well as freedom from major adverse cardiovascular events were higher in the cilostazol group (87 versus 68 percent, 77 versus 46 percent, respectively). There was no major bleeding in either group during the follow-up period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261592148\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are in agreement with the recommendations of the American College of Chest Physicians (ACCP) 2012 guideline on antithrombotic therapy for peripheral artery occlusive disease which states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients undergoing peripheral artery percutaneous transluminal angioplasty with or without stenting, we recommend long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"     <li>",
"      For patients undergoing peripheral artery percutaneous transluminal angioplasty with stenting, we suggest single rather than dual antiplatelet therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909615517\">",
"    <span class=\"h1\">",
"     LIMB AND CARDIOVASCULAR OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on peripheral artery disease (PAD), which were produced in collaboration with major vascular medicine, vascular surgery, and interventional radiology societies, suggested the following rates of limb and cardiovascular outcomes at five years in patients with noncritical claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For limb morbidity &mdash; stable claudication in 70 to 80 percent, worsening claudication in 10 to 20 percent, and critical limb ischemia in 1 to 2 percent",
"     </li>",
"     <li>",
"      For cardiovascular morbidity and mortality &mdash; nonfatal myocardial infarction or stroke in 20 percent, and death in 15 to 30 percent (three-quarters due to cardiovascular causes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the 1 to 2 percent of patients with critical limb ischemia, the guidelines suggested the following outcomes at one year:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alive with two limbs &ndash; 50 percent",
"     </li>",
"     <li>",
"      Amputation &ndash; 25 percent",
"     </li>",
"     <li>",
"      Cardiovascular mortality &ndash; 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis for both limb loss and survival is significantly worse in diabetic patients and those who continue to smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/0/38921/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/49/34578?source=see_link\">",
"       \"Patient information: Peripheral artery disease and claudication (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=see_link\">",
"       \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermittent claudication, defined as a symptomatic deficiency in blood supply to exercising muscle that is relieved with rest, is generally a reliable indicator of occlusive arterial disease. Classic claudication is a cramping pain that is consistently reproduced with exercise and relieved with rest. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H909632859\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for revascularization in patients with claudication are limited to lifestyle-limiting claudication that does not respond to conventional medical therapy. We also consider percutaneous intervention for patients with more severe disease when there is a focal stenosis or occlusion, some cases to augment a surgical procedure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for revascularization'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=see_link\">",
"       \"Medical management of claudication\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The guidelines from the Inter-Society Consensus for the management of peripheral artery diseases (TASC II) presents a scheme that classifies arterial lesions as type A, B, C, or D based upon overall success rates of treating the lesion using endovascular or surgical means. Type A lesions represent focal short stenosis of the iliac, femoral, and popliteal arteries while Type D lesions represent diffuse disease and chronic occlusions. In general, endovascular therapy is the treatment of choice for TASC type A lesions and endovascular treatment is preferred over surgical treatment for type B lesions. Patients with type C lesions who are not good risk candidates for surgery may also benefit from percutaneous intervention. The patient&rsquo;s comorbidities, fully informed patient preference, and the operator&rsquo;s long-term success rates must be considered when making treatment recommendations for type B and type C lesions. (See",
"      <a class=\"local\" href=\"#H909615388\">",
"       'TASC classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/1\">",
"      Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/2\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/3\">",
"      Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/4\">",
"      2011 WRITING GROUP MEMBERS, 2005 WRITING COMMITTEE MEMBERS, ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/5\">",
"      Pell JP. Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group. Eur J Vasc Endovasc Surg 1995; 9:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/6\">",
"      Currie IC, Wilson YG, Baird RN, Lamont PM. Treatment of intermittent claudication: the impact on quality of life. Eur J Vasc Endovasc Surg 1995; 10:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/7\">",
"      Zannetti S, L'Italien GJ, Cambria RP. Functional outcome after surgical treatment for intermittent claudication. J Vasc Surg 1996; 24:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/8\">",
"      Becker GJ, Katzen BT, Dake MD. Noncoronary angioplasty. Radiology 1989; 170:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/9\">",
"      Wolf GL, Wilson SE, Cross AP, et al. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199. J Vasc Interv Radiol 1993; 4:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/10\">",
"      Johnston KW, Rae M, Hogg-Johnston SA, et al. 5-year results of a prospective study of percutaneous transluminal angioplasty. Ann Surg 1987; 206:403.",
"     </a>",
"    </li>",
"    <li>",
"     Rutherford, RB, Durham, J. Percutaneous balloon angioplasty for arteriosclerosis obliterans: Long-term results. In: Technologies in vascular surgery, Yao, JST, Pearce, WH (Eds), WB Saunders, Philadelphia 1993. p.329.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/12\">",
"      Murphy TP, Hirsch AT, Cutlip DE, et al. Claudication: exercise vs endoluminal revascularization (CLEVER) study update. J Vasc Surg 2009; 50:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/13\">",
"      Leville CD, Kashyap VS, Clair DG, et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. J Vasc Surg 2006; 43:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/14\">",
"      Palmaz JC, Laborde JC, Rivera FJ, et al. Stenting of the iliac arteries with the Palmaz stent: experience from a multicenter trial. Cardiovasc Intervent Radiol 1992; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/15\">",
"      Tetteroo E, van der Graaf Y, Bosch JL, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet 1998; 351:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/16\">",
"      Bosch JL, van der Graaf Y, Hunink MG. Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. The Dutch Iliac Stent Trial Study Group. Circulation 1999; 99:3155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/17\">",
"      Klein WM, van der Graaf Y, Seegers J, et al. Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease: The Dutch Iliac Stent Trial Study. Radiology 2004; 232:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/18\">",
"      Scheinert D, Schr&ouml;der M, Ludwig J, et al. Stent-supported recanalization of chronic iliac artery occlusions. Am J Med 2001; 110:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/19\">",
"      Martin EC, Katzen BT, Benenati JF, et al. Multicenter trial of the wallstent in the iliac and femoral arteries. J Vasc Interv Radiol 1995; 6:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/20\">",
"      Vorwerk D, Guenther RW. Mechanical revascularization of occluded iliac arteries with use of self-expandable endoprostheses. Radiology 1990; 175:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/21\">",
"      Mendelsohn FO, Santos RM, Crowley JJ, et al. Kissing stents in the aortic bifurcation. Am Heart J 1998; 136:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/22\">",
"      Schwarzenberg H, M&uuml;ller-H&uuml;lsbeck S, Gl&uuml;er CC, et al. Restenosis of peripheral stents and stent grafts as revealed by intravascular sonography: in vivo comparison with angiography. AJR Am J Roentgenol 1998; 170:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/23\">",
"      Vroegindeweij D, Vos LD, Tielbeek AV, et al. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol 1997; 20:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/24\">",
"      Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol 1999; 18:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/25\">",
"      Gray BH, Sullivan TM, Childs MB, et al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 1997; 25:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/26\">",
"      Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/27\">",
"      Grimm J, M&uuml;ller-H&uuml;lsbeck S, Jahnke T, et al. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol 2001; 12:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/28\">",
"      Sapoval MR, Long AL, Raynaud AC, et al. Femoropopliteal stent placement: long-term results. Radiology 1992; 184:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/29\">",
"      Ascher E, Marks NA, Schutzer RW, Hingorani AP. Duplex-guided balloon angioplasty and stenting for femoropopliteal arterial occlusive disease: an alternative in patients with renal insufficiency. J Vasc Surg 2005; 42:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/30\">",
"      Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis. Report of a prospective randomized trial in a selected group of patients. J Vasc Surg 1989; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/31\">",
"      Matsi PJ, Manninen HI, Vanninen RL, et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3-year follow-up. Radiology 1994; 191:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/32\">",
"      Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 1991; 83:I70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/33\">",
"      Taylor LM Jr, Porter JM. Clinical and anatomic considerations for surgery in femoropopliteal disease and the results of surgery. Circulation 1991; 83:I63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/34\">",
"      Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/35\">",
"      Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008; 118:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/36\">",
"      Sabeti S, Schillinger M, Amighi J, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology 2004; 232:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/37\">",
"      Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/38\">",
"      Krankenberg H, Schl&uuml;ter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 2007; 116:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/39\">",
"      Pokrajac B, P&ouml;tter R, Maca T, et al. Intraarterial (192)Ir high-dose-rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna-2-trial radiotherapy parameters and risk factors analysis. Int J Radiat Oncol Biol Phys 2000; 48:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/40\">",
"      Krueger K, Landwehr P, Bendel M, et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology 2002; 224:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/41\">",
"      Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty : results of a prospective randomized study. Circulation 2000; 102:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/42\">",
"      Bonvini R, Baumgartner I, Do DD, et al. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. J Am Coll Cardiol 2003; 41:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/43\">",
"      Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol 2006; 48:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/44\">",
"      Schwarten DE, Cutcliff WB. Arterial occlusive disease below the knee: treatment with percutaneous transluminal angioplasty performed with low-profile catheters and steerable guide wires. Radiology 1988; 169:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/45\">",
"      Brown KT, Moore ED, Getrajdman GI, Saddekni S. Infrapopliteal angioplasty: long-term follow-up. J Vasc Interv Radiol 1993; 4:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/46\">",
"      Feiring AJ, Wesolowski AA, Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. J Am Coll Cardiol 2004; 44:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/47\">",
"      Hanna GP, Fujise K, Kjellgren O, et al. Infrapopliteal transcatheter interventions for limb salvage in diabetic patients: importance of aggressive interventional approach and role of transcutaneous oximetry. J Am Coll Cardiol 1997; 30:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/48\">",
"      Gardiner GA Jr, Meyerovitz MF, Stokes KR, et al. Complications of transluminal angioplasty. Radiology 1986; 159:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/49\">",
"      Laird, JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther 2006; 13(Suppl II):II.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/50\">",
"      Rits J, van Herwaarden JA, Jahrome AK, et al. The incidence of arterial stent fractures with exclusion of coronary, aortic, and non-arterial settings. Eur J Vasc Endovasc Surg 2008; 36:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/51\">",
"      Mewissen MW. Primary nitinol stenting for femoropopliteal disease. J Endovasc Ther 2009; 16:II63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/52\">",
"      Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/53\">",
"      Iida O, Nanto S, Uematsu M, et al. Influence of stent fracture on the long-term patency in the femoro-popliteal artery: experience of 4 years. JACC Cardiovasc Interv 2009; 2:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/54\">",
"      Woodburn KW, Fan Q, Kessel D, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg 1996; 14:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/55\">",
"      Rockson SG, Kramer P, Razavi M, et al. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin). Circulation 2000; 102:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/56\">",
"      Allemang MT, Rajani RR, Nelson PR, et al. Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures. Ann Vasc Surg 2013; 27:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/57\">",
"      Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2012; 8:CD002071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/58\">",
"      Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 2012; 22:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/59\">",
"      Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008; 155:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/60\">",
"      Soga Y, Yokoi H, Kawasaki T, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009; 53:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/61\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/0/38921/abstract/62\">",
"      Ouriel K. Peripheral arterial disease. Lancet 2001; 358:1257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8207 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38921=[""].join("\n");
var outline_f38_0_38921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H909632859\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H909615388\">",
"      TASC classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519588553\">",
"      Lesions amenable to percutaneous intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PERCUTANEOUS INTERVENTIONAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AORTOILIAC OCCLUSIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FEMOROPOPLITEAL OCCLUSIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incidence of restenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevention of restenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Local delivery of paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Endovascular radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Atherectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INFRAPOPLITEAL OCCLUSIVE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PHOTOANGIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H909615712\">",
"      ANTIPLATELET THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261592148\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H909615517\">",
"      LIMB AND CARDIOVASCULAR OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8207|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/28/8640\" title=\"diagnostic image 1\">",
"      Percutaneous transluminal angioplasty of iliac stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8207|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/15/23806\" title=\"figure 1\">",
"      Long term follow up iliac stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8207|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/14/43244\" title=\"table 1\">",
"      Percutaneous intervention for claudication guideline summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/8/10380\" title=\"table 2\">",
"      Fontaine stages and Rutherford categories PAD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1031?source=related_link\">",
"      Classification of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44376?source=related_link\">",
"      Indications for surgery in the patient with lower extremity claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/49/34578?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_0_38922="Poison oak";
var content_f38_0_38922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81173%7EDERM%2F54814%7EDERM%2F81397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81173%7EDERM%2F54814%7EDERM%2F81397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison oak",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison ivy fruit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cream-colored fruit of poison ivy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison ivy leaves and flowers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Green or green-reddish leaves grow in groups of three and have smooth, fine-toothed, or lobed margins, and small, yellow-green flowers form cream-colored fruit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38922=[""].join("\n");
var outline_f38_0_38922=null;
var title_f38_0_38923="Causes of T wave inversion";
var content_f38_0_38923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected causes of prominent T wave inversions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Primary T wave inversions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Normal variant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Juvenile T wave pattern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       \"Early repolarization\" variant (sometimes associated with T wave inversions)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myocardial ischemia or infarction (including takotsubo syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Left or right ventricular overload syndromes (formerly called \"strain\" patterns)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cerebrovascular injury (T waves may be massively inverted)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       \"Memory T waves\" (eg, with intermittent left bundle branch block, intermittent ventricular pacing, or intermittent Wolff-Parkinson-White pre-excitation)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-tachycardia T wave pattern",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Apical hypertrophic cardiomyopathy (Yamaguchi's syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other myocardial/pericardial diseases - dilated and restrictive cardiomyopathies, arrhythmogenic right ventricular cardiomyopathy (dysplasia), pericarditis, myocardial tumor, etc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic global T wave inversions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Secondary T wave inversions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Left bundle branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Right bundle branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wolff-Parkinson-White patterns and variants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ventricular beats (paced, premature or escape)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38923=[""].join("\n");
var outline_f38_0_38923=null;
var title_f38_0_38924="Causes of metabolic acidosis";
var content_f38_0_38924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of metabolic acidosis according to mechanism and anion gap",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"25%\">",
"     </colgroup>",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism of acidosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Increased AG",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal AG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"14\">",
"        Increased acid production",
"       </td>",
"       <td>",
"        Lactic acidosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ketoacidosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Starvation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcohol-associated",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ingestions",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Methanol",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ethylene glycol",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aspirin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Toluene (if early or if kidney function is impaired)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Toluene ingestion (if late and if renal function is preserved - due to excretion of sodium and potassium hippurate in the urine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diethylene glycol",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Propylene glycol",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D-lactic acidosis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyroglutamic acid (5-oxoproline)",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Loss of bicarbonate or bicarbonate precursors",
"       </td>",
"       <td rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Diarrhea or other intestinal losses (eg, tube drainage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 2 (proximal) renal tubular acidosis (RTA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posttreatment of ketoacidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbonic anhydrase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ureteral diversion (eg, ileal loop)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Decreased renal acid excretion",
"       </td>",
"       <td rowspan=\"3\">",
"        Chronic kidney disease",
"       </td>",
"       <td>",
"        Chronic kidney disease and tubular dysfunction (but relatively preserved glomerular filtration rate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 1 (distal) RTA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 4 RTA (hypoaldosteronism)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38924=[""].join("\n");
var outline_f38_0_38924=null;
var title_f38_0_38925="Clin features panc neoplasm";
var content_f38_0_38925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key demographic and clinical features of patients with pancreatic cystic neoplasms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serous cystadenoma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mucinous cystadenoma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main duct intraductal papillary mucinous neoplasm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Branch duct intraductal papillary mucinous neoplasm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Solid pseudopapillary neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Age of presentation",
"        </strong>",
"       </td>",
"       <td>",
"        Variable, usually 5th to 7th decade",
"       </td>",
"       <td>",
"        Variable, usually 5th to 7th decade",
"       </td>",
"       <td>",
"        Variable, usually 5th to 7th decade",
"       </td>",
"       <td>",
"        Variable, usually 5th to 7th decade",
"       </td>",
"       <td>",
"        Usually 2nd to 3rd decade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gender distribution",
"        </strong>",
"       </td>",
"       <td>",
"        Females &gt; males",
"       </td>",
"       <td>",
"        Exclusively females",
"       </td>",
"       <td>",
"        Females = males",
"       </td>",
"       <td>",
"        Females = males",
"       </td>",
"       <td>",
"        Females &gt; males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Typical clinical presentation",
"        </strong>",
"       </td>",
"       <td>",
"        Incidental or abdominal pain or mass effect",
"       </td>",
"       <td>",
"        Incidental or abdominal pain or malignancy related",
"       </td>",
"       <td>",
"        Incidental or pancreatitis or pancreatic insufficiency or malignancy related",
"       </td>",
"       <td>",
"        Incidental or pancreatitis or malignancy related",
"       </td>",
"       <td>",
"        Incidental or abdominal pain or mass effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Typical imaging characteristics",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Microcystic/ honeycomb appearance",
"        </p>",
"        <p>",
"         Oligocystic appearance less common",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Unilocular or septated cyst +/- wall calcifications",
"        </p>",
"        <p>",
"         Solid component, if present, may suggest malignancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Dilated main pancreatic duct +/- parenchymal atrophy",
"        </p>",
"        <p>",
"         Solid component, if present, may suggest malignancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Dilated pancreatic duct branch or branches",
"        </p>",
"        <p>",
"         Solid component, if present, may suggest malignancy",
"        </p>",
"       </td>",
"       <td>",
"        Solid and cystic mass +/- calcifications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Typical aspirate characteristic",
"        </strong>",
"       </td>",
"       <td>",
"        Thin, often bloody",
"       </td>",
"       <td>",
"        Viscous",
"       </td>",
"       <td>",
"        Viscous",
"       </td>",
"       <td>",
"        Viscous or thin",
"       </td>",
"       <td>",
"        Bloody",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Typical cytology findings",
"        </strong>",
"       </td>",
"       <td>",
"        Cuboidal cells that stain positive for glycogen; yield &lt;50 percent",
"       </td>",
"       <td>",
"        <p>",
"         Columnar cells with variable atypia",
"        </p>",
"        <p>",
"         Stains positive for mucin; yield &lt;50 percent",
"        </p>",
"        <p>",
"         High yield from solid component for malignancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Columnar cells with variable atypia",
"        </p>",
"        <p>",
"         Stains positive for mucin; yield &lt;50 percent",
"        </p>",
"        <p>",
"         High yield from solid component for malignancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Columnar cells with variable atypia",
"        </p>",
"        <p>",
"         Stains positive for mucin; yield &lt;50 percent",
"        </p>",
"        <p>",
"         High yield from solid component for malignancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Characteristic branching papillae with myxoid stroma",
"        </p>",
"        <p>",
"         High yield from solid component",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Typical carcinoembryonic antigen (CEA) level",
"        </strong>",
"       </td>",
"       <td>",
"        &lt;5-20 ng/mL in majority of lesions",
"       </td>",
"       <td>",
"        &gt;200 ng/mL in approximately 75 percent of lesions",
"       </td>",
"       <td>",
"        &gt;200 ng/mL in approximately 75 percent of lesions",
"       </td>",
"       <td>",
"        &gt;200 ng/mL in approximately 75 percent of lesions",
"       </td>",
"       <td>",
"        Insufficient data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Typical DNA analysis",
"        </strong>",
"       </td>",
"       <td>",
"        Allelic loss affecting chromosome 3p rarely detected",
"       </td>",
"       <td>",
"        <p>",
"         K-ras mutation specific (&gt;90 percent), not sensitive (&lt;50 percent)",
"        </p>",
"        <p>",
"         High DNA amount or high amplitude allelic loss seen in malignancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         K-ras mutation specific (&gt;90 percent), not sensitive (&lt;50 percent)",
"        </p>",
"        <p>",
"         High DNA amount or high amplitude allelic loss seen in malignancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         K-ras mutation specific (&gt;90 percent), not sensitive (&lt;50 percent)",
"        </p>",
"        <p>",
"         High DNA amount or high amplitude allelic loss seen in malignancy",
"        </p>",
"       </td>",
"       <td>",
"        Insufficient data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Relative malignant potential",
"        </strong>",
"       </td>",
"       <td>",
"        Negligible",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low to moderate",
"       </td>",
"       <td>",
"        Moderate to high",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Treatment",
"        </strong>",
"       </td>",
"       <td>",
"        Resect if symptomatic",
"       </td>",
"       <td>",
"        Resection",
"       </td>",
"       <td>",
"        Resection and post resection surveillance",
"       </td>",
"       <td>",
"        <p>",
"         Closely monitor or resect",
"        </p>",
"        <p>",
"         Post resection surveillance required",
"        </p>",
"       </td>",
"       <td>",
"        Resection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified and reprinted by permission from: Macmillan Publishers Ltd. Khalid, A, Brugge, WR. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007; 102:2339. Copyright &copy; 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38925=[""].join("\n");
var outline_f38_0_38925=null;
var title_f38_0_38926="Age choking game vs suicide";
var content_f38_0_38926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Age distribution of deaths attributed to  the \"choking game\" versus suicide by hanging or suffocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age distribution of youths aged 6-19 years whose deaths were attributed to the \"choking game\" (n = 82) during 1995-2007, compared with youths whose deaths were attributed to suicide by hanging/suffocation (n = 5101) during 1999-2005 - United States.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Unintentional strangulation deaths from the \"choking game\" among youths aged 6-19 years - United States, 1995-2007. MMWR 2008; 57:141.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38926=[""].join("\n");
var outline_f38_0_38926=null;
var title_f38_0_38927="IVUS technique";
var content_f38_0_38927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Technique of intracoronary ultrasonography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The intracoronary ultrasound catheter is advanced down the coronary artery, past the stenotic lesion. This visualizes the artery in cross section, perpendicular to the axis of the catheter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_0_38927=[""].join("\n");
var outline_f38_0_38927=null;
